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Abstract
Background: Patients with chronic kidney disease (CKD) face a markedly increased risk
of cardiovascular morbidity and mortality. In this setting, aberrant endothelial function is
a key initiating event in vascular disease. Haemodialysis (HD) patients characteristically
exhibit significant abnormalities in vascular structure and function, which impact
cardiovascular morbidity and mortality. Micro- and macro-vascular dysfunctions are the
principle factors contributing to the increased risk of morbidity and mortality associated
with obesity. Impaired endothelial function represents the earliest abnormality in the
development of vascular disease in obesity and exhibits increased risk of cardiovascular
disease. We first aimed to investigate the effect of HO and obesity on the vascular
reactivity through directly examines the isolated subcutaneous arteries using wire
myography. The second goal was to study changes that might underlie altered vascular
responses following bariatric surgery and whether reduction in weight improves
endothelial function. We also intended to correlate the ex vivo myography data with the
in vivo results of pulse wave velocity (PWV) and blood pressure (BP) in both HO and
obese patients. Methods: Abdominal subcutaneous fat biopsies were obtained from HO
patients (n= l l ) during non-HO visits through small lower abdominal incisions using
local anaesthetics; obese patients (n=12) during the time of bariatric surgery (using a
laparoscopic port); and non-HD, non-obese healthy controls (n=26) during the time of
elective surgery (hernia repair). Additional abdominal subcutaneous fat samples (n=4)
were also obtained from obese patients at six months after bariatric surgery through an
extra incision in the lower abdominal region using local anaesthetics. Different-sized
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arteries (small with internal diameter between 200 urn - 500 urn and large between 600
urn - 900 urn) were dissected, mounted and conducted on a wire myography on the same
day. Cumulative concentration-response curves were constructed for the following
vasoactive agents: noradrenalin (NA), endothelin-I (ET-I), U46619, angiotensin II
(AngII), vasopressin, bradykinin (BK), acetylecholine (Ach) and sodium nitroprusside
(SNP). Carotid-to-femoral arterial PWV was measured using an oscillometric device
(Vicorder, Skidmore Medical Ltd., UK) for HD and obese patients in addition to
measuring blood pressure (BP). Laboratory data were expressed as mean ± SEM and
groups were compared by t-test. Results: In both HD and obese patients, greater
contractile response to different vasoconstrictors was observed in different-sized arteries
compared to control group. Although the potency of these drugs was similar between HD
patients and controls, large vessels of HD patients were highly potent to U46619 and
vasopressin compared to controls. Similarly, in obese patients, large vessels were also
significantly more sensitive to U46619 and vasopressin than that of controls, while small
vessels were highly potent to vasopressin response. The maximum vasorelaxation
response of small and large vessels to Ach and BK (endothelium-dependent vasodilators)
was significantly lower in both HD and obese patients than vessels of controls. A similar
response to SNP (an endothelium-independent vasodilator) was obtained in all groups.
However, the potencies of all vasodilators in all groups were similar. In HD patients, in
vivo PWV was significantly correlated with the maximum contractile response of large
arteries to vasopressin response (r = 0.829, P = 0.042). PWV was positively correlated
with the percentage of maximum contractile response of small arteries to vasopressin (r =
0.886, P = 0.019). The diastolic but not systolic BP of HD patients was significantly
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inversely correlated with the response of large vessels to SNP (r = -0.954, P = 0.012), it
was also negatively correlated with the percentage of contractile response of small
arteries to vasopressin (r = -0.829 P = 0.042). There was no correlation observed in the
responses of isolated small arteries to the other vasoconstrictor substances in terms of
PWV or BP. In obese patients, The PWV was significantly correlated with the maximum
contractile response of large arteries to U46619 (r = 0.928, P = 0.006), and with the
maximum contractile response of small arteries to vasopressin (r = 0.885, P = 0.033).
However, positive correlation was obtained between systolic (but not diastolic BP) of
obese patients and the response of large vessels to U46619 (r = 0.785, P = 0.048). There
was no significant difference in the vasocontractile or vasorelaxation responses of
isolated vessels in obese patients before and after surgery; however, a trend of more
contractile response to vasoconstrictors was observed in the obese group before surgery
compared to those after surgery. Conclusion: These results suggest that HO and obesity
can alter endothelial function via an incremental increase in vasocontractility in response
to various stimuli and an impaired vasodilatation response to endothelium-dependent
agonists in isolated different-sized vessels. In both groups, ex vivo arterial responses
were correlated to in vivo assessment of arterial function. The association between these
risk groups and endothelial dysfunction in isolated arteries would be expected to
accelerate cardiovascular events, which impacts cardiovascular morbidity and mortality
among these groups of patients. Therefore. the development of cardiovascular disease is
mediated, at least partly, by functional alterations at the level of microcirculation.
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Chapter 1
General Introduction
Chapter 1: General introduction
1.1 Chronic Kidney Disease (CKD)
1.1.1 Background and definition
Each kidney consists of approximately one million nephrons (the functional
filtering units of the kidney) that are continuously responsible for filtering blood while
removing waste products (urea, creatinine etc.), salts and excess fluid from the body.
Kidneys can fail in two ways: rapidly, which occurs over days, weeks or months (acute
renal failure), or slowly, which occurs over a period of years (chronic renal failure). The
most common diseases associated with chronic renal failure are diabetes mellitus,
hypertension and glomerular disease (Sowers and Epstein, 1995). Chronic kidney disease
(CKD) is increasingly recognised as a worldwide major health problem that affects the
population, resulting in multiple adverse outcomes, including renal failure,
cardiovascular disease (CVO) and premature death.
The definition of CKD is based on the impairment of kidney function, damage
and an assessment of chronicity. Assessment of kidney function is most usually based on
the measurement of serum creatinine and estimation of the glomerular filtration rate
(eGFR). According to the kidney disease outcome quality initiative (KlDOQI, 2(02)
(Eknoyan and Levin, 2002), kidney damage can be defined as structural and functional
abnormalities in the kidney with or without decreased GFR for three months or more.
This is manifested by either pathologic abnormalities or markers of kidney damage,
including abnormalities in the composition of the blood or urine or abnormalities in
imaging tests. CKD can also be defined as a reduction in eGFR « 60 mUminl1.73m2)
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for three months or more with or without kidney damage, irrespective of cause (Goolsby,
2002). This destruction of renal mass can lead to irreversible fibrosis and loss of
nephrons and, in turn, can cause progressive decline in eGFR.
Kidney damage can be ascertained firstly by a reduction in the estimated
glomerular filtration rate. This can be estimated from calibrated serum creatinine using
the Modification of Diet in Renal Disease (MDRD) study equation, which is an accurate
equation that predicts GFR as measured by an accepted method (urinary clearance of
125I-iothalamate) (Levey et al., 2003). Another measurement for clinical assessment of
kidney disease is measured creatinine clearance using 24 hr urine collection, which is
inconvenient and frequently inaccurate compared to the estimated GFR using MDRD
equations (Levey et al., 1999). Also, urinary cystatin C is independently associated with
acute kidney injury (Nejat et al., 2010). Haematuria and proteinuria are also predictors of
developing CKD stage 3 or higher (Yamagata et al., 2007). The presence of proteinuria
(either unselective or albuminuria) is known to be the most important marker of kidney
damage, measured as albumin-to-creatinine ratio> 30 mg/g in at least two of three spots
of urine specimens.
Other markers of kidney damage include urine sediment abnormalities (epithelial
and tubular casts), imaging abnormalities (polycystic kidney disease, hydronephrosis,
and small 'echogenic' kidneys) and abnormalities in the urine and blood composition
(nephrogenic diabetes insipidus, renal tubular acidosis, Fanconi syndrome, etc.).
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1.1.2 Classification of CKD
Following the proposed classification by the National Kidney Foundation
KlDOQI 2002, CKD can be divided into five stages (Tablel). This simple and initial
classification is based on the severity of renal failure and the level of eGFR using eGFR
estimated equations.
Table 1 KlDOQI 2002 classification of CKD (Based on the severity)
Stages renal function GFR
mVminll.73 m2
related terms
Stage 1 normal kidney function ~90 Albuminuria, proteinuria
haematuria
mild reductions in RF 60- 89 Albuminuria, proteinuria
haematuria
Stage 2
Stage 3 moderate reduction in RP 30-59 Chronic and early renal
Insufficiency
Stage 4 sever reduction in RP 15 - 29 Chronic and late renal
Insufficiency-pre ESRD
Stage 5 kidney failure and ESRD < 15 Renal failure, uremia
ESRD
Abbreviation: CKD chronic kidney disease, ESRD end-stage renal disease, GFR glomerular
filtration rate, RF renal function.
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1.2 End stage renal disease
1.2.1 Background
End stage renal disease (ESRD) is the last stage of CKD (CKD stage five), which
can be defmed as a reduction in eGFR by less than 15 mlIminl1.73 m2• The reduction in
eGFR results from progressive and irreversible loss of renal function that makes the
kidneys fail to perform their normal functions. Renal replacement therapy (RRT) must be
considered for patients who have developed ESRD or CKD stage five to replace renal
function, either by haemodialysis (HD), peritoneal dialysis (PO) or renal transplantation.
1.2.2 Epidemiology of CKD and ESRD
In the twentieth century, the major cause of death and disability were infectious
disease; however, in this century, non-communicable, non-infectious chronic diseases
have become the major cause of morbidity and mortality (Yach et al., 2004, Beaglehole
and Yach, 2003). The number of patients developing ESRD is increasing annually.
Diabetes mellitus is the most common chronic disease affecting the worldwide
population, and its prevalence is predicted to double in the next decades, particularly in
developing countries (Wild et al., 2004). The majority of diabetic nephropathy patients
usually die from cardiovascular complications before reaching ESRD (Rossing et al.,
1995). Hypertension, together with diabetes, is now the major cause of ESRD worldwide,
not only within the developed world, but also increasingly within the developing world.
The incidence of ESRD in the UK, as calculated by the number of new patients
undertaking RRT, varies between 80 and 110 patients per million of population (pmp)
per year (UK Renal Registry 2(02). The prevalence rate of ESRD in the UK increased
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from 724 pmp in 2006 to 746 pmp in 2007 according to the UK renal registry (UKRR) in
2008 (Farrington UKRR 2008). This prevalence rate remained lower in England (746
pmp) than in Northern Ireland (791 pmp), Scotland (797 pmp) and Wales (798 pmp),
(Farrington et al., 2009) as shown in Table 2.
Table 2 Prevalence of RRT therapy of adults in UK (2007)
England Wales Scotland N Ireland UK
All UK centres 37,614 2,377 4,101 1,392 45,484
Total population, 51.1 3.0 5.1 1.8 61.0
mid-2007(millions)
Prevalence pmp HD 318 339 346 393 323
Prevalence pmp PD 74 109 77 60 76
Prevalence pmp dialysis 392 448 423 453 399
Prevalence pmp transplant 344 350 374 338 347
Prevalence pmp total 736 798 797 791 746
Confidence intervals 729-744 766-830 773-822 750-833 739-753
Total
Abbreviations: RRT, renal replacement therapy; PO, peritoneal dialysis; HO, haemodialysis.
Adaptedfrom Farrington et aI2009.
Similarly, this elevated trend has also been seen in the United States. The
prevalence rate of patients treated by dialysis and transplantation from 1999 to 2004 was
higher than in the period from 1988 to 1994 (Palmer et al., 1988b). The study observed
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an increase in diagnosed diabetes and hypertension from 10% in 1988-1994 to 13.1% in
1999-2004. It also showed that the percentage of both albuminuria and reduction in
eGFR were increased from 1988-1994 to 1999-2004, based on the measurement of
persistent microalbuminuria (>30 mg/g) and estimated GFR using the MDRD study
equation. The overall increase in the prevalence rate of CKD, particularly among older
people and those with diabetes and hypertension suggests that plans for future health
services will be focused on the management of CKD.
1.3 Cardiovascular disease in CKD patients
1.3.1 Background
Cardiovascular disease is the major cause of morbidity and mortality in CKD
patients, and this is frequently complicated by cardiac and vascular changes. Since the
introduction of RRT in the form of dialysis and renal transplantation, patients with ESRD
have been successfully treated and no longer die of uraemia; however, the most
threatening cause of death among that group is now premature cardiovascular death.
Cardiovascular disease was believed to occur only in the late stages of CKD and dialysis
patients; however, previous studies have shown evidence of its development even in the
early stages of the disease (Go et al., 2004). Go et al., in a community-based study
involving one million adults, observed that the risk of both cardiovascular events and
death were increased even in the earliest stages of CKD where eGFR decreased below
60mVminl1.73m2. The study also showed that the highest risk group were those with
CKD stages 4 and 5 (Go et al., 2004, Ritz, 2003) (Figurel). This association between
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renal function, death, and cardiovascular events may highlight the importance of
determining and controlling modifiable cardiovascular risk factors in the earlier stages of
CKD.
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Figure 1 Age standarized rates of
cardiovascular events (A) and death from any
cause (B) in relation to eGFR
Large population-based longitudinal study
(Adapted from Go et al, 2004).
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A cardiovascularevent was defined as;
hospitalization for coronary artery disease,
heart failure, ischemic stroke, and peripheral
arterial disease.
The risk of morbidity and mortality from cardiovascular disease in CKD patients
is significantly higher. Previous studies have indicated that 40% to 50% of deaths from
cardiovascular disease were observed in patients with ESRD (Foley et al., 1998). The
risk of cardiovascular mortality in patients receiving haemodialysis (HO) or peritoneal
dialysis (PD) was shown to be 10 to 20 times higher than that of the general population
(Foley et al., 1998). Cardiovascular morbidity was also higher among that group, and
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approximately 75% of patients receiving dialysis therapy developed left ventricular
hypertrophy as detected by ultrasound. (Foley et al., 1995).
Mcintyre et al. (2008) has shown that patients on long-term haemodialysis
therapy are at high risk of developing vascular ischemia, particularly, myocardial
ischemia which, in tum, results in the development of regional wall motion abnormalities
(RWMA) and myocardial stunning even in the absence of coronary artery disease
(McIntyre et al., 2(08). This study demonstrated for the first time that haemodialysis is
associated with significant reduction in myocardial blood flow (MBF). It has been shown
that patients on dialysis therapy who have acute myocardial infarction have higher
mortality rate from cardiac causes and poor long-term survival rate (Herzog et al., 1998).
Moreover, the most prevalent pathological forms of cardiovascular disease among that
group are: left ventricular hypertrophy, atherosclerosis and arteriosclerosis.
1.3.2Cardiovascular risk factors in CKD
Cardiovascular diseases (CVD) are quite common in CKD and dialysis patients,
due to the high prevalence of conventional risk factors. The increased prevalence of CVD
in CKD patients may result from the consequences of higher prevalence of diabetes
mellitus, hypertension, hyperlipidaemia, and aging (Fuster et al., 2011). There are some
concerns about intervention management to decrease the risk of incidence and prevalence
of CVD. These include angiotensin converting enzyme blockers, angiotensin receptor
blockers, platelet inhibitors, thrombolytic, and aspirin usage, which may be unexploited
among CKD patients, though their utility among this group of patients (Saran and
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DuBose, 2008). Additional non-traditional risk factors unique to these patients have been
suggested to playa part in the progression of CVD (Samak and Levey, 2000). These
factors have been identified to be involved in a number of mechanisms of cardiac
damage and are predictive of adverse outcomes in individuals with CKD stages 3 and 4
(Samak and Levey, 2000, Weiner et al., 2008). However, vascular abnormalities,
especially arterial calcification and stiffness are important risk factors contributing to
cardiovascular mortality and morbidity in late CKD patients (stages 4 and 5) (London et
al.,2003).
Traditional and non-traditional risk factors have been implicated in the elevated
CVD development in CKD patients (Menon et al.• 2005). The prevalence of hypertension
and diabetes mellitus is higher in CKD and play an important role in increased mortality
and morbidity among this group. However, these traditional risk factors play major roles
in vascular damage and alteration in left ventricular function in CKD patients (Zoccali et
al., 2003). One of the most important non-traditional cardiovascular risks in CKD
patients is albuminuria, which is known as a continuous cardiovascular risk factor in
CKD and diabetic patients. Normal albuminuria is defined as the urinary albumin /
creatinine ratio (ACR) < 30 mg/g. The role of albuminuria as cardiovascular risk was
first recognised to macroalbuminuria, in which the ACR > 300 mg/g (Grimm et al.,
1997), but this level was extend to microalbumiuria (ACR. 30 to 300 mg/g) (Keane and
Eknoyan, 1999). The reason why microalbuminuria is a powerful predictor of CVD is yet
unknown; however, one of the principle pathophysiological mechanisms has been
proposed to the consequences of endothelial damage or to the pathogenicity of
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miroalbuminuria itself (Schiffrin et al., 2007). The other important non-traditional risk
factors are discussed in section 1.4.3.
Table 3 Traditional and non-traditional risk factors
Pathology Traditional risk factors Non-traditional risk factors
Cardiomyopathy
Older age Albuminuria
Hypertension Reduced glomerular filtration rate
Valvular disease Anemia
Dvslinidemia Inflammation
Smoking Arteriosclerosis
Diabetes Extracellular fluid volume overload
Atherosclerosis Older age
Albuminuria
Male gender Reduced Jdomerular filtration rate
Hypertension Anemia
Diabetes Inflammation
Dvslipidemia Oxidative stress
Smoking Endothelial dvsfunction
Ph~sical inactivity Homocysteine
Le t ventricular hvpertrophv Lipoprotein
Malnutrition
Thrombogenic factors
S~«:thetic activity
Ins . resistance/metabolic syndrome
Arteriosclerosis Older age Albuminuria
Male gender Reduced }domerular filtration rate
Smoking Endothelial dysfunction
Hypertension Abnormalcalcium.phosphate
Diabetes metabolism
Dvslipidemia Metabolic syndrome
Adapted from (Menonet al., 2005)
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1.4 Vascular endothelium and CKD
1.4.1 Vascular endothelium
The interior surface of blood vessels of the circulatory system from heart to
capillaries is lined with a single layer of endothelial cells, which is a specialized type of
simple squamous epithelium separated from the surrounding outer layers by a basal
lamina (Gunthner et aI., 2009) see Figure 2. These cells control the passage of
materials-and the transit of white blood cells-into and out of the bloodstream.
Endothelial cells have mechanoreceptors that allow them to sense shear stress due to
flow of blood over their surface. By signalling this information to the surrounding cells
(smooth muscle cells), it enables blood vessels to adapt their diameter and wall thickness
to suit the blood flow (Simionescu et al., 1984), a maintain end organ perfusion in the
setting of altering systemic blood flow.
Endothelium normally provides a non-thrombogenic surface and reduces
turbulence of blood flow. This layer acts as a selective barrier between the vessel lumen
and surrounding tissue, and regulates angiogenesis, vessel tone and function, and
mediates inflammatory processes (Cines et al., 1998). It additionally plays an important
role in the biology of arterial wall via release of vasoactive and trophic factor. The most
important cellular component in the tunica media is the vascular smooth muscle layer
that responsible for vasodilatation and vasoconstriction through secretion of various
hormones and growth factors that regulate proliferation, migration and extracellular
matrix formation in this layer (Betsholtz and Armulik, 2006).
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Smooth muscle cell
Figure 2 Cross-section of a vessel wall
Adapted from (Gunthner et al., 2009)
Vascular endothelium plays an important role in the regulation of vascular
function by providing a protective action through modulation of vascular structure, tone
and interaction of blood components with the vascular wall (Annuk et al., 2001, Baragetti
et al., 2007). It has an atheroprotective effects through production and release of a wide
range of vasoactive substances that include vasoconstrictors such as endothelins,
thromboxane A2, and vasodilators nitric oxide (NO), prostacyclin, arachidonic acid
derivatives and endothelium-derived hyperpolarising factors (EDHF) (Cross, 2002).
Different chemical substances such as acetylcholine (Ach), bradykinin (BK), serotonin,
and substance P stimulate the endothelium to initiate the vasodilatation mechanism
(Vallance and Chan, 2001). This occur either through endothelium-deriving relaxing
factor which was first demonstrated as NO (Furchgott and Zawadzki, 1980) or through
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mediated hyperpolarization of vascular smooth muscle cells via NO-independent
pathway (Busse et al., 2(02).
1.4.2 Measurement of endothelial function
Several techniques are now available for the assessment of endothelial function in
humans including invasive and non-invasive techniques. These methods are based on the
assessment of endothelium-mediated responses of peripheral arteries by measuring the
effects of their receptor agonists on the vascular resistance.
The initial in vivo studies on the endothelial function was on investigating
coronary circulation, involved local infusion of Ach with measurement of the vascular
diameter using coronary angiography (Cox et al., 1989). Subsequently, these methods
have been repeated using Doppler flow wires to measure resistance of the vascular
function (Drexler and Zeiher, 1991). The physiological responses of vascular
endothelium to various stimuli including Ach, BK, and substance P have also been
investigated in vivo using flow-mediated dilatation (FMD) of conduit arteries (Nabel et
al., 1990). A number of alternative non-invasive methods have also developed to
investigate endothelial function in peripheral circulation, particularly, forearm resistance
vessels. These include venous occlusion plethysmography, which is one of the widely
used techniques in cardiovascular research (Benjamin et al., 1995). This method is based
on the measurement of increase in forearm volume after suppression of the venous return
by using specific pneumatic cuff placed at the level of the arm. Another non-invasive
assessment method of endothelium function in peripheral arteries is studying the effects
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of their receptor agonists on blood flow using non-invasive Doppler and intravascular
ultrasound imaging (Donald et al., 2(06). Laser Doppler is also one of the widely used
method to assess the endothelium function of cutaneous microcirculation (Johnson et al.,
1984).
A number of ex vivo technique have been also introduced to investigate the
endothelial function through measurement of vascular contractility and various aspects of
excitation-contraction coupling process. These include wire myograph (Mulvany and
Aalkjaer, 1990), that described in details in methodology chapter section 2.4. The other
technique is pressure myograph, which is used to study the physiological function of
small isolated vessels, it allows to investigate the pharmacological effects of different
vasoactive stimuli on the isolated vessels under near physiological conditions (Halpern
and Kelley, 1991). Both techniques are widely used in the ex vivo research which
enabling the researchers to directly investigate the vascular function in isolated vessels
from different tissues. However, in these methods, vessels possess many of their in vivo
properties.
1.4.3 Endothelial dysfunction in CKD
Endothelial dysfunction can be defmed as an alteration in the normal function of
the endothelium. It can also be defined as partial or complete loss of balance between
vasoconstrictors, growth and inhibiting factors, pro-coagulant and anti-coagulant factors
(Caballero, 2(03). During endothelial dysfunction, endothelial cells release paracrine
factors such as vascular endothelial growth factor (VEGF), endothelin-l and interleukin-
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6 that act either as growth factors to induce smooth muscle cell proliferation, or as
chemokines to stimulate circulating inflammatory cells (Bolton et al., 2001). Endothelial
damage is recognised as a common risk of vascular damage in many conditions
associated with increased cardiovascular risk including CKD.
Endothelial dysfunction has been implicated in different pathological diseases
including CVD, CKD, obesity, hypertension, diabetes mellitus, and peripheral vascular
disease (Schiffrin, 2004). Endothelial dysfunction has been reported to occur in various
stages of CKD even in the early stages (Go et al., 2004). However, the occurrence of
endothelial dysfunction in CKD can be independently to traditional factors, this may
highlight the presence of other 'kidney-specific' mechanisms that contribute to CKD~
related endothelial dysfunction. For example, Kari et al. observed the presence of
endothelial dysfunction in uremic children without hypertension and dyslipidaemia (Kari
et al., 1997). In 1990, the endothelial dysfunction was first demonstrated in forearm
vessels of hypertensive patients (Panza et al., 1990). Impaired endothelium-dependent
vasodilatory function was demonstrated in ESRD patients in ex vivo (Morris et al., 2001,
Luksha et al., 2011) and in vivo studies (Morris et al., 2000, Bolton et al., 2001, Yildiz et
al., 2003). Moreover, such impairment has also been observed in obese patients in ex vivo
(Georgescu et al., 2011, De Ciuceis et al., 2011) and in vivo studies (Nielsen et al.• 2004).
endothelial dysfunction can also occurs in other conditions including assessment of the
vascular function in peripheral vascular beds of hypertensive (Park et al., 200 1)
(Schiffrin et al., 2000) and diabetic patients (Rizzoni et al., 2001a, Schofield et al., 2002).
The pathophysiological mechanisms of endothelial dysfunction in CKD patients is
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complex and incompletely understood, however many proposed mechanisms have been
suggested.
Several studies investigating the mechanisms of endothelial dysfunction in
uremic patients have focused mainly on the impairment of NO bioavailability resulting to
impaired endothelium-dependent vasodilation as the principal event that leading to
endothelial dysfunction. The exact mechanisms for altered NO activity in uremic patients
is yet unclear, however some non-traditional uraemia-specific risk factors are being
widely discussed, including excessive oxidative stress and reactive oxygen species
(Ferraro et al., 2003, Hasdan et al., 2002, Miyazaki et al., 2000), hyperhomocysteinemia
that found in the majority of renal patients (Bostom and Culleton, 1999) and elevated
plasma levels of endogenous competitive inhibitors of nitric oxide synthase (eNOS), such
as asymmetric dimethyl arginine (ADMA) in dialysis patients (Vallance et al., 1992),
which has been discussed in details in this chapter.
1.4.3.1 L-argentine- NO pathway and endothelial dysfunction
NO is a soluble gas that is synthesized from the amino acid I-arginine in
endothelial cells by a calcium-calmodulin-dependent enzyme (endothelium nitric oxide
synthase eNOS (Palmer et al., 1988b). L-arginine is an amino acid known to be a
physiological precursor for NO synthesis in the culture of vascular endothelial cells
(Palmer et al., 1988a). The synthesis of NO occurs after oxidation of guanidine nitrogens
terminal of L-arginine by NO synthase enzyme, activated by an increase in endothelial
intracellular calcium concentration, to produce NO and L-citruline (Bredt, 1999). The
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generator cell (endothelial cell) releases NO as a gas or attached to other molecules to the
target cell (smooth muscle cell) (figures 3 and 3.1). In the target cell, NO stimulates
soluble guanylayl cyclase and subsequently produce an increased concentration of cyclic
guanosine monophosphate (cGMP) (MacAllister and Vallance, 1994). This in turn leads
to different activities, such as decrease intracellular calcium levels and smooth muscle
relaxation.
Generator cell (endothelial cell)
Target cell (smooth muscle cell)
l·NMMA02 L-Citrulline
NO-Haem GC
!r~
NO synthase GTP cGMP
Figure 3 L-arginine- NO pathway.
Abbreviation, L-NMMA (NG-monomethyJ-L-arginine), GC (guanyJayJ cyclise), GTP
(guanosine
triphosphate), cGMP(cycIic guanosine monophosphate).
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Figure 3.1 Proposed metabolisms of methylearginines within the endothelial cell
Figures 3 and 3.1 are Adapted from MacAllister 1994.
NO has appeared as the most notable endothelium-derived vasorelaxant released
from the vascular endothelium following stimulation of endothelial cells by numerous
stimulating factors including; acetylcholine, thromboxane All, thrombin, bradykinin,
histamine (Cannon, 1998). It can promotes vascular homeostasis such as maintaining
vascular function, regulates local cell growth and protects the vessel from blood
circulating cells and platelet aggregation (Michel and Vanhoutte, 2010). In addition to its
vasodilator effect, NO can inhibit the following; Platelet aggregation and adhesion,
vascular smooth muscle proliferation, vascular smooth muscle contraction, endothelin
production, monocyte adhesion and migration, and expression of adhesion molecules
(Radomski et al., 1987).
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1.4.3.2 NO inhibitors and the effect of renal failure on NO synthesis.
Different substances have been proposed to directly affect NO synthesis. These
include a group of guanidine compounds such as W-dimethyl-L-arginine (asymmetrical
dimethylarginine, ADMA), methylguanidine, and W-monomethyl-L-arginine (L-
NMMA). These endogenous naturally occurring substances are accumulated in renal
failure as a result of reduced excretion and/or metabolism. They accumulate in sufficient
amounts to competitively inhibit NO synthase enzyme (NOS) (Cross, 2002).
Dimethylearginines (OMAs) that include asymmetric dimethylarginine (AOMA) and
symmetric dimethylarginine (SOMA) have been shown to be accumulated in plasma of
patients suffering from renal failure (Cross, 2(02).
Plasma ADMA is water soluble substance derived from the catabolism of
proteins containing methylated arginine residues (Chan and Chan, 2002). It has been
shown that more than 10 mg of plasma AOMA is normally excreted in urine over 24 hr
(Vallance et al., 1992), however patients with ESRD who are oligouric or anuric,
excretion of plasma ADMA is blocked (Matsuguma et al., 2006). AOMA directly
inhibits eNOS and reduces NO synthesis (Vallance et al., 1992), while SOMA does not
inhibits eNOS, but may competes with L-arginine for transport into endothelial cells
(Teerlink et al., 2(02). These circulating inhibitors are accumulated in a sufficient
amount to inhibit NO synthesis in patients with renal failure, though the precise
mechanism underlying accumulation of ADMA and SOMA in uremic CKD patients is
not fully understood. DMAs are freely filtered and removed from the plasma of dialysis
patients along with various uremic toxins during dialysis procedure (Anderstam et al.,
1997). However, accumulation of these compounds occurs as a result of poor clearance
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during dialysis procedure and substantial rebound that occurs at the end of dialysis
session (Eloot et al., 2(05).
Many studies have demonstrated marked elevation of plasma ADMA in patients
with ESRD. In 1992, Vallance et al. reported for the first time that concentration of
plasma ADMA and SOMA are up-to 4-fold increase in uremic patients compared to
control groups in a study recruited 9 HO patients and 6 normal controls (Vallance et al.,
1992). Kielestein et al. highlighted markedly increased plasma AOMA in early stages of
non-smoking, non-diabetic CKD patients (even those with normal eGFR), with highly
significant differences between patients and control groups (Kielstein et al., 2002).
Moreover, Fleck et al. in his large study that include 221 patients with different stages of
renal diseases, observed that plasma ADMA concentration were raised by 38% in CKD
group, whereas plasma SOMA was elevated by 250% in CKD compared to healthy
subjects (Fleck et al., 2(03) (see figure 4). The study also showed that both AOMA and
SOMA are elevated further by about 5.5-fold in haemodialysis patients (HO) compared
to normal controls. However, following renal transplantation, only the concentrations of
SOMA were decreased compared to non-transplant HO group, whereas ADMA remains
nearly unchanged. Furthermore, the study suggested that SOMA is another risk marker
for endothelial dysfunction and both OMAs may contribute to increased risk of CV
mortality and enhancement of hypertension in CKD patients.
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Figure 4 ADMA and SDMA concentrations in patients with different RRT
Renal failure (CRF), haemodialysis (HD), renal transplant (RT), and Control group
n= patients numbers, *significantly different from control;
+significant difference to CRF; #significant difference between
RT and HD (p < 0.05).Adaptedjrom Fleck et al 2003.
1.4.3.3 NO inhibitor (ADMA) and cardiovascular dysfunction
It has been shown that NO inhibitors may contribute to cardiovascular
dysfunction. Kielstein et al. demonstrated the effect of plasma ADMA on cardiac output,
systemic vascular resistance and blood pressure. The study involved healthy subjects
infused with different concentrations of ADMA intravenously to assess the effect of
ADMA on NO production and renal haemodynamic (Kielstein et al., 2004). It observed
that an acute elevation in plasma ADMA concentrations within the physiological relevant
range (2-lOJlmollL) can cause a significant decrease in plasma cyclic guanosine
monophosphate concentration (cGMP), the main second messenger of NO in the
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cardiovascular system. It also showed that infusion of healthy subjects with 0.10 mg.kg
I.min-I concentration of ADMA can result to a significant sustained reduction in cardiac
output and increased systemic vascular resistance (figure 5 and 5.1 respectively).
AT
4+-~~~~~.-~~~~~~~~~~~~
o 20 40 60 80 100 120 140 160 180 200 220
time (min)
Figure 5 Effects of ADMA on cardiac output on healthy volunteers.
Data adapted from (Kielstein et aI., 2004).
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Figure 5.1 Effects of ADMA on systemic vascular resistance on healthy volunteers.
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1.4.3.4 Uremia and endothelial dysfunction
Uremic toxins are attributed to the progressive retention of a large number of
compounds, which under normal conditions are excreted by the healthy kidneys. These
compounds are called uremic retention solutes, or uremic toxins when they interact
negatively with biologic functions (Vanholder et aI., 2001). A number of uremic
compounds have been identified including low molecular weight solutes, protein-bound
solutes and middle molecules such as guanidines. These physiological molecules are
difficult to remove by dialysis (Vanholder et aI., 2001, Vanholder et al., 2008). Table 4,
illustrates some of the currently known uremic retention solutes, classified according to
the characteristics that potentially influence their removal pattern during dialysis
(Vanholder et al., 2003, Vanholder et al., 2008). The pathophysiological mechanisms by
which uremic toxins can cause endothelial damage is still understood, however some of
these toxins can induce release of endothelins and enhance angiogenesis by stimulating
vascular endothelial growth factors (Anagnostoulis et al., 2008).
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Table 4 Compounds with the pel tential to provoke vascular damage.
Small water-
soluble compounds
Protein-bound molecules
Middle molecules
Guanidines (ADMA, SOMA, Methylguanidine,
Argininic acid, guanidinopropionic acid,
Guanidinoacetic acid, Guanidonosuccinic acid,
Taurocyamine).
AGE (3-deoxyglucosone, Fructoselysine, Glyoxal,
Methylglyoxal, Pentosidine, dinucleotide
polyphosphates, indoxyl sulphate), indoles (Indole-3-
acetic acid, Indoxyl sulphate, Kinurenine).
Homocysteine, leptin, Phenylacetic acid, TNF- u,
AGE, dinucleotide polyphosphates, leptin, TNF- u,
Adrenornedullin , Atrial natriuretic peptide, -endorphin
B2-microglobulin, Cystatin, Endothelin, Interleukin-l B,
Interleukin-6
Methionine-enkephalin, Neuropeptide, Parathyroid
hormone.
Abbreviation:AGE, advanced glycationend products;TNF tumour necrosis factor alpha,ADMA,
asymmetric dimethyl argentine; SOMA, symmetric dimethyl argentine. Data adapted from
Vanholder et al. 2008.
Uremia is associated with other conditions that probably accelerate the
development of atherosclerosis, such as increased production of reactive oxygen species
(ROS), increased homocysteine levels, acidosis, recurrent infections, and complementing
activation, which may contribute to impaired endothelial function (Gunthner et al.,
2009). Similarly, other conditions including diabetes, hypertension, hyper-
cholesterolaemia, congestive heart failure, and hyper-hornocystinaemia have been
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associated with endothelial dysfunction (Cannon, 1998). In these conditions, alteration in
endothelial cells can promote inflammation, oxidation of lipoproteins, smooth muscle
proliferation, platelet activation, thrombus formation, extracellular matrix deposition and
accumulation of lipid-rich materials. All these consequences may contribute to the
pathogenesis of atherosclerosis. However, these inflammatory conditions may predispose
to endothelial damage.
1.4.3.5 Oxidative stress and endothelial dysfunction
Oxidative stress plays a pivotal role in the pathogenesis of vascular injury and in
the progression of atherosclerosis. This can occurs through several mechanisms, some of
which are associated with inhibition of NO synthase activity and inactivation of NO by
reactive oxygen species (Harrison, 1997). Oxidative stress has been found to be elevated
in different stages of CKD patients (Pawlak et al., 2004). Release of reactive oxygen
species (ROS) in uremic patients can occur as a result of an imbalance between pro-
inflammatory and anti-inflammatory mechanisms which can be manifested by decreased
NO levels (Morena et al., 2005). Impaired NO bioavailability as a result of excessive
production of ROS may contribute to endothelial cell damage and vascular dysfunction
(Morena et al., 2005). Although endothelial cells have an antioxidant defence mechanism
against these products, over production of ROS gradually over time can damage these
cells. Many experimental and clinical studies have demonstrated that uraemia is
associated with an increased state of oxidative stress (Ferraro et al., 2003, Hasdan et al.,
2002). This condition is characterized by an increase of lipid peroxidation products and
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retention of oxidized solutes (Cruz et al., 2008). Moreover, Annuk et al. observed the
direct relation between increase plasma markers of uremic oxidative stress and
endothelial dysfunction (Annuk et al., 2001).
1.4.3.6 Homocysteine and endothelial dysfunction
Homocysteine is a sulphur-containing amino acid, known to be an independent
cardiovascular factor that is associated with endothelial dysfunction (Clarke et al., 1991).
Homocysteine has been shown to be associated with increased risk of atherosclerosis and
venous thromboembolism. Approximately 50% of patients with severe hyper-
homocysteinaemia develop a clinically significant vascular event even prior to the age of
30 (Mudd et al., 1985). Homocysteine is frequently seen in patients with CKD and it has
been found in more than 90% of patients on dialysis treatment (Francis et al., 2004). It is
one of the uremic factors that accumulates in renal failure and contributes to endothelial
and cardiovascular dysfunctions (Mallamaci et al., 2002). Although, the precise
mechanism underlying the effect of hyper-homocysteinaemia on endothelial dysfunction
remains unclear, several studies have suggested that hyper-homocysteinaemia is
indirectly associated with endothelial dysfunction. One mechanism proposed that the
defect can occurs via impaired NO bioavailability (Sydow et al., 2003), either through its
oxidation to hydrogen peroxide and other reactive oxygen species (Lang et al., 2000) or
secondary to accumulation of endogenous NO synthase inhibitor (ADMA) (Boger et al.,
20(0). It has also been shown that increased plasma homocysteine but not cysteine
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concentration between 10-50 umol/L might inhibit endothelial cell proliferation (Wang
et al., 1997).
Various studies have determined that hyper-homocysteinaemia is a risk marker of
cardiovascular mortality and morbidity in haemodialysis patients (Mallamaci et al., 2002,
Buccianti et al., 2004). It has been shown, in dialysis patients, that hyper-
homocysteinaemia can be successfully treated by folic acid therapy via administration of
folate and B-vitamins. Baragetti et al. compared 19 peritoneal dialysis patients receiving
oral folic acid (5-methyltetrahydrofolate therapy) with other dialysis group without
treatment for the same period of time (12 week follow-up) (Baragetti et al., 2007). The
study showed that treatment with folic acid can lowers, but does not normalize, plasma
homocysteine level with 30% reduction in plasma homocysteine levels among the
treatment group (see figure 6). It also observed significant improvement in the
endothelial function measured using B-mode Ultrasonography in the brachial artery by
daily administration of the drug among treatment group, independently to the reduction
in homocysteine plasma levels. However, recent randomised clinical trials assessing
clinical effectiveness of homocystein-lowering interventions (HLI) in non-CKD people
with or without pre-existing cardiovascular disease did not observe the evidence to
support the use of HLI to prevent cardiovascular events (Marti-Carvajal et al., 2009).
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Figure 6 Effects of 5-MTHF treatment on plasma homocysteine level
Assessment of homocysteine level was at (T'I and T2) in dialysis (treatment and control
group). Endothelial function measured by B-mode ultrasonography in the brachial artery
(Baragetti et al., 2007).
r.s Wire myograph
Wire myograph is an ex vivo technique that used to investigate the vascular
function of isolated small resistance vessels and tubular tissues including ureters and
bronchi. Bevan and Osher firstly described the technique in 1972. They investigated
small vessels with internal diameters around 100 urn to assess the contractility of small
isolated arteries to agonist stimulation (Bevan and Osher, 1972). This technique,
thereafter, was developed by Mulvany and Halpern to allow an in vitro measurement of
both active and passive properties of small arteries (with internal diameter 60 urn to 300
urn) under isometric conditions using wire myograph (Mulvany and Halpern, 1977). In
this system, vessel segments are threaded on two small wires (40 urn) as a ring
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preparation. Each wire is secured to each of the jaws, one of the wires is fastened to a
force transducer and the other is attached to micrometer for adjustment of vessel
circumference and the application of tension. This arrangement helps the researchers to
measure the internal circumference of the vessel, wall tension, and isometric force
responses to chemical drugs (agonists and antagonists).(Rizzoni et al., 2003). Details of
the myography technique and procedures are described in methodology chapter, section
2.4.
1.6 In vivo vascular studies in CKD
Structural remodelling in vascular resistance has been observed in uremic and
hypertensive humans and animal models. In experimental uremic hypertensive animals,
structural changes characterised by an increased wall/lumen ratio with decreased lumen
diameter have been observed in the mesenteric arteries of Wistar-Kyoto rats, suggesting
that these vessels undergo remodelling in uremic hypertension (New et al., 2004).
Impaired peripheral vascular perfusion, measured in vivo using laser Doppler perfusion
imaging, has been observed in uremic rats induced by subtotal nephrectomy (Jacobi et
al.,2006).
In humans, several in vivo studies have confirmed impaired endothelial-
dependent vasodilation in peripheral vascular beds of uremic patients. Morris et al.
examined endothelial function in uremic peripheral forearm vessels by measuring
changes in the forearm blood flow induced by carbachol (endothelium-dependent
vasodilator) and SNP (endothelium-independent vasodilator) using forearm
plethysmography (Morris et al., 2000). The study observed reduced vasodilatation
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responses to carbacol in uremic patients, with preserved vasorelaxation function in
response to SNP. Hand et al. identified impaired endothelium-dependent vasodilatation
in adult haemodialysis patients using non-invasive vascular measurements of dorsal hand
veins (Hand et al., 1998). The study examined 12 haemodialysis patients and 8 healthy
controls (non-HD) comparing responses of Ach (activator of NO synthase) and glyceryl
trinitrate (GTN, a NO donor) to preconstricted dorsal hand vessels before and after
dialysis using dorsal hand vein measurement. This study observed an impaired
venodilatation response to Ach before dialysis, which corrected after each dialysis
session. whereas venodilatation in response to GTN was similar before and after dialysis.
The study also showed that Ach-dependent venodilatation was corrected before dialysis
by co-infusion of L- but not D-arginine. From these findings, the authors suggested that
patients on haemodialysis have impaired Ach-mediated venodilation as a result of
accumulated NOs inhibitors, which are cleared by dialysis therapy. Baragetti et al. also
examined the endothelial function in the forearm vessels of uremic dialysis patients
(Baragetti et al., 2(07) using B-mode (Biosound) ultrasonography on the brachial artery
as discussed in detail in section 1.4.3.6.
1.7 Ex vivo vascular studies in CKD
An ex vivo study of small arteries is an important and helpful tool for assessing
vascular abnormality in uremic patients who are at high risk of developing the structural
and functional cardiovascular abnormalities that may occur as a result of microvascular
dysregulation.
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In ex vivo animal studies, altered myogenic constriction and impaired EDHF-
mediated relaxation has been observed in isolated small vessels of uremic hypertensive
rats (Vettoretti et al., 2006). Decreases in Ach-mediated vasorelaxation but not in SNP-
mediated response have been demonstrated in isolated small vessels of severely
hypertensive uremic rats induced by renal mass reduction (Benchetrit et al., 2003).
Moreover, endothelial function in isolated uremic arteries has been investigated using
arterial responses to different concentrations of acetylcholine (Ach) and sodium
nitoprusside (SNP) in controls (non-uremic) and uremic rats induced by nephrectomy
(Thuraisingham and Raine, 1999). The study observed that normal agonist-induced
endothelium-dependent relaxation was maintained in experimental uraemia.
Despite the high prevalence of cardiovascular events in CKD, few studies have
examined vascular and endothelial function in isolated subcutaneous vessels of uremic
patients. For example, Morris et al. examined the effects of uraemia on the vascular
function through measurement of isolated human subcutaneous resistant arteries using
wire myography. In this study, subcutaneous fat biopsies were obtained from the anterior
abdominal wall from twelve uremic patients with different stages of CKD at the time of
peritoneal dialysis catheter insertion or renal transplantation, and eight control samples
without kidney disease at the time of abdominal elective surgery. Small resistant arteries
were dissected and conducted by wire myography, and cumulative concentration-
response curves for norepinephrine (NA), endotheline-I (ET-I), acetylcholine (Ach), and
sodium nitroprusside (SNP) were constructed (Morris et al., 2001). This study showed no
significant differences between both groups in response to NA and ET-l (see Figure 7),
however more tendency of increased maximum contraction to the highest doses of these
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compounds were observed in uremic patients than control group. The potency and
maximum relaxation to SNP (endothelium-independent vasodilator) were similar in the
two groups, while the maximum % of relaxation to Ach (endothelium-dependent
vasodilator) was significantly lower in uremic patients compared to control group (Figure
8).
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Figure 7 Concentration response curves for vasoconstrictors in uremic and controls
Data are mean ± SEM. Norepinephrine (NA), endotheline-l (ET-I) in uremic (A) and
control (.) groups.*P = 0.001 and *p = 0.01 respectively (Morris et al., 2001).
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Figure 8 Concentration-response curves for vasodilators in uremic and controls
Data are mean ± SEM, (*P = 0.001, Sodium nitroprusside (C) and acetylcholine (D) in
uremic (A) and control ( .) groups. Figures Adapted from Morris et al., 2001.
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Effects of uremia on the structure and function of isolated subcutaneous small
arteries has also been studied recently in ESRD patients using both wire and pressure
myography (Luksha et al., 2011). In this study. 35 patients starting peritoneal dialysis
were matched with 30 healthy controls. It observed impaired endothelium-dependent
vasodilatation in response to Ach, while preserved endothelium-independent function in
response to SNP. However. the study found that the vasocontractile function of isolated
vessels in response to NA. ET-I. and angiotenisn II was similar between both groups.
On the other hand, vascular dysfunction due to other disorders such as
hypertension has been well investigated in human subcutaneous resistance arteries by
myography. Such studies have examined vascular dysfunction and remodelling (James et
al., 2006. Rizzoni et al., 2006). as well as, evaluate the use of some pharmacological
interventions (Buus et al., 2007, Schiffrin et al., 2002). Early morphological studies on
the conduit arteries have shown that vascular alterations are characterized by
atherosclerosis in HD patients (Pascazio et al., 1996. London and Drueke, 1997). In
experimental uraemia, increased wall-to-Iumen ratio in intra-myocardial small vessels
with significant architectural abnormalities in the aorta has been shown in uremic rats
(Amann et al., 1995a).
1.S Obesity and cardiovascular dysfunction
1.S.1 Background and Epidemiology
Obesity is a major worldwide health problem. and well known as one of the most
common risk factors for cardiovascular disease. The Framingham Heart study data has
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indicated that obese and overweight people are associated with an increased relative risk
for development of cardiovascular events (Wilson et aI., 2002). It has been recognised as
a major modifiable cardiovascular risk factor. Obesity and excessive weight gain
significantly increase the risk for coronary artery disease, hypertension, and diabetes in
both men and women (Sharma, 2003). Increased risk of developing congestive heart
failure has been observed in obese people compared to controls with normal BMI
(Kenchaiah et aI., 2(02).
The risk of cardiovascular morbidity and mortality is increased in obese people as
a result of vascular dysfunction, particularly coronary complications (Ninomiya et aI.,
2004). Obesity is associated with increased risk of premature death, particularly from
cardiovascular events. It has been recognised that the life expectancy of obese people in
the current and future generations is expected to be reduced as a result of cardiovascular
events and other associated chronic diseases (Karuparthi et al., 2008). Several central and
peripheral abnormalities have been identified in obesity that contributes to the
development of high blood pressure (Rahmouni et al., 2005). These include activation of
the rennin-angiotensin-aldosteron system, and activation of the sympathetic nervous
system (Figure 9).
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Figure 9 Mechanismsand hormonal system involved in obesity
Abbreviations: SNA, sympathetic nerve activity; FFA, free fatty acid; RAS, rennin angiotensin
system.Data adapted from (Rahmouniet al., 2005).
1.8.2 Obesity and endothelial dysfunction
Obesity, insulin resistance, and metabolic syndrome have been shown contribute
to vascular endothelial dysfunction and decreased arterial compliance (Fomoni and Raij,
2005, Ritchie et al., 2004). The association between obesity and endothelial dysfunction
is decisive because the crucial role of endothelial dysfunction in the pathogenesis of
atherosclerosis and development of cardiovascular events (Widlansky et al., 2003).
It has been shown that obesity-related conditions such as diabetes mellitus,
hypertension, and hyperlipidaemia may cumulatively damage vascular endothelium
(Meyers and Gokce, 2007). The mechanisms responsible for endothelial dysfunction in
obese patients are yet unclear; however it is likely that various mechanisms may be
involved. An endothelial cell adhesion molecule that facilitates cellular adhesion and
52
endothelial cell migration has been reported in obese patients (Escobar-Morreale et al.,
2(03). Increased vascular endothelial expressions of some oxidase enzymes and elevated
endothelial oxidative stress have also been found in obese and overweight subjects
(Silver et al., 2(07). Impaired NO bioavailability has a major role in endothelial
dysfunction. Since NO plays a crucial role in maintaining vascular tone, monocyte
adhesion, cellular proliferation and inhibits platelet aggregation, therefore reduction in
NO function may contributes to the development of macrovascular disease in obesity.
The exact mechanism by which impaired NO function can cause endothelial dysfunction
in obesity is not completely understood. However, a number of contributory factors
including insulin resistance (Steinberg et al., 1996), increased concentration of pro-
inflammatory cytokines (Aldhahi and Hamdy, 2003), increased free fatty acid levels
(Steinberg et al., 2000), and increased endothelin-dependent vascular tone (Mather et al.,
2002), have all been observed in obesity. Therefore these factors may responsible for the
underlying mechanisms that mediate vascular endothelial dysfunction (Poirier et al.,
2006).
1.8.2.1 Increased concentrations of pro-inflammatory cytokines and lipotoxicity
It is now clear that adipose tissue secretes different bioactive proinflammatory
substances and hormones, such as adiponectin and leptin, which have been shown
elevated in obese people. Dysregulation of these substances can lead to the incidence of
obesity-related diseases including glomerulopathy and CKD (Trayhurn et al., 2008).
Leptin is a hormone produced from adipocytes that stimulates the hypothalamus gland
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resulting in appetite suppression (Trayhurn et al., 2(08). It has been found that the
concentration of circulating leptin is directly proportionate to the amount of adipose
tissue present (Bagby, 2004, Sharma and Considine, 1998). Reduction in the
concentration of circulating leptin has been observed in obese people who undergo
weight loss (Leichman et al., 2(08). In ex vivo animal studies, it has been shown that
leptin stimulates the proliferation of cultured glomerular endothelial cells through the
generation of reactive oxygen species (Bouloumie et al., 1999). In rats, administration of
high doses of leptin can increase glomerulosclerosis and proteinuria (Wolf et al., 1999).
Lipotoxicity is a process of lipid overload seen in obesity that promotes the cellular
deposition of free fatty acids (FFAs) and triglycerides (TGs) which contributes to organ
dysfunction (Wahba and Mak, 2(07). In lipotoxicity, the continuous production of
mediators, such as FFAs, other adipokines like interleukin-6 (IL-6) and tumour necrosis
factor alpha (TNF- a), can increase platelet activity, activate renin-angiotensin system,
impair insulin action and mediate insulin resistance. All of which contribute to
glomerulonephritis, acute renal failure and tubulo-interstitial nephritis (Wahba and Mak,
2007). It has also been demonstrated that different mediators in obesity, such as TNF- a,
interleukin (lL)-6, resistin and leptin, have some direct and / or indirect effects on the
vascular endothelium (Aldhahi and Hamdy, 2(03). The chronic inflammatory cascade
that occurs in obesity contributes to the development of atherosclerotic diseases which
predict increased risk of cardiovascular mortality and morbidity in this group.
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1.8.2.2Increased insulin resistance
It has been shown that obese patients with hyperfiltration have extremely high
levels of insulin resistance (Chagnac et al., 2000), however, the exact underlying
mechanism behind this remains unclear. One potential underlying mechanism is that
insulin increases sodium reabsorption in the proximal tubules, thick ascending limb and
distal tubule. This leads to associated fluid retention and the development of systemic
hypertension (Tiwari, 2007, El-Atat, 2004). There is also increased extracellular
proliferation, increased lipid production, and hyaluronate deposition, which act to
increase intrarenal pressure. This causes compensatory lowered renal vascular resistance,
raised kidney plasma flow, glomerular hyperfiltration and activation of the renin-
angiotensin system (El-Atat, 2004).
It remains to be determined whether changing these potential factors contribute to
improvement in the vascular function in obesity. Therefore, decreased obesity may
improve vascular function and reduce cardiovascular disease in these high-risk subjects.
1.8.3Bariatric surgery
Different bariatric surgical procedures are available to reduce the weight in obese
people. The principle target in this procedure is to achieve weight loss by reducing the
size of stomach. This can be achieved either by gastric banding which is performed by
implanting a medical device, or gastric bypass surgery, which resections and reroutes the
small intestines to a small stomach pouch. A third approach is billiopancreatic diversion,
which is performed through the removal of a small portion of the stomach with a
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duodenal switch. Long term studies on obese people have observed that a significant
reduction in the body weight is associated with significant improvement in the
cardiovascular risk factors (Robinson, 2009).
1.8.4Bariatric surgery and renal function
Few studies have established the relation between bariatric surgery and renal
function. In a study of eight obese patients without kidney disease, the glomerular
filtration rate (GFR), renal plasma flow (RPF), BMI, and albuminuria were studied
before and after bariatric surgery and compared with controls (Chagnac et al., 2003). In
this study, obese patients had a higher baseline GFR and RPF than controls by 61% and
32% respectively. Over a period of 12 to 17 months, BMI decreased from 48 +/-
2.4kg/m2 to 32.1+/-1.5 kg/m2 and GFR and RPF both decreased by 24% and 13%
respectively. Albumin excretion also reduced with weight loss from 161lg/ml (range, 4 to
1521lg/ml) to 51lg/ml (range, 3 to 371lg/ml). Another study followed-up 61 extremely
obese patients over a period of 24 months after bariatric surgery and compared with
normal weight controls (Navarro-Diaz et al., 2006). At baseline the weight, BMI, GFR
(calculated by 24 hour creatinine clearance), and 24-hour proteinuria were higher in the
obese patients than in the controls. After one year, all the above parameters improved in
obese patients with only albuminuria continuing to decrease at the end of the second
year. This was attributed to the slowing of weight loss after the first year. In obese
patients with established CKD and ESRD, one study showed stabilisation or
improvement of the initial renal disease in nine patients out of 31 after bariatric surgery,
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but each was presented as a case study, and measurements were not uniform (Alexander
et al., 2(09).
Decrease in weight following bariatric surgery is associated with an improvement
in a number of cardiovascular risk factors. At two and ten-year follow ups it was shown
that surgery patients had a lower incidence rate of diabetes, hypertriglyceridemia, and
hyperuricemia than controls (van Etten et al., 2002, Dixon et al., 2008). Improvement in
left ventricular relaxation has been shown in adult obese patients after nine months post-
surgery (Ouchi et al., 2003, Leichman et al., 2(08). Reduction in left ventricular
hypertrophy has also been shown in adults with weight reduction post-surgery
(Ikonomidis et al., 2007).
1.S.S In vivo vascular studies in obesity
Endothelial dysfunction that manifests either as abnormal circulating products of
endothelial cells or impaired physiologic responses to endothelium-dependent vasodilator
stimuli has been demonstrated in both human and animal obesity (Laight et al., 2000). In
the animal model, impaired NO-dependent dilatation in muscular arterioles has been
observed in hypertensive diabetic obese rats using television microscopy, and vessel
dilatation was measured with a video micrometre (Frisbee and Stepp, 2001). The study
found that impaired vascular perfusion in obese rats was due to elevated oxidative stress.
In humans, several in vivo studies using non-invasive techniques have suggested
impaired endothelial function in the peripheral vessels of obese patients. Perticone et al.
assessed endothelial function through measurement of forearm blood flow in response to
acetylcholine (Perticone et al., 2001). The authors observed that the presence of
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endothelial dysfunction in obese humans is due to reduce NO bioavailability secondary
to the increased production of reactive oxygen species. Another in vivo study assessed
endothelial function in obese patients underwent a dietary restriction regimen through the
measurement of forearm blood vessels (Sciacqua et al., 2003). The study demonstrated
significant improvement in the maximal vasodilator responses of forearm vessels to the
high dose of acetylcholine in healthy obese subjects following an energy-restricted diet.
Moreover, endothelium-dependent and independent vasodilatation has also been assessed
in the forearm vessels of patients with visceral obesity using non-invasive
plethysmography (Nielsen et al., 2004). Arkin et al. examined endothelial function in two
groups of obese patients including super-obese group (BMI~50) and morbidly obese
patients (BMI~40), investigating the vascular response to endothelium-dependent and
independent vasodilatation using flow-mediated dilatation on brachial artery (Arkin et
al., 2008). The study observed significant impairment in endothelium-dependent
dilatation in the super-obese group compared with the other obese group, with similar
vasorelaxation response to nitroglycerin-mediated dilatation has observed between both
groups.
1.8.6 Ex vivo vascular studies in obesity
Several ex vivo studies have been conducted in animal models. Vascular and
cardiac functions have been examined in rats with diet-induced obesity (Boustany-Kari et
al., 2(07). The study observed increased vascular contractility and decreased coronary
vascular relaxation of isolated vessels to various stimuli. Chinen et al. demonstrated
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impaired endothelium-dependent vasodilatation in isolated aortic vessels of obese rats
using wire myography (Chinen et al., 2007). The author found that reduction in the
vasorelaxation response to Ach in obese Zucker rats was induced by FFAs and the
overproduction of ROS. It also observed that the vasorelaxation response to SNP was
identical in the two groups.
In humans. some studies have identified impaired endothelium-dependent
vasodilatation in isolated resistance arteries of obese patients. De Ciuceis et al. examined
endothelium-dependent vasodilatation in the isolated subcutaneous arteries of
normotensive and hypertensive obese patients compared to non-obese controls (De
Ciuceis et al., 2011). The study showed significant impairment in acetylcholine-
dependent relaxation in both normotensive obese and hypertensive obese patients
compared to controls. The authors also observed improvement in endothelial relaxation
in response to acetylcholine in a small number of obese patients one year after bariatric
surgery. Significant impairment in acetylcholine-induced relaxation has been observed in
isolated subcutaneous arteries from severely obese patients compared to lean subjects (P
< 0.01), with preserved endothelium-independent vasodilatation in response to SNP
(Grassi et al., 2010b). Impaired endothelial-dependent vasodilatation response has been
reported in other conditions such as diabetes mellitus. Rizzoni et al. observed impaired
vasorelaxation response of small isolated vessels to Ach and BK in normotensive and
hypertensive diabetic patients (Rizzoni et al., 200 1b).
In addition to microvascular disturbances, structural remodelling in small vessels
characterised by an increased media-to-lumen ratio has been observed in the obesity
milieu (Rizzoni et al., 2012). Vascular alterations such as thickening of the intima and
59
media of the vessel wall are frequently found in obesity, promoting endothelial damage
and initiating atherosclerosis and cardiovascular disease (Georgescu et al., 2011). Grassi
et al. also found that media thickness and media-to-Iumen ratio were significantly greater
in the subcutaneous resistance arteries of obese patients compared with non-obese
controls (Grassi et al., 201Ob). The authors also observed that these structural alterations
were accompanied by changes in endothelial function. Moreover, in a study compared 14
lean healthy controls, 13 obese patients, and 12 participants with metabolic syndrome
(Grassi et al., 2010a). Small arteries isolated from abdominal subcutaneous fats were
investigated for structural and functional properties. The study found that media
thickness and media-to-Iumen ratio of the resistance arteries were significantly greater in
the metabolic syndrome and obese groups compared with controls. Impaired Ach-
induced endothelium-dependent relaxation was also observed in the obese and metabolic
syndrome groups but not in the control group.
1.9 Vasoconstrictors
Vasoconstriction can be defined as a narrowing of the internal diameter of blood
vessels as a result of contraction of their muscular layer, particularly small arterioles,
large arteries and veins. This process is important for controlling haemorrhage and acute
blood loss (Hynynen and Khalil, 2006). The muscular layer of all blood vessels from
heart to capillaries are involuntary controlled in response to various substances,
chemicals and hormones resulting in either vasoconstriction or vasodilatation. During
constriction of blood vessels, blood flow is restricted or decreased resulting to an
increase in vascular resistance (Groeneveld et al., 1988). Generalised vasoconstriction
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usually causes an increase in systemic blood pressure; however, vasoconstriction may
also occur in particular tissues leading to localised reduction in the blood flow. This
process can initiate tissue ischemia and necrosis (Black et al., 2(03). One proposed
mechanism of vasoconstriction is that increased concentration of calcium (Ca2+ ions)
within vascular smooth muscle cells (Brayden and Nelson, 1992).
1.9.1 Noradrenaline (Norepinephrine)
Noradrenaline (NA) is an endogenous potent vasoconstrictor catecholamine that
acts as a-adrenergic receptor agonist. It is the neurotransmitter of the sympathetic
nervous system. It stimulates alpha adrenoceptors that are found throughout the vascular
system resulting in contraction of the muscular layer within the vascular system,
therefore causing restriction of blood vessels and elevation of blood pressure (Teerlink et
al., 1994). NA is chemically similar to adrenaline; both are synthesized and secreted from
adrenal glands. It is well-recognised that NA promotes high K+- depolarisation which
activates Ca2+ influx and induces maintained contraction whereas epinephrine induces an
initial transient contraction through releases of Ca2+ from the vascular cells, followed by
activation of Ca2+ influx to induce sustained contractions (Bolton, 1979). In humans and
animals, it has been shown that infusions of NA can elevates arterial pressure and
peripheral resistance without any changes on the cardiac output (Lansing and Stevenson,
1958). The vascular endothelium when exposed to vasoconstrictor stimuli such as NA, it
can modulates and maintains the normal vascular tones and homeostasis through the
secretion of endothelium-derived relaxing factors such as NO. NA has been tested in
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several ex vivo studies to assess the vascular function in uremic CKD patients (Morris et
al., 2001), hypertensive (Rizzoni et al., 2oo1a, Amann et al., 2001, Black et al., 2003),
and obese patients (Georgescu et al., 2011). Moreover, it has been tested in vivo to
examine the vascular reactivity in haemodialysis patients (HD)(Morris et al., 2000).
Intravenous infusion of NA in haemodialysis patients during haemodialysis session can
induce vasoconstriction and increased in the total peripheral resistance that improve
haemodynamic instability (Nette et al., 2006).
1.9.2 Endothelins
Endothelin is an endogenous potent 21-amino-acid vasoconstrictor amino acid
peptide produced primarily in the endothelium, discovered in 1980s (Yanagisawa et al.,
1988). There are four subtypes of endothelins including; ET-I, ET-2, ET-3, and ET-4.
The main isoform is endothelin-l (ET -1) which released from the endothelial cells and
acts by stimulating endothelin receptors in the endothelial cells and vascular smooth
muscles (VSM) resulting to control of cellular growth, proliferation and regulation of
vascular function (Luscher and Barton, 2000). The vascular endothelin system can
control and modulate vascular tone, growth, and function. ET-1 may contribute to the
elevation of blood pressure that observed in both human and experimental models, seems
to be a risk factor in many cardiovascular diseases (Hynynen and Khalil, 2006).
However, the exact roles of endothelins and its receptors in the regulation and
pathogenesis of hypertension is still unclear. The proinflammatory effects of ET-l
induces vasoconstriction may promotes fibrosis and it has an effects on the VSM through
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stimulation of specific receptors on the VSM cells resulting in VSM proliferation. This
may suggest the involvement of ET-l in the process of thickening of vascular intima and
media in uremic patients and therefore development of cardiovascular disease (Amann et
al.,2(01).
1.9.3 Thromboxane AIl (U46619)
Thromboxane A2 (TXA2) is a vasoconstrictor and potent hypertensive agent that
potentiates platelets aggregation. Firstly discovered by Hamberg et al. (1975) as an
eicosanoid that synthesized in platelets from prostaglandin H2 (archidonic acid
derivatives) through thromboxane-A synthase enzyme (Hamberg et al., 1975). The extent
of TXA2 induced alteration in the microcirculation is basically dependent on the
endothelial function. Endothelial damage such as endothelial calcification or
atherosclerosis may associated with a reduction in TXA2 inhibitors and thus promotes
platelet activation and adhesion at the site of endothelial injury, which ends by thrombus
formation (Schror, 1990). For that reason, in myocardial ischemia, the major source of
TXA2 seems to be due to platelet activation. TXA2 was shown to cause contraction in
human coronary arteries by thrombin-stimulated platelets, this kind of response was
resulting from platelet-derived TX2 (Ellis et al., 1976). It has been tested in vivo to
induce coronary vasoconstriction which in turn resulting to sever myocardial ischemia
and sudden death in rabbits (Lefer et al., 1980).
Similarly, Terashita et al. 1978 confirmed these vasocontractile effects in isolated
small coronary microcirculation in ex vivo animal model (Terashita et al., 1978). The
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study observed that TXA2 can cause strong contraction in renal vascular beds in isolated
glomerulous of rats (Cavarape et al., 2003). TXA2 was believed as predisposing factor
that lead to coronary and cerebral vascular ischemia as a result of its potent
vasocontractile effects associated with platelets aggregation (Smith et al., 1980).
1.9.4 Angiotensin II
Angiotensin is an oligopeptide hormone that acts as an endocrine hormone
constricting blood vessels and involved in the regulation of rennin-angiotensin system.
Angiotensin II (AngII) when given in low doses, may raise blood pressure slowly and
progressively (Griffin et al., 1991). It is derived from the precursor angiotensinogen, a
globulin that synthesized in the liver. Angiotensin I converted to AngII through removal
of two C-terminal residues via the enzyme called angiotensin converting enzyme (ACE)
(Skurk et al., 2001). AngII has a prothrombotic effect through aggregation and adhesion
of platelets (Skurk et al., 2001, Gesualdo et al., 1999). Renin-angiotensin system can be
activated during cardiac and vascular damage such as atherosclerosis and endothelial
alteration (Gesualdo et al., 1999). By stimulation of angiotensin-l receptor, AnglIcan
initiates different actions including vasoconstriction, sodium and water retention,
facilitates adrenergic nerve activity and production of reactive oxygen species.
AngII also acts as a vascular growth factor promoting vascular smooth muscle
proliferation and atherogenesis (Kanaide et al., 2003). An in vitro testing of AngII on the
vascular smooth muscle has been shown to have a mitogenic (Lyall et al., 1988) and
trophic effects (Berk et al., 1989). It has not been demonstrated to have these effects in
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vivo, though it's capability to promote a new vessel formation (Fernandez et al., 1985). In
the animal model, it has been observed that infusion of AngII in low doses for 10 days
raises arterial pressure slowly and progressively, causing structural change in resistance
vessels and increased cardiac weight (Griffin et al., 1991). AngII has been shown to
induce other vascular changes such as vascular smooth muscle growth, vascular cell
adhesion, deposition of extracellular matrix proteins, cell migration and inflammation
(Intengan and Schiffrin, 2(01). AngII has a role in the vascular hypertrophy through
significantly increase vascular media thickness and media / lumen ratio (Griffin et al.,
1991). The contractile effect of AngII has been investigated in vivo in rats by intravenous
perfusion of 100 oM (10-7 M) of the drug which potentiates the contraction of resistant
arteries through endothelial production of endothelin (Dohi et al., 1992).
1.9.5 Vasopressin
Vasopressin is a vasoconstrictor peptide hormone (also known as anti-diuretic
hormone), synthesized in the hypothalamus and secreted in response to hypovolemia,
hypotension, hyperosmolarity and sympathetic stimulation (see Figure 10). The
vasopressin prohormone with its glycopeptides is transported through nerve axons to pars
nervosa of the posterior pituitary gland where it is stored as granules (Giovannucci and
Stuenkel, 1997). It has the following two main principle sites of action: the first place is
in the kidney, it stimulates vasopressin 2 receptor (V2 receptor) located on the renal
collecting tubules and regulates extracellular fluid volume by increase water permeability
and decrease urine formation, leading to increase blood volume, cardiac output and blood
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pressure (Maturi et al., 1991). The second action is on blood vessels, vasopressin can
initiate the process of vasoconstriction and elevation of arterial pressure through
stimulation of V1 receptor on the vascular smooth muscle .
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The normal physiological concentrations of vasopressin are less than its
vasocontractile range. However, in severe hypovolemic shock or hypotension, the
production of vasopressin is increased resulting to compensatory increase in systemic
vascular resistance (den Ouden and Meinders, 2005). Vasopressin is a contractile agent
that increases systemic vascular resistance and causes an elevation in arterial blood
pressure. It has also been shown that infusion of low-dose vasopressin can promote renal,
cerebral and pulmonary vasodilatation mediated by endothelial release of nitric oxide
(Vanhoutte et al., 1984). Vasopressin has been tested to study vascular contraction in
isolated human cerebral arteries (de Aguilera et al., 1990). In this study human cerebral
medium size arteries (500 - 700 11m diameter) were isolated during autopsy of 15
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patients and cumulative concentration response curves for vasopressin were constructed
in arteries with endothelium and without endothelium (mechanically removed), the study
observed powerful constrictor effects of vasopressin on both groups through direct
stimulation of vasopressin-l receptor that located in the vascular smooth muscle.
1.10 Vasodilator agents
Vasodilatation is a mechanism that leads to relaxation of the smooth muscle of
blood vessels, either in the arteries, which results in decrease in systemic vascular
resistance or in veins, which leads to reduction in venous blood pressure (Shapira et al.,
1999). Some vasodilator agents, including arteriolar vasodilators, can be used in the
treatment of hypertension and heart failure, while venous vasodilators are effective in the
treatment of angina (Daly et al., 1984). Some vasodilator agents have functional ability to
dilate both arteries and veins. The vascular endothelium plays an important role in the
regulation of blood flow through mechanical control of vascular smooth muscle.
Common substances that mediate endothelium relaxation are nitric oxide (NO) and
prostaglandin 12 (prostacyc1in, PGI2), both of which are known as endothelium-derived
chemicals that exhibit a potent vasorelaxation (Tormakangas et al., 2006). The third
substance is endothelium-derived hyperpolarizing factor (EDHF) that mediates
hyperpolarization of smooth muscle cells through activation of potassium channels in
both smooth muscle and endothelial cells (Feletou and Vanhoutte, 1999). Arterial
pressure is also regulated by vasodilator substances such as bradykinin, acetylcholine,
mineral ions (potassium and magnesium), endogenous nitric oxide, carbon dioxide and
hydrogen gases.
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1.10.1 Bradykinin
Bradykinin (BK) is one of the most potent endogenous endothelium-dependent
vasodilator amino acid peptide that formed of nine amino acids. It causes vasodilatation,
increase vascular permeability and natriuresis (increase urinary sodium excretion)
causing reduction in blood pressure (Han et al., 2002). BK stimulates two types of BK
receptors including B1 receptor which expressed during tissue injury and inflammation
(Mclean et al., 2(00) and has a role in endothelial cells receptor pathway (Duchene et al.,
2007). The action of BK on B2 receptor is mainly associated with vasodilatation. It is
well recognized that BK stimulates endothelial cells resulting to release of different
vasorelaxant agents such as NO and EDHF (O'Kane et al., 1994). BK has been widely
investigated in many ex vivo studies of the vascular function (Rizzoni et al., 200 1b,
Hadoke et al.• 2000. Lang et al., 2(07). Moreover. it has been demonstrated that BK-
induced relaxation of isolated human coronary artery was principally endothelium
dependent (Forstermann et al., 1988. Okamura et al., 1989). Some studies showed that
BK stimulates the release of endothelium-derived nitric oxide (Forstermann et al., 1988)
and hyperpolarizing factor (Nakashima et al.• 1993). BK has also been tested in vivo as a
potent vasodilator in human forearm resistance vessels, resulting to vasorelaxation via
hyperpolarization of the vascular wall independent of NO (Honing et al., 2000).
1.10.2 Acetylcholine (Ach)
Ach is a neurotransmitter chemical compound that stimulates both peripheral and
central nervous system. Ach is primarily synthesized from their precursor compounds
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choline and acetate in neurons through the enzyme choline acetyltransferase (Blusztajn et
al., 1987). Ach acts to stimulate two main types of receptors including nicotinic receptors
which located in the muscles, central nervous system and autonomic ganglia. This type
of receptor is stimulated by both nicotine and Ach to promote sodium, potassium and
chloride permeability (Jones, 2005). The second type is muscarinic receptors, these
located in different tissue and organs in the body resulting to various biological
functions. Stimulation of Ach to muascarinic receptors in blood vessels and heart can
results to decrease cardiac contraction and cardiac output. Ach stimulates endothelium-
dependent vasodilation in most of isolated mammalian arteries (Vanhoutte and Miller,
1985). This relaxation is mediated by activation of muscarinic receptors on the
endothelial cells (Furchgott and Zawadzki, 1980), resulting to increase production of
cyclic guanosine monophosphate (cGMP). Endothelial cells that exposed to Ach
stimulation can produce various diffusible substances known as endothelium-derived
relaxants. Early studies have proposed that adenosine and adenosine monophosphate are
endothelium-dependent relaxant factors, however many substances released from the
endothelium in response to Ach promotes the vasorelaxation mechanism, these factors
are known as endothelium-derived hyperpolarizing factors (EDHF) (Furchgott and
Zawadzki, 1980).
1.10.3 Sodium nitroprusside (SNP)
SNP is a complex chemical compound that has a potent endothelium-independent
vasorelaxation effect. It was first prepared and investigated in the middle of nineteenth
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century (Lefebvre, 1995). The hypotensive action of SNP was established first in 1929. It
has been given intravenously in severe and acute hypertensive emergencies and during
surgical procedures to control blood pressure. It is also an effective vasodilator agent in
congestive heart failure (Subramanyam et al., 1982). SNP breaks down in the blood and
releases NO which activates the guanylate cyclase in the vascular smooth muscle and
enhances the production of intracellular (cGMP) which in tum promotes the process of
smooth muscle relaxation and therefore vasodilation (Grossi and D'Angelo, 2005). It has
been frequently used to test endothelium-independent vasodilation in many ex vivo
(Morris et al., 2001, James et al., 2006, Rizzoni et al., 2006, Thuraisingham and Raine,
1999) and in vivo studies (Morris et al., 2000, Hand et al., 1998, Annuk et al., 2001) in
humans and animals.
1.11 Aims ofthe thesis
Alterations in the microcirculatory structure and function may be considered an
important mechanism of organ damage. This project has been planned to test the
following hypothesis:
Uremia and obesity induces alteration in the vascular function through variable
enhancement in the contractile responses of isolated different-sized arteries of HD and
obese patients respectively in response to various vasoconstrictors, and impaired
endothelium-dependent vasodilatation with preserved endothelium-independent
vasodilatation. This alteration may progress to development of major cardiovascular
consequences in both risk groups.
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Ex vivo assessment of vascular function in uremic and obese patients is not a new
technique and has been carried-out in few studies. However, most of previous studies
were focused on investigating small-sized arteries in response to a limited suit of
vasoactive agents. This study is novel in that it is designed to investigate the vascular
function in different-sized arteries isolated from subcutaneous fats of a homogenous
uremic group of patients who purely on HD and obese patients underwent bariatric
surgery with comparison to non-uremic non obese control groups. Since pulse wave
velocity (PWV) as measures of arterial stiffness is correlated with increased risk of
cardiovascular disease in both risk groups, we hypothesised presence of a relationship
between elevated PWV and changes in the ex vivo vascular function. Therefore to test
this hypothesis the following aims will be addressed:
Firstly, to investigate the vascular function in isolated different-sized arteries
obtained from subcutaneous fats of HO patients using wire myography, to establish
whether uremic HO patients show enhanced vasocontractility and impaired endothelial-
dependent vasodilation. In addition, to assess how that ex vivo intrinsic function
correlates to in vivo assessments of cardiovascular status. The results of these aims are
presented in chapter 3.
Secondly, this study also aimed to assess an arterial function in isolated different-
sized arterial segments obtained from subcutaneous fat of obese patients undergoing
bariatric surgery. This was to investigate the vascular reactivity in obese patients through
measurement of their responses to different vasoconstrictors and vasodilators. The study
also addressed changes that might underlie altered vascular responses associated with
obesity and following surgery (decrease in weight). This work is presented in chapter 4.
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Chapter 2
General Methodology
Chapter 2: Methodology
2.1 Ethical approval
The study recruited haemodialysis (HD) patients for subcutaneous fat samples,
entering them in multi-centre randomised controlled cross-sectional trials. The recruited
patients were all males and females willing and able to provide consent, age ~ 16 years
old, all within the 90 days of having started dialysis at least 03 times a week. They will
be recruited from both main hospital and satellite dialysis units of five centres (Derby
Hospitals NHS Foundation Trust, University Hospitals of North Staffordshire NHS Trust
at Stoke, University Hospitals of Leicester NHS Trust, Heart of England NHS
Foundation Trust and University Hospital Birmingham NHS Foundation Trust in
Birmingham. Obese patients involved in the observational study "Improvement of Renal
Disease and Cardiovascular Function in Patients Undergoing Bariatric Surgery" were
recruited for subcutaneous fat samples. This study was conducted according to the
standards of Good Clinical Practice Guideline, Research Ethics Committee regulations,
Trust and Research Office policies and procedures. All protocols were approved and
granted by the Derbyshire Research Ethics Committee and the local NHS Research &
Development department to allow for the collection of subcutaneous fat biopsy samples
from HD patients, obese patients, and normal controls (non-HD, non-obese patients).
All participants were provided with an information sheet describing their biopsy
procedure and with sufficient information for subjects to make an informed decision
about their participation in the study. Subjects signed a consent form to indicate that they
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were giving their valid consent to participate. Few and minimal risks to the subjects were
associated with the biopsy technique.
2.2 Human subcutaneous fat samples
2.2.1 Background
The majority of subcutaneous fat biopsies that have been previously studied to
examine vascular function by myography were obtained from either a patient's gluteal
region or an anterior abdominal wall, and they were obtained under local anaesthesia
using 3-5 ml of 1% or 2% lignocain hydrochloride (Rizzoni et al., 2003, Aalkjaer et al.,
1987, De Ciuceis et al., 2(07). In these studies, the biopsy size varied from 1-3 cm long,
0.5-1 em wide and 0.5-1.5 em deep. These biopsies were taken through a standard skin
biopsy technique using a horizontal (1-2 em-long) incision of the skin in the upper
external gluteal quadrant or lateral abdominal wall. Many ex vivo studies have used this
technique to obtain fat samples of 1 cm long, 0.5 cm wide and 0.5 cm deep from
superficial gluteal tissue (Joannides et al., 2006, Wang et al., 2000, Wang et al., 2003,
Intengan et al., 1999). In the present study, human subcutaneous fat biopsies were
obtained from the following sources: haemodialysis patients (to measure ex vivo vascular
function in haemodialysis patients, and to establish the effects of uraemia on vascular
function); obese patients (to investigate the vascular reactivity in obese patients, and to
study changes in the vascular response that might occur following bariatric surgery); and
from non-haemodialysis, non-obese control patients (to compare them with the
haemodialysis and obese patient samples).
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2.2.2 Human haemodialysis fat samples
The present study involved HD patients in a multi-centre, randomised controlled
cross-sectional trials ''The effects of cooling a dialysate on systolic dysfunction in
Haemodialysis patients". This study is conducted by our research team to investigate
whether or not cooling the dialysate fluid will reduce the degree of cardiac systolic
dysfunction and the incidence of cerebral ischemia. In this study, patients were randomly
given either standard temperature dialysis or individualised cooled dialysis within 90
days of starting HO. The recruited patients were included males and females aged ::::16
years old having HO treatment at least three times per week. Patients with heart failure
grad IV and cardiac transplant recipients were excluded. Consenting patients underwent
two visits: a baseline assessment visit and a follow-up visit after one year. Investigations
that were carried out in each visit are illustrated in (Figure 11). In each visit (that taken
on the non-HD session day), all patients had cardiac and brain MRI at Nuffield Hospital /
Derby. Thereafter, each patient was transferred to the study area at Graduate Entry
Medical School, University of Nottingham, Royal Derby Hospital/Department of Renal
Unit for fat sampling.
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Figure 11 Summary of cooling study including the time of fat sampling.
All subcutaneous fat biopsies were performed by trained renal researchers who
conducted the cooling study using local anaesthetic (1% lignocaine, 2-3 ml). A small (1-
2 em long) right or left lower lateral abdominal single transverse incision was made
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under full aseptic technique. The subcutaneous adipose tissue was then dissected
carefully and separated from the adherent skin using a scalpel. Using a forceps, a piece of
fat was held up gently and, using surgical scissors, a piece of subcutaneous fat tissue was
taken (in the majority of samples the piece of fat was small diamond in shape with nearly
1.5cm long, 1 cm wide and 1 cm deep).
Following cleaning and cessation of any small bleeding from the site of the
operation, the wound was closed under full aseptic technique using 2-3 wire sutures.
Suture removal occurred during the normal healing time. which was usually less than two
weeks. In our patients, the majority of samples were straightforward, taken without
complications. However. two patients developed prolonged bleeding that was relieved by
prolonged pressure on the site of operation.
All samples were immediately placed in chilled physiological salt solution (PSS)
and transferred to the clinical sciences laboratory department for dissection and mounting
of vessels to the myography (see myography techniques, section 2.4) on the same day of
biopsy.
2.2.3 Human obese fat samples
Subcutaneous fat samples were obtained from patients undergoing bariatric
surgery. This was part of a prospective observational study "Improvement of Renal
Disease and Cardiovascular Function in Patients Undergoing Bariatric Surgery,
observational single centre pilot study". The study was designed to investigate the effects
of obesity on vascular function, renal function and cardiovascular function before and
after surgery. All non-diabetic, non-cirrhotic obese patients with age of 18 or over were
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invited to participate in the study. Each patient was assessed at four weeks before surgery
and then again at three and six months post-surgery (details of patient's assessment in
this study are described in Figure 12). Samples of subcutaneous fat tissue were obtained
at zero months (baseline samples) and at six months post-surgery. The baseline
subcutaneous fat samples were approximately 2cm long, 1.5 cm wide and 1.5 cm deep
was taken at the time of operation using laparoscopic port. The second subcutaneous fat
samples were obtained at six months following bariatric surgery using extra lower
abdominal incision (as described in HD fat samples). Once harvested, the biopsy was
immediately transferred in a container with chilled PSS to the laboratory sciences
department for dissection and mounting on the same day of the biopsy (as described in
section 2.4.3).
2.2.4 Control fat samples
Normal control samples were provided from appropriately consented patients
(non-obese non-haemodialysis patients) who underwent either elective laparoscopic or
abdominal surgery (elective hernia repair). All information about the size of fat biopsy
that must be obtained to get enough sample size was provided to the surgeon who
responsible to take the biopsy. Most of the samples that harvested from these patients
were approximately 2cm long, 1.5 cm wide and 1.5 cm deep). Following harvesting,
samples were immediately transferred in cold PSS to the laboratory sciences to be
dissected and experimented on the day of biopsy as described before.
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• Padents Identified from referral
I.ttera and Information sheet
sent with explanatory letter
Inclusion criteria:
Male or female. aged ~18 years
Undergoing barlatrlc surgery
Willing to provide consent
Exclusion criteria:
Diagnosis of diabetes
Liver cirrhosis
Chronic Kidney Disease stage 5
Unable to stop ACEUARB
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Inability to understand English
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• lohexol clearance
• Cardiovascular assessment
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Figure 12Bariatric study design and timeline.
* Angiotensin Converting Enzyme inhibitors (ACE) and Angiotensin Receptor Blockers (ARB).
(The figure Adapted from bariatric study protocol).
• Fasting bloods
• 24 hr urine collection
• lohexol clearance
• Cardiovascular assessment
• Body assessment
• Fat sampling (If consented)
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2.3 Materials
2.3.1 Physiologic salt solutions
Two types of solution were made to conduct each experiment. These including;
Physiologic Salt Solution (PSS), which is a solution that intended to act as a medium for
maintaining live tissue and blood vessels providing some buffering to maintain the pH of
the solution. It is composed of different salts with different concentrations (Table 5).
Sodium chloride (NaCL). potassium chloride (KCL). calcium chloride (CaCL), sodium
bicarbonate (NaHC03), calcium dehydrate (CaClz,2H20), Dsglucose, and EDTA were
purchased from Sigma-Aldrich (USA), while magnesium sulphate (MgS04.7h20) and
potassium dihydrogen sulphate (KH2P04) were purchased from Fisher Scientific
Chemicals (UK) and BDH Laboratory Suppliers (UK) respectively. The second type of
physiologic solution is Potassium Physiologic Salt Solution (KPSS), which is the same as
PSS, but with potassium chloride concentration (124 mmollL) substituted for sodium
chloride (Table 5.1). KPSS is used to assess the integrity of arteries by their ability to
contract by at least 5 mN (0.5g tension) to a high KPSS buffer. It has been determinant
that high K+- depolarization activates Ca 2+ influx to induce maintained contraction.
Table (5 and 5.1) illustrates the molecular weight and concentration of different
chemicals that make both PSS and KPSS that have been used in all experiments. Salts
were dissolved completely in double distilled water before adding the calcium chloride.
The mixture was bubbled in 5% CO2 in O2 for 20 minutes and then the calcium chloride
was added to the mixture. The solution was bubbled again for a further 10 minutes until
79
the pH of the solution reached 7.4. Both solutions were made on the day before the
biopsy conduction and stored in cold room (-4c).
Table 5 The composition of PSS.
Chemical Molecular weight Concentration (mmol/L) Amount g/L
Sodium chloride 58.44 119 6.954
(NaCL)
Potassium chloride 74.56 4.7 0.35
(KCL)
2.5 0.368Calcium dehydrate 147.02
(CaCL2.2H20)
5.5 1.091
Mesium sulphate 246.68
(MgSO". 7H20)
25 2.1Sodium bicarbonate 84.01
(NaHCO\) 1.18 0.161
Potassium phosphate 136.1
(KH2PO,,) 372.24 0.027 0.010
EDT A
D-Glucose 198.77 1.17 0.289
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Table 5.1 The composition of KPSS.
Chemical Molecular weight Concentration (mmol/L) Amount g/L
Sodium chloride 58.44 0 0
(NaCL)
Potassium chloride 74.56 123.7 9.223
(KCL)
0.368Calcium dehydrate 147.02 2.5
(CaCL2.2H20)
1.17 0.289Mesium sulphate 246.68
(MgSO.. 7H20)
84.01 25 2.1
Sodium bicarbonate
(NaHCO,)
136.1 l.18 0.161
Potassium phosphate
(KH2PO.) 372.24 0.027 0.010
EDTA
D-Glucose 198.77 5.5 l.091
2.3.2 Vasocontractile agents
Vasoconstrictor agents that have been investigated in this project included; L-
Noradrenalin hydrochloride (NA), endothelin-l (ET-I), a thromboxane All mimetic
(U46619), angiotensin II (AngII) and vasopressin. L-Noradrenalin hydrochloride (lOO
mg) and vasopressin acetate salt (Irng) were purchased from Sigma-Aldrich (UK), while
ET-I, a human porcine (lOO ug), U46619, (lmg) and AngII (5mg) were purchased from
Tocris Bioscience (USA). These drugs have been tested to examine vascular function in
resistant arteries in ex vivo and in vivo studies as described in introduction chapter. 1 mg
of L-noradrenalinhydrochloridepowder (M. Wt = 205.64)was dissolved in 486.3 ~L of distilled
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water and stock concentration of 10-2 M (10 mM) of the solution was prepared. ET-1 10-4M
(100 J.1M)was made and stored as stock concentration by adding ET-1 human porcine
100 ug (M. Wt = 2492) to 401.3 ilL distilled water. Stock concentration of U46619 10-2 M
(10 mM) was made by dissolve 1 mg of U46619 (M. Wt = 350.5) in 285.3 J.1Lof methyl
acetate. AngII (M. Wt = 1046.2) was purchased as 5 mg powder and the drug was
dissolved in 477.9 ul, of distilled water to make 10-2 M (10 mM) stock concentration.
Vasopressin 10-3 M (1 mM) stock concentration was prepared by dissolve 1 mg of
vasopressin acetate salt (M. Wt = 1084.2) in 922.3 fJLdistilled water. Fresh serial dilutions
from stock concentration of these vasocontractile agents were prepared on the same day
of experiment.
2.3.3 Vasodilator agents
Vasodilators that have been examined in this project were include; acetylcholine
(Ach), sodium nitroprusside (SNP) and bradykinin (BK). Ach and SNP (25 g bottles)
were purchased from Sigma-Aldrich (UK), while BK (5 mg) was purchased from Tocris
Bioscience (USA). These agents have been used to investigate vascular function in ex
vivo and in vivo studies (see introduction chapter). Ach 10-2 M (10 mM) stock
concentration was made by dissolve 1 mg of Ach powder (M. Wt = 181.66) in 550.4 fJL
distilled water. SNP 10-2 M (10 mM) stock concentration was made by dissolve 1 mg of
SNP dehydrate solid powder (M. Wt = 298.0) in 335.5 ul,distilled water. The Ach and SNP
stock concentrations and fresh serial dilutions were prepared on the same day of
experiment. BK 10-2 M (10 mM) was made and stored as stock concentration by
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dissolve 5 mg of BK white solid powder (M. Wt = 1060.2) in 471.6 J.1Ldistilled water. Fresh
serial dilutions of BK were prepared on the same day of biopsy. Details of different
vasocontractile agents and their stock concentration, dissolves and concentration curves
are described in Table 6.
Table 6 Vasoactive drug concentrations.
Drug Stock Concentration Dissolved in Cumulative Concentration
Noradrenaline 10.
2 M(10 mM) Distilled water 100pM-IOO JIM
Endothelin-1 10'" M(100 JIM) Distilled water 1 pM -1 JIM
U466l9 10.
2 M (10 mM) Methyl acetate 1 pM -1 J.1M
~
Angiotensin n 10'· M(10 mM) Distilled water 1 pM -1 JIM
Vasopressin 10·3M(1 mM) Distilled water 1pM -1 JIM
.~
Bradykinin (BK) 10· M(lOmM) Distilled water 100 pM-lOO JIM
Acetylcholine (Ach) 10.2 M(10 mM) Distilled water 100 pM-lOO JIM
~
Sodium nitroprusside (SNP) 10'· M(10 mM) Distilled water 100pM-lOO JIM
Abbreviaticas are: M, molar; m~1,millimolar; JI~I, micromolar; pM, piccmolar
2.4 Wire myography
2.4.1 Background
Wire myography is an in vitro technique that is used to investigate the functional
responses and vascular reactivity of isolated low-resistance vessels. This technique
allows an in vitro measurement of both active and passive properties of small arteries
(with internal diameter 60 to 300 J.1m) under isometric conditions as described before
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(Mulvany and Halpern, 1977). In the present study we used multi-chamber wire
myography. This model of myography was intended for the study of four isolated vessel
ring preparations with diameters ranging from 60 to 1000 urn, which were assessed
simultaneously, arteries with diameter larger than 1000 urn were mounted using hocks.
Each round chamber is stainless steel (for easy cleaning) and it has separate controlled
gas inflow and suction conduits (Figure 13). The sensitive force transducer permits
measurements of isometric muscle tension, while the micrometer site allows the setting
of vessel diameter. This system is automatically heated to a user-defmed set temperature.
Figure 13 Multi chamber wire myograph system-620 M.
The apparatus composed of; two stainless steel jaws, micrometer, force
transducer, ports for oxygenation and solution removal and two mounting wires (30 urn
to 40 urn diameters) (Figure 14). In this system, vessel segments are threaded on two
small wires (40 urn) as a ring preparation. Each wire is secured to each of the jaws, one
of the wires is fastened to a force transducer and the other is attached to micrometer for
adjustment of vessel circumference and the application of tension (Figure 15).
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This arrangement can helps to measure the following parameters; internal circumference
of the vessel, wall tension, isometric force responses to chemical drugs (agonists and
antagonists), effective pressure, and media to lumen ratio (MIL) of blood vessels in
normalized condition.(Rizzoni et al., 2003).
Figure 14 Myography jaws.
Figure 15 Vessel segments are threaded on 2 stainless steel wires in the myography.
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2.4.2 Myography calibration
The myography was calibrated before each experiment. Standard operating
procedures, settings and the protocol for myography calibration are attached in the
appendix 1 (chapter 6).
2.4.3 Myography
2.4.3.1 Dissection procedure
After the biopsy was obtained following surgical procedure, the sample was
immediately placed in cold PSS (4 CO) and transferred to the laboratory. It was placed
onto a dissection tray (about 9 cm in diameter) under the microscope. The dissection tray
contains ice-cold PSS. Under a dissecting microscope, manipulation and dissection of the
vessels was carefully and gently carried out using dissection scissors and Dumont forceps
to search for arteries. Some features can helps to differentiate between arteries and vein
such as arterial wall usually thicker than venous wall, the branch point of arteries are V-
shaped compared to U- shaped in veins (figure 16), and the lumen of the vein usually
collapsed.
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Vein U-shaped
V-shapedArtery
Figure 16 Differences between the artery and the vein
During the dissection procedure, adipose tissue was dissected away to expose the
artery and vein to identify them, then the vein was dissected away from the artery using
scissors to cut the connective and adipose tissue between them. The fine membrane
between the artery and adipose tissue was carefully cut to avoid any damage that might
happen to the artery, and then the artery was cut away from the tissue and placed in a
fresh beaker of iced PSS. The excess sample was disposed in a container tube to be
wasted in disposable bin and not be used for further investigation. The arteries were
taken from the beaker and placed back onto a clean dissecting petri dish with fresh PSS.
The arteries were further cleaned of all excess tissue using scissors and forceps. Once the
artery was cleaned, it was cut into small segments (2-3 mm). Arterial segments were
placed into a clean beaker with fresh PSS to be ready for mounting. The duration of
vessel dissection, cleaning and cutting into segments were ranged from 1-3 hr depends on
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the size and vasculature of subcutaneous fat samples. Some samples especially from HD
and controls patients were small containing few and small superficial branches that been
difficult to dissect and mount.
2.4.3.2 Mounting procedure
Following dissection and cleaning procedure, vessels are ready for mounting as a
ring preparation on the myography (see Figure 17). The equipment that required for
mounting procedure includes: a stereomicroscope, fibre light source, two pairs of fine
forceps, and pair of fine scissors, small screwdriver and wires.
Comec1edlo
micrometer
Connected ID force
tIalsdueer
Figure 17 Diagram of small arterial segments mounted in wire myography
The figure is adapted from (Wang et aI., 2000).
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Myography chambers were filled with cold PSS (about 3 ml), and arteries were
mounted one by one under the microscope with the micrometer support to my left, and
partly both jaws were closes. The first wire was hold with forceps and placed between
the two heads of the jaws, when the wire was in position, both jaws were tightening
together. The bottom end of the first wire was fixed to the bottom left screw. The vessel
segment to be investigated was gently hold and placed close to the proximal end of the
wire (I had hold the arteries using the adherent tissue of the vessel by the tips of forceps,
then the artery was mounted onto the wire. Both jaws now were released (jaws were
opened) and the segment was pulled gently towards the space between both jaws. The
top end of the wire was fixed to the top left screw. The second wire was carefully guided
into the lumen of the vessel along the first wire. Both jaws were adjusted closely
together, and carefully the top end of the second wire was fixed under the top right screw
head (at this stage 1 have looked at the vessel to be not stretched or moved in the
longitudinal direction). The lower end of the second wire was fixed under the bottom
right screw head. Both wires now were parallel, straight and tight. Once mounted, the
myography tail is connected to the interface, with all vessels kept at 37°C in PSS and
aerated with 5%C02 and 95%02.
2.4.3.3 Normalization
The normalization of microvessels has been investigated by Professor Michael
Mulvany who determined that the optimal pre-tension conditions (internal
circumference) for microvascular studies is best defined as the size when the vessel is
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fully relaxed and under a trans-mural pressure of 100 mmHg (Mulvany and Halpern,
1977). It is a process during which the artery will be measured and stretched to an
optimum tension (0.9 Ll00). The aim of the normalization procedure is to determine the
internal circumference at which the vessel would be relaxed and under a transmural
pressure of 100 mmHg. A standard normalization procedure can be achieved after three
to four stretches of arteries by applying effective transmural pressure exceeding 13.3kpa
(100 mmHg) (Hadoke et al., 2000, Schiffrin et al., 2002), then the internal circumference
of the vessel will be calculated (Mulvany and Halpern, 1977). In the present study, we
aimed to dissect different-sized subcutaneous arteries which categorized into small
subcutaneous arteries with diameter < 600 J..1mand large subcutaneous-sized arteries with
diameter > 600 J..1m. This classification based on the literature, where some studies have
classify small arteries with diameters < 600 J..1m(Paisley et al., 2009, Rizzoni et al., 2012)
and the others categorized large arteries with ID > 600 J..1m(Blacher et al., 2002, Hadoke
et al., 2000, Lu and Kassab, 2011). Before the experiment has been conducted, the
myography was calibrated one day before the experiment or being calibrated recently
during two weeks before the experiment. During the normalization of vessels, all
myography jaws were closed together and the normalization process was started by
applying the tension on the vessel (stretching of vessels) gradually using the adjusting
micrometer until the pressure of 13.3 KPa or more has obtained and the internal
circumference (lC) of the vessel was recorded by Lab Chart Program. The internal
diameter of the arteries (ID) was then calculated by dividing the internal circumference
by n as following:
ID (J..1m)= IC In (3.12)
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2.5 General protocol of experiment
Following mounting, and warming process, resistance vessels were continuously
bubbled with 5% C02 and 95% 02 for about 30 minutes, and then arteries were
subjected to standard normalization process. The integrity of arteries was tested by their
ability to contract by at least 5 mN (0.5g) tensions either to a high potassium physiologic
buffer KPSS or contract to a thromboxane A2 mimetic (U46619). Following
normalization procedure, arteries were first exposed twice to a high KPSS solution. After
KPSS stimulation in each conducted segments, arteries were washed-out three times
(every 2-3 minutes) with PSS solution to allow arteries relaxed back to the baseline. All
arteries were then contracted by stimulating them using 50 nmol/L (5 x 10-8 molar)
thromboxan A2(U46619) with addition of 10 nmol/L U46619 every 3-5 minutes for each
artery until the plateau contraction phase had been reached. Once the fixed contraction
has reached, then 10 IlM of bradykinin (endogenous vasorelaxant) was added to assess
whether the endothelium function / intact. Then all arteries were washed-out again three
times (every 2-3 minutes) with PSS until the base line have been reached. Vessels that
respond to contraction by at least (5 mN) to either KPSS or U46619 were completed the
cumulative concentration response curves for different vasoconstrictor agents. Whereas
those did not respond to both KPSS and U46619 were discarded.
2.5.1 Vasoconstrictor protocol
Once all arteries have been relaxed back following a wash out of vessels and re-
establish the base line (as described in the general protocol), cumulative-concentration
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response curves were constructed for the following vasoconstrictors; NA (10-10 mollL -
104 mollL), ET-l (10-12 mollL - 10-6mollL), U46619 (10-12 mollL - 10-6 mollL), AngII
(10-12 mollL - 10-6 mollL), and vasopressin (10-12 mollL - 10-6 mollL). In each
myography chamber, stimulation of each arterial segment with specific drug was starting
with the lowest concentration of the drug allowing 3-5 minutes per stimulation until the
highest concentration. The cumulative concentration of each drug is detailed in Table 6.
In each experiment, we dissected different-sized arteries (ranged from 6-12 segments
depends on the arteries available in each fat sample). Therefore, we could not test the
arterial segments that dissected from each patient to all vasoconstrictors. We planned that
the target number of arterial segments in each sized-arteries of HD and obese groups is 6,
while in control group is double of those of HD which is 12. However, we did not dissect
different-sized arteries from each patient (in all groups), the reason for that because few
numbers of samples were small in size and consists only of small arteries and capillaries.
2.5.2 Vasodilators protocol
Separate protocol was carried out for vasodilator drugs. Following a washout
period and re-establishment of the baseline (as described in the general protocol), arteries
was first contracted using a combination of (100 nmollL U46619 and 1 nmollL ET-1).
Once the peak steady contraction of arteries had reached, cumulative-concentration
response curves were constructed for different vasodilator drugs including BK, Ach, and
SNP. Stimulation of each artery with a specific drug was starting from the lowest
concentration of the drug to the highest concentration, allowing 3-5 minutes per
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stimulation (Table 6). The drug concentration that used for these vasodilators was started
from lOOpM (10-10 molar) to lOOJ.1M(10-4 molar).
Similarly, we could not test the arterial segments of each patient (in all groups) to
all vasodilators. For example, some patients were tested only to BK and SNP but not
Ach, since in some samples; there were no enough segments to test them to each of
vasoactive agent.
2.5.3 In vivo haemodynamic measurements
PWV and blood pressure were measured in a supine position after 10 minutes
rest. Brachial artery blood pressure was measured in the non-fistula arm using an
oscillometric device (Datex-Ohmeda, GE Healthcare, USA). Carotid-to-femoral arterial
PWV was measured using an oscillometric device (Vicorder, Skidmore Medical Ltd,
Bristol, UK) as previously described (Pucci et al., 2013). A carotid pressure cuff is
applied over the neck to detect the right carotid artery and a pressure cuff is placed
around the proximal right upper thigh to detect the femoral artery. The distance from the
suprasternal notch to the middle of the thigh cuff was measured and entered into a PC
running the Vicorder software. The cuffs are simultaneously inflated to a low pressure
40-60 mm Hg and signal from each cuff is analysed to derive arterial transit time. PWV
is calculated by the software by dividing arterial transit time by measured distance. The
mean of 2 measurements was recorded.
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2.6 Statistical methods
The statistical methodology varied depending on the individual analysis used. All
statistical analysis was undertook by the author using software package prism 5 for
windows (GraphPad Prism-5 software Inc, San Diego, USA) and SPSS V12 (SPSS Inc,
Chicago, USA). Some complex statistical analysis was advised by an independent
statistician employed by Nottingham University and by our colleagues conducting
cooling study. The power calculation is based on detecting a significant change in
increased vasocontractility in response to vasoconstrictors and / or decreased
vasorelaxation in response to endothelium-dependent vasodilators from the baseline. A
sample size would appear to be sufficient to detect a significant difference between the
groups. The sample size is also similar to the previous studies that using similar
technique (Morris et al., 2001, Luksha et al., 2011). However, not all the arterial
segments that dissected from the fat samples were included in the analysis, arteries those
did not respond to KPSS and I or U46619 were discarded.
Once each experiment has completed, increased in contraction for each drug stimulation
was recorded from the Lab Chart, then all data was transferred to the excel file. Increased
in milliNewtons (mN) from the base line for each agent in each artery (Rmax) was
calculated as following:
Rmax = contraction per stimulation (mN) - base line (mN)
However, the percentage relaxation from the preconstrictor state (Rmax) for each
vasodilator drug was calculated as following:
~ = preconstriction stable contraction (mN) - base line (mN)
R = relaxation per stimulation (mN)
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% relaxation = preconstriction stable contraction (mN) - R I ~ x lOO
All continuous variables were tested for normality using their histograms and
normality tests. Contractile responses were expressed as an increased contraction in
milliNewtons (mN) above the isometric baseline and related to vessel segment length
(mm), which described the developed wall tension (mN/mm). The maximum contractile
response (Rmax) for each agent in all groups were calculated and drug potency (EC50)
value (defined as the concentration of drug required to produce 50% of the maximum
response), while the response for vasodilators BK, Ach, and SNP was expressed as
maximum % relaxation from the preconstriction state. All data were expressed as mean
with standard error of the mean (mean ± SEM). The differences were tested at multiple
dose-response time points for all data. The comparison between HD and control groups,
obese and control groups was carried out using students Hest for unpaired observations
and the differences were considered significant when P < 0.05. PWV and blood pressure
data of each HD and obese patient were correlated with the response of each vessel size
to each vasoconstrictor and vasodilator drug. PWV data was expressed as mean ± SEM
and the analysis was undertaken using either SPSS V12 and / or GrapbPad Prism-5
software. The comparison of in vivo haemodynamic measurements of PWV and blood
pressure with ex vivo responses of all sized arteries to different stimuli was undertaken
using spearman's rho correlation coefficient. The correlation was considered significant
at *p = 0.05, and **p = 0.01 levels (2-tailed). Arterial segments that dissected from
obese patients at six month following bariatric surgery were experimented to the same
vasoactive agents that experimented in obese patients at baseline. Differences in the
arterial responses of obese patients before and after surgery were determined either by
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paired Hest or repeated measures of two-way analysis of variance (ANOVA) with
Bonferroni's post tests for multiple comparisons.
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Chapter 3
Results of Haemodialysis patients
Chapter 3: The effect of lID on vascular function in isolated
subcutaneous arteries.
3.1 Introduction
HO patients are characterised by a wide range of both structural and functional
abnormalities of the cardiovascular system. These include small vessel vascular structure
and function. There is strong emerging evidence that the HD procedure itself causes
significant systemic circulatory stress (Burton et al., 2009). This circulatory stress
interacts with complex haemodynamic factors causing perfusion anomalies that
accelerate end organ damage in a wide range of vulnerable vascular beds (McIntyre,
2010). Fixed structural abnormalities of the vascular tree develop during the lifetime of a
progressive CKD patient. These include coronary arterial calcification and other drivers
of reduced arterial compliance. These changes are the result of fixed vascular structural
change but importantly additional functional microvascular abnormalities are potentially
superimposed onto these processes (Sigrist and McIntyre, 2(08). These may be more
important in determining the propensity to multi organ based demand ischaemia.
It is unclear to what degree the observed abnormalities of microvascular function
are related to the uremic milieu and exposure of relatively normal vasculature to a variety
of functionally modifying factors, and to what degree there are intrinsic defects in pressor
response in these vessels. Vascular endothelium plays an important role in the regulation
of vascular function and tone through production and release of a wide range of
vasoactive substances including endothelin, nitric oxide (NO), and thromboxane A2
(Stankevicius et al., 2(03)
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Arterial hyperreactivity to some vasoconstrictors such as noreadrenalin (NA) and
endothelin-l (ET -1) has been shown in isolated subcutaneous arteries from uremic CKD
patients (Morris et al., 2(01). However recent studies observed similar contractile
response to NA and ET-l between the isolated arteries of ESRD (patients starting PD)
and controls (Luksha et al., 2012). In fact, there are no data available about the effect of
HO on the isolated arterial response to different vasoconstrictors.
Vascular endothelium plays a crucial role in the regulation and control of vascular
tone through release of various vasoactive substances. Vasorelaxation is mediated by the
release of endothelium-derived relaxants including nitric oxide (NO) and prostaglandin
12 (Stankevicius et al., 2003). Both substances are known as potent endothelium
vasodilators (Tormakangas et al., 2006). Vascular endothelium would seem a reasonable
target for different factors that ends by alterations in their function and structure.
Different mechanisms have been proposed to cause endothelial dysfunction in
HO patients, which is largely due to a defect in the endothelial NO bioavailability
(Baylis, 2008). Several uremia-associated factors (discussed in details in section 1.4.3)
including oxidative stress and reactive oxygen species (Hasdan et al., 2002, Ferraro et al.,
2003), homocysteine (Bostom and Culleton, 1999) and plasma ADMA (Vallance et al.,
1992) are found in high levels in the plasma of HO patients and may also contribute to
endothelial dysfunction. However, the exact underlying mechanisms involved remain
unclear. Endothelial dysfunction has been reported to occur in various stages of CKD
even in the early stages (Go et al., 2004). This may explain the accelerated rate of
cardiovascular diseases associated with renal impairment.
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In uremic patients, some in vivo and ex vivo studies have suggested that
functional alterations in blood vessels are primarily based on impaired NO bioavailability
resulting in impaired endothelium-dependent vasodilatation. Such defect has been
observed in other conditions, namely hypertension (Taddei and Salvetti, 2(02),
hyperlipidaemia (Warnholtz et al., 2(01) and diabetes (van Etten et al., 2002). Early in
vivo studies have demonstrated that NO-dependent flow-mediated vasodilation is
decreased in HD patients (van Guldener et aI., 1998, Holvoet et al., 1996). Such
impairment was also observed in peripheral vessels of uremic CKD (pre-dialysis and post
peritoneal dialysis (PD) patients) using forearm plethysmography (Morris et al., 2000,
Annuk et al., 2001).
Most of the limited number of initial ex vivo studies to date (Morris et aI., 200 1,
Luksha et al., 2011, Luksha et al., 2012), have examined small isolated arteries (using
myography) removed from uremic patients selected to be undergoing a surgical
procedure relating to their ongoing care needs (PO catheter insertion and renal transplant)
and challenged with a limited suite of vasoactive agents (comprising of NA, ET-I, Ach,
and SNP).
Some reports have shown that the HD procedure itself may effects on endothelial
function. Miyazaki et al. has demonstrated that a single haemodialysis session
significantly blunted endothelium-dependent vasodilatation measured by non-invasive
flow-mediated dilation (FMD) in the brachial artery (Miyazaki et al., 2000). Moreover,
the HO procedure can acutely impairs endothelial function assessed by FMD in
children's brachial artery (Lilien et al., 2005). The Lilien's study observed decreased in
FMO in HD children compared to healthy control children. It was also observed that HD
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induces further decreases in FMD when measured during an HD session. Therefore, it
remains unknown whether the HD per se causes endothelial dysfunction. However, the
underlying mechanism may be multifactorial.
Vascular remodelling and arterial stiffening in uremic patients have been
identified in epidemiological studies as an independent risk factors that contribute to
increased cardiovascular mortality in ESRD patients (Guerin et al., 2005, London, 2000).
Such vascular alterations (increased media-to-lumen ratio and vascular smooth muscle
hypertrophy), are frequently found in patients with hypertension (Mulvany, 2002),
diabetes mellitus (Hadoke et al., 2000), obesity (Rizzoni et al., 2012), and sever
renovascular hypertension (Brunner et al., 2(05). These vascular changes develop rapidly
in uremic CKD patients and believed to be responsible for increased incidence of
cardiovascular risks and all-cause mortality including ischemic heart disease, left
ventricular hypertrophy, congestive heart failure, and sudden death, particularly those
receiving dialysis therapy (Blacher et al., 2001, Guerin et al., 2008). In addition, vascular
calcification and associated cardiovascular dysfunction have been demonstrated in
patients with CKD stage 4, HD, and patients on PD with significant differences between
all groups (Sigrist et al., 2(06). This represents a fixed vascular structural change onto
which microvascular abnormalities are potentially superimposed (Sigrist and McIntyre,
2008).
Measurement of pulse wave velocity (PWV) is another helpful method to assess the
vascular function. Large vessel compliance (arterial stiffness), as measured by increased
PWV, is higher in patients on dialysis (and with non-dialysis dependant CKD) compared
with the general population (Shinohara et al., 2004). Increased PWV is associated with
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elevated cardiovascular morbidity and mortality risks in patients with CKD stage 5
(Blacher et al., 1999). A strong association has been observed between PWV and
abdominal aorta calcification in HO patients (Raggi and Bellasi, 2007). Arterial stiffness
was also demonstrated in HO patients undergoing transplantation compared with non-
dialysis controls (Chung et al., 2010). This change in compliance is partially due to
material alterations in the conduit arteries, however it is also blood pressure (BP) and
endothelial dysfunction related, and modifiable by long-term treatment with angiotensin
converting enzyme inhibitors (ACEIs) in CKD (Agata et al., 2004) and non-uremic
hypertensives (Ong et al., 2011). It remains uncertain whether the isolated large arteries
of uremic patients had similar relaxation response to small arteries.
3.2 Aims
In view of this background literature, we hypothesised that uremia may induces
microvascular dysfunction in HD patients characteristically through enhanced
vasocontractility and impaired endothelium-dependent vasodilatation of isolated
different-sized arteries of HO patients in response to various stimuli.
This defect was observed previously in isolated arteries (small sizes) obtained
from uremic CKD patients (non HO), investigating a limited suit of vasoactive stimuli.
Therefore, the current project is novel in that, firstly we extend this principle of
investigation to include different -sized arteries isolated from a homogenous uremic group
of patients who purely on HO and testing them to various stimuli including NA, ET-I,
U46619, AngII, vasopressin, BK, Ach, and SNP, with comparison to appropriate
matched non uremic control arteries, isolated from an identical sampling site, using wire
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myography. Secondly, to establish whether these vessels exhibit impaired endothelial-
dependent vasodilation, as previously suggested (Morris et al., 2001, Luksha et al., 2011,
Luksha et al., 2012). However, it remains uncertain whether the isolated large arteries of
HD patients had similar contractile and relaxation responses to small arteries. The study
also intended to characterize the relation between ex vivo vascular changes and in vivo
parameters, correlating ex vivo myography data with in vivo results of pulse wave
velocity (PWV) and blood pressure (BP) for each patient.
3.3 Materials and Methods
3.3.1 Participants and subcutaneous tissue biopsies
Subcutaneous fat samples were obtained from 11 HD patients (8 males; average
age 62.3±15.6), who were within the first 90 days of starting dialysis. Control fat samples
were obtained from 26 appropriately consented healthy volunteers (24 males; average
age 63.9±11.17) without documented renal disease, who underwent either elective
laparoscopic or abdominal surgery (elective hernia repair). The ethical approval was
sought and granted by the Derbyshire Research Ethics Committee and the local NHS
R&D department. Informed written consent was obtained in accordance with Good
Clinical Practice guidelines according to the principles expressed in the Declaration of
Helsinki. Different-sized arteries (small < 600 urn and large> 600 urn) were dissected
from each sample and mounted as a ring preparation on wire myography. Details on
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obtaining, transfer of fat samples for experimental study and the techniques of arterial
dissection and mounting on wire myography are described in section 2.4.3.
3.3.2 Preparation of vasoactive agents
Vasoconstrictors and vasodilators that have been used to investigate the vascular
function in isolated arteries of HD patients were include NA, ET-I, AngII, U46619,
vasopressin, BK, Ach, and SNP. Purchases and preparation of these agents and other
physiologic salt solutions are described in details in section 2.3.2 and 2.3.3
3.3.3 Protocol of experiment
Following mounting, arteries were kept for 15-30 minutes to be acclimatized and
then subjected to normalization process. The general protocol of experiment is detailed in
section 2.5. The internal diameter of arteries was calculated as described in section 2.4.3.
For vasoconstrictor protocol, following a wash out of vessels and re-establish the base
line, cumulative-concentration response curves were constructed for the following
vasoconstrictors; NA (10-10 mol/L - 10-4 mollL), ET-l (10-12 mollL - 10-6 mollL),
U46619 (10-12 mollL - 10-6mollL), AngII (10-12 mollL - 10-6mollL), and vasopressin
(10-12 mollL - 10-6mollL) starting with the lowest concentration of the drug allowing 3-5
minutes per stimulation as detailed in chapter 2 and Table 6.
For vasodilator protocol, separate protocol was carried out for vasodilators.
Following washout period and re-establishment of the baseline (as described before in
the general protocol), arteries were first contracted by stimulating them to a combination
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of (lOO nmol/L U46619 and 1 nmollL ET-I). Once the peak steady contraction had
reached, cumulative-concentration response curves for different vasodilators including;
bradykinin (BK), acetylcholine (Ach), and sodium nitroprusside (SNP) were constructed
starting with the lowest concentration of the drug to the highest concentration, which was
100 pM (10-10 molar) to 100 J.lM(104 molar) for all vasodilators allowing 3-5 minutes
per stimulation (as described in section 2.5.2 and Table 6). There were some differences
in the baseline relaxation starting points between both groups (but not significant),
however, we used a combination of low concentration of (100 nmollL U46619 and 1
nmollL ET-1) for preconstriction until got a steady contraction before starting
vasorelaxation response curves.
3.3.4 In vivo haemodynamic measurements
Carotid-to-femoral arterial PWV was measured using an oscillometric device
(Vicorder, Skidmore Medical Ltd, Bristol, UK). Brachial artery blood pressure was
measured in the non-fistula arm using an oscillometric device (Datex-Ohmeda, GE
Healthcare, USA). PWV is calculated by the software by dividing arterial transit time by
measured distance. The mean of 2 measurements was recorded (as described in section
2.5.3).
3.3.5 Statistical analysis
Contractile responses were expressed as an increased contraction in milliNewtons (mN)
above the isometric baseline. Details on Lab Chart data calculation are described in
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section 2.6. The maximum contractile response (Rmax)for each agent in all groups were
calculated and EC50 value (defined as the concentration of drug required to produce 50%
of the maximum response), while the response for vasodilators BK, Ach, and SNP was
expressed as maximum % of relaxation from the preconstriction state. All data were
expressed as mean with standard error of the mean (mean ± SEM) and the analysis was
using GraphPad Prism-5 software. All continuous variables were tested for normality
using their histograms and normality tests. The differences were tested at multiple dose-
response time points for all data The comparison between all groups was performed by
using students t-test and differences were considered significant when P < 0.05. We
correlated the PWV and blood pressure data of each patient with each vasoactive drug in
each vessel size. All PWV and blood pressure data was expressed as mean ± SEM.
Relationships between in vivo and ex vivo data was determined using spearman's rho
correlation coefficient, which considered significant at *p = 0.05, and **p = 0.01 levels
(2-tailed). All statistical analysis was undertaken using GraphPad Prism-S software and
SPSS VI2.
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Table 7 Characteristics or HD and control patients
Characteristic (~l) 1) &1l!~cl P value= _6)
Age (Yean) 61.3:t 1~.6 53.9t11.1 0936
Sex M = S, F =3 1\1= 2'+, F = 2 ~s
Systollc BP (/IIi11 HgJ 1.+1.6± 10,6 13.t,~± 16,~ o -SI
Diastolic BP (11/11/ HgJ -s,-+ ± 10,~ SQ,6± 9,5 0891
)'1AP 11C.05:t81 9S,-± -,1 0356
Creatinine' (lima! L J ~A 8U ± 59 ~~
eGFR (ml-nsinL. -3 I!r'! ~A S-+,·U:5,2 ~S
B)'ll 2-,5:t18 26,2± 2.3 C." -+6
Smoker (n) 3 10 )J'S
IHD 2
CVA 0
Abbreviation: N, number of patients; eGFR, estimated glomerular filtration rate; BP, blood pressure; MAP,
main arterial pressure; BMI, body mass index; IHD. ischemic heart disease; CVA, cerebrovascular accident;
NA. non-annlicable: NS. non-significant.
3.4 Results
The background characteristics of HD patients and control group are described in
(Table 7). There was no difference in the important characteristics of HD and non-HD
patients other than uremic status Age and sex were similar between both groups, and
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there was no statistically significant difference in systolic and diastolic blood pressure
between HD and controls.
3.4.1 Vaseular size
The total number of all small vessels investigated per vasoactive agents was 48 in
HO (08 arteries were discarded) and 72 in control groups (11 arteries were discarded)
(Table 8), whereas in large arteries, it was 42 in HD (03 arteries were discarded) and 65
in controls (07 arteries were discarded) (Table 9). The diameter of small vessels in HD
patients was ranged between 192 urn - 580 urn, while in normal controls was between
220 urn - 575 urn, whereas the size of large vessels was (612 urn - 922 urn in HD and
610 urn - 886 urn in controls). In vessels investigated per vasocontractile agent. the
average internal diameter (ID) was similar between HD and control groups, it was 472.6
± 42.4 urn in HO (n = 30) versus 449.3 ± 78.7 urn in control (n = 45). P = 0.821.
Similarly, there was no significant difference in the size of large vessels between both
groups, it was 738.4 ± 96.2 urn (n = 27) versus 716.5 ± 88.6 urn (n = 40) in HD and
controls respectively. P = 0.869.
In vessels that investigated per vasodilator drugs, there was a similarity in the
vessel size between HO and controls. The average ID of all small arteries was 478 ± 81.2
urn in HO (n = 18), and 512.3 ± 44.7 urn in controls (n = 27), P = 0.691. While in large
arteries, the average ID was 761.5 ± 62.3 urn (n = 15) and 744.8 ±91.2 urn (n = 25) in
HO and controls respectively, P = 0.896.
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Table 8 The internal diameter of smaUarteries size in HD and controls
ADsmaD arteries size of the used experiments testing the effects of DD on all vasoactive
agents.
HD (n = 11) Control (n = 26) Pvalue
Noradrenalin
Number 6 10
Le 436.6 :68.1 4013 : 65.1 0.728
Endothelin-l
Number 6 9
Le 4253: 82.1 411.1 : 53.6 0.633
U4
Number 6 9
Le 381.1 ± 81.4 424.4 ± 78.1 0.716
Anmotensi II
Number 6 8
Lo 458.8 ±292 435.5 ± 39.2 0.686
v~ressinN er 6 9
Lo 472.3 ± 32.9 453.7 ±67.3 0 ..835
Bradvkinin
Number 6 9
Le 5375±47.8 521.1± 46.6 0.817
Acetvlechohne
Number 6 9
Le 482.6±44.6 504.2± 60.1 0.797
Sodium JUtnu,rosside
Number 6 9
Le 474.8 ±41.8 519.4± 41.8 0.482
Abbreviation: n, number of patients; HD, haemodialysis; Number, is the number of small arteries used for
concentration-response curves to all vasoactive agents. Lo is the normalized internal diameter of arteries; U4,
thromboxane A2. Data are expressed mean ± SEM and the comparison is by t-test.
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Table 9 The internal diameter of large arteries size in HD and controls
AD smaD arteries size of the used experiments testing the effects of HD on all vasoactive
agents.
.o ______
lID In = III Control {n =261 Pvalue
oo ________ .·~_,,_·,
.~-,~---.-~.--- ....•~,~~-~-
Noradrenaline
Number 6 9
La 735.8 ± 78.3 683.8 ±42.2 0.532
Endothelin-I
Number 5 9
La 770.4 ± 80.5 749.2 :1:92.6 0.871
U4
Number 6 8
La 733.8 ± 84.6 702.1 ±42.8 0.724
Angiotensi n
Number 5 7
La 676.8 :1:54.4 693.1 ±66.2 0.861
Vasopressin
Number 5 7
La 724.1 ±68.1 681.1±57.5 0.635
Bradvkinin
Number 5 8
La 722.6 ±63.8 715.2 :1:41.1 0.922
Acetvlecholine
Number 5 8
La 785.1 ± 76.7 710.8 ± 55.9 0.447
Sodium nitruprosside
Number 5 9
La 720.2 ± 77.7 729.1 ±79.5 0.944
Abbreviations: n, number of patients; HD, haemodialysis; Number, is the number of large arteries used for
concentration-response curves to all vasoactive agents. Lo is the normalized internal diameter of arteries; U4,
thromboxane A2. Data are expressed as mean ± SEM, and the comparison is by Hest.
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3.4.2 Vascular function
3.4.2.1 Effects of lID on the KPSS contractile response in different-sized vessels
The contractile response to KPSS in all size arteries (in vasoconstrictor and
vasodilator experiments) was measured. In all small-sized arteries, the difference in the
maximum KPSS contraction between both groups was not statistically significant. This
response was 9.1 ± 5.6 mN in HO (n = 48), and 6.9 ± 1.8 mN in controls (n = 72), P =
0.663. Similarly, there was no significant difference in the average of maximum KPSS
between both groups in all large arteries, it was 14.1 ± 4.2 mN in HD (n = 42), and 13.0
± 6.5 mN in controls (n = 63), P = 0.899. However, from the bar chart (Figure 17), we
observed that, largest diameter arteries had higher maximal contractile responses to
KPSS in each group.
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Figure 18 The maximum KPSS response in different-sized vessels of HD and controls
Abbreviations:KPSS. Potassiumphysiologicsalt solution;HD. haemodialysis
3.4.2.2 Effects of lID on the contractile response of different-sized arteries to
different vasoconstrictors
In small vessels, results for the maximum contractile response of small arteries to
all vasocontractile agents (Rma.). and the potency of drug (ECso) are described in Table
10. The maximum contractile responses of small vessels (mN) to ET-I, U46619, AngII
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and vasopressin were greater in HD compared to controls, being highly significant in
U46619, AngII, and vasopressin (P < 0.0001 in each drug) as showed in Figures 19 C, D,
and E. In NA response curve, the contractile response was similar between the two
groups (Table 10 and Figure 19 A). Our results also showed that, the highest contractile
response in HD group was in response to vasopressin (15.1 mN ± 0.3), whereas in
controls was in response to U46619 (9.3 mN ± 0.3). The lowest contractile response in
HD group was in response to NA (5.7 mN ± 0.1), while in control group was in response
to AngII (4.8 mN ± 0.2). The potency of each vasocontractile agent (NA, ET-I, U4,
AngII and vasopressin) was similar between both groups (no significant difference in the
ECso between HD and controls in each type of drug (see Table 10 and Figure 19).
In large vessels, details for all vasoconstrictor results of large arteries in both
groups are showed in (Table 11 and Figure 20). Similarly, the contractile response to
different vasoconstrictors in large arteries was greater in HD than controls. This
contraction was highly significant in response to U46619, Ang II, and vasopressin as
showed in Figures 20 C, 0, and E. In NA and ET-I, the response was higher in HD
compared to controls with (P = 0.022 and P = 0.082 respectively). Unlike small arteries,
large arteries of HD patients require significantly less concentration of U46619 and
vasopressin than controls to give 50 % of maximum contraction (see Table II, and
Figures 20 C and E). From these response curves, we observed that the potency of NA,
End-I, and Ang II in large arteries was similar in both groups (no statistical difference
between the two groups). Moreover, we observed that the response of isolated large
vessels of HO patients to vasopressin was the highest in the group of vasoconstrictors
(16.8 mN ± 0.4), whereas in control group the highest vasocontraction was in response to
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U46619 (12.4 mN ± 0.4). The lowest contractile response in both groups was in response
to AngII (11.9 ± 0.3 mN in HD group and 6 ± 0.2 mN in controls).
Table 10 The maximum response of small arteries and Potency of aU vasoconstrictors in
HD and controls
R_ HD [n ss l l ) Control (n = 26)
Noradrenaline 5.7±0.1 mN 5.6±0.1 mN
Endothelin-l 11.1 ±0.2mN 8.9±0.6mN
U46619 14.1 ±0.3 mN 9.3 ±0.3 mN
Angiotensin IT 7.3±0.2mN 4.8±0.2mN
Vasopressin 15.1 ±0.3 mN 7.0±0.4mN
Pvalue
0.6875
0.0155
<0.0001
< 0.0001
<0.0001
ECso
Noradrenaline 7.7 ±0.1 8.2 ± 0.1
Endothelin-l 9.9±0.1 10.3 ± 0.1
U46619 8.3 ±O.O 8.3 ±0.1
Angiotensin IT 9.2±0.0 9.4 ±0.1
Vasopressin 10.5±0.1 10.1±0.2
0.085
0.051
0.951
0.316
0.224
Abbreviations; n. number of patients; R max. maximum response in mN; ECso' potency of drug
(expressed as the negative logarithm of the ECso); HD. haemodialysis; U46619, thromboxane A2.
Data are mean ± SEM. and comparison is by t-test.
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Table 11 The maximum response of large arteries and Potency to aU vasoconstrictors in HO
and controls
R_ lID (n e l l) Control (n = 26) Pvalue
.-...-.-- .•---.--.-.--.
Noradrenaline 13.1±0.3mN 11.1 ±0.5 mN 0.022
Endothelin-l 12.7fOJmN 1l.7fO.3 mN 0.082
U46619 16.0fO.4mN 12.4±0.4mN 0.0002
Angiotensin II 11.9±O.3 mN 6.0±0.2mN <0.0001
Vasopressin 16.8fO.4mN 11.3 fO.5 mN < 0.0001
ECso
Noradrenalin 7.4fO.3 7.7±0.1 0.091
Endothelin-1 9.4 fO.l 9.8 ±0.2 0.061
U46619 9.5 ±0.4 8.9 fOA 0.008
Angiotensin II 9.6 ±O.l 9.6±O.6 0.861
Vasopressin 10.3±O.1 9.3 fO.l 0.001
Abbreviations; n, number of patients; R max. maximum response in mN; ECso' potency of drug
(expressed as the negative logarithm of the ECso); HD. haemodialysis; U466l9. thromboxane A2.
Data are mean ± SEM. and comparison is by Hest.
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Figure 19 Concentration-response curves for vasoconstrictors in small vessels of HD and
controls
Data are expressed as mean ± SEM. NA (A), ET-l (B), U4 (thromboxaneA2) (C), AngII (D)
and vasopressin (E). The differences were tested at multiple dose-response time points.
Comparison is by students r-test, *p < 0.05, • •P < 0.001, ·"P < 0.0001.
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Figure 20 Concentration-response curves for vasoconstrictors in large vessels of HO and
controls
Data are expressed as mean ± SEM. NA (A), ET-l (B), U4 (thromboxane A2). (C), AngII
(D) and vasopressin (E). The differences were tested at multiple dose-response time
points. Comparison is by students r-test, *p < 0.05, **p < 0.001, ***p < 0.0001.
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3.4.2.3 Effects of lID on the contractile response of ditTerent-sized arteries to
V8SOCOnstrictors-KPSS
The contractile response of small and large vessels to different vasoconstrictors
was also expressed as a percentage of maximum KPSS-induced contraction in an effort
to normalise the data. In HD patients the percentage maximum contractile response of
small arteries to all vasoconstrictors (NA. ET-I. U46619. AngII, and vasopressin) was
significantly higher compared to controls (Table 12). In both groups the highest % of
maximum contractile response of small vessels was in response to U46619 (144.3 ± 3.3
% KPSS in HD and 120.9 ± 3.1 % KPSS in controls), while the lowest % of contraction
was in response to AngII (78.9 ± 2.1 % KPSS in HD and 65.3 ± 2.1 % KPSS in controls).
However, the potency of all vasoconstrictors was similar in both groups.
In large vessels, the % of maximum KPSS-induced contraction to all
vasoconstrictors was significantly greater in HD group compared to controls (Table 13).
In HD and controls, the contractile response to vasopressin was the highest in the group
(135.8.0 ± 3. J % KPSS in HD, and 113.2 ± 3.7 % KPSS in controls, P < 0.05), whereas
the lowest % was in response to AngII (85.3 ± 2.5 % KPSS and 74.6 ± 1.9 % KPSS in
HD and controls respectively. P < 0.05). However. vasopressin and U46619 was less
potent in large arteries of control group compared to HD patients. The potency of
vasopressin was (9.3 ± 0.1 in control versus 10.2 ± 0.1 in HD. P < 0.(01). while in
U46619 was (8.9 ± 0.1 in controls versus 9.6 ± 0.1 in HD. P < 0.05). The ECso of NA,
ET-I. and AngII was similar between the two groups.
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Table 12 The % maximum KPSS -induced contraction in smaU arteries of HD and controls
~.MaxKPSS HO (n =11) Control (n = 26) Pvalue
Noradrenalin 108.9± 2.5 % 89.9 ± 2.8 ~/o 0.0004
Endothelin-I 134.5 ± 4.5 % 102.5 ± 2.7 % < 0.0001
U46619 144.3 ± 3.3 0.''0 120.9 ± 3.1 % 0.0003
Angiotensin II 78.9 ± 2.1 % 65.3 ± 2.1 % 0.001
Vasopressin 137.0 ± 3.5 % 90.6± 3.1 % < 0.0001
Abbreviations; ~"IMax KPSS, percentage of maximum KPSS contraction;Data are mean ± SEM,
~ comparison is by Hest.
%Max KPSS HD (n =11) Control (n = 26) Pvalue
Noradrenalin 107.4± 2.9 % 80.4± 2.5 % < 0.0001
Endothelia -1 102.9 ± 3.1 % 96.8 ± 2.7 % 0.007
U46619 118.2 ± 3.3 % 99.5 ± 3.6 % 0.003
Angiotensin II 85.3 ± 2.5 % 74.6 ± 1.9 ~'o 0.006
Vasopressin 135.8.0 ± 3.1 % 113.2 ± 3.7 ~'o 0.001
Abbreviations; % Max KPSS, percmtage of maximum KPSS contraction; Data are mean ± SEM,
an~ comparis<D is byt-test,
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3.4.2.4 Effects or lID on the vasorelaxation response of ditTerent-sized arteries to
diff'erent vasodilators
In small arteries. details for the percentage of maximum relaxation (Rmax)and the
potency of drug (ECso) to all vasodilator agents are described in Table 14. The potency of
all vasodilator drugs (BK. Ach and SNP) was similar between the two groups; however.
the % of relaxation in response to BK and Ach was significantly lower in HO compared
to controls (see Figures 21 A and B). In Ach group. the % of relaxation was 36.2 ± 1.2 %
in HD. and 53.8 ± 1.3 % in controls (P < 0.0001). While in BK group. it was 35.6 ± 0.7
% and 40.0 ± 0.6 % in HD and controls respectively (P < 0.05). Relaxation to SNP was
similar between the two groups as described in Table 14 and Figure 21 C.
In large vessels. the percentage of maximum relaxation to all vasodilator agents
(Rmax)and the potency of drug (ECso) are described in Table 15. Similarly. the results of
large arteries showed no statistically significant difference in the potency of all
vasodilator drugs (ECso) between HD and control groups; however significantly lower
relaxation response curves to BK and Ach were obtained in HO patients compared to
controls. The % relaxation of large arteries to Ach was 38.7 ± 1.8 % in HD and 65.6 ±
1.4 % in controls (P < 0.0001). while in the BK group. it was 46.2 ± 0.9 % in HD and
52.8 ± 0.8 % in controls (P < 0.000 1). A similar relaxation response curve to SNP was
observed in both groups (64.2 ± 1.9 % in HD and 67.5 ± 1.3 % in controls). see Figure 22
C).
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Table 14 The % relaxation of small arteries and Potency to vasodilators in UD and
controls
R_ lID Control (n = 26) Pvalue
Bradykinin 35.6±0.7% 40.1 ±0.6% 0.001
Actt}ichdint 36.2 ± 1.2~. 53.8±1.3% < 0.0001
Sodium nitropusside 59.4 ± 1.2 ~Io 62.4 ± 1.3 % 0.134
ECso
Bradykinin 6.7 ±O.l 6.9 ±O.l 0.187
Acttylchdine 7.3 iO.! 7.1 iO.! 0.142
Sodium nitropusside 7.2 ±O.O 7.0±0.3 0.155
Abbreviations: R_. maximum percentageofrelaxation(~\); ECso,potencyofdrug (expressed as the
negat:i\'e logarithm oftbe [C50). Data aremean±SEM, and comp arison is by stu~nts t-test.
Table 15 The % relaxation of large arteries and Potency to vasodilators in HD and controls
R_ HO (n=ll) Control (n = 26) Pvalue
Bradykinin 46.2 ±0.9~. 52.8±0.8% < 0.0001
Acetylchdine 38.7 ± 1.8 ~/i 65.6± 1.4% <0.0001
Sodium nitropusside 64.2 ± 1.9°/, 67.5 ± 1J % 0.160
EC50
Bradykinin 7.1 ±0.2 7.2 ±O,! 0.880
Acetylchciine 7.6±0.6 7.4±0.2 0.164
Sodium nitropusside 7.0±OJ 7.2±0.3 0.147
Abbmiations: R_.maximum percentage of relaxation ('4); [Cso,potency of drug (expressed as the
negative logarithm of the £Cso)' Data aremean:l:SEM, and comp arison is by students t-test.
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Figure 21 Concentration-response curves for vasodilators in large vessels of HD and
controls
Data are expressed as mean ± SEM. BK (A), Ach (B), and SNP (C). The differences were
tested at multiple dose-response time points. Comparison is by students r-test, *p < 0.05,
**p < 0.001, ***p < 0.0001.
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Figure 22 Concentration-respome curves for vasodilators in large vessels of HO and
controls
Data are expressed as mean ± SEM. BK (A), Ach (B), and SNP (C). The differences were
tested at multiple dose-response time points. Comparison is by students r-test, *p < 0.05,
• • p< 0.001, • • •P < 0.0001.
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3.4.2.5 Effects of lID on ditTerent vasoactive response in each vessel size
To investigate the pattern of the vascular response in different-sized vessels of
HO and control individuals, we compared the arterial response in small arteries with
those large sizes in each group (Table 16 and 17). In both HO and controls, the
contractile response (Rmax) to all vasoconstrictors was significantly higher in large
arteries than small ones. In addition, our results showed that larger size arteries from HO
patients significantly relax more to BK and SNP than small arteries. This variable
relaxation response when comes in Ach stimulation a trend of more relaxation appears in
large arteries compared to small ones, though the difference was not statistically
significant. In control group. significantly higher relaxation responses to BK and Ach
were obtained in large vessels compared to small vessels, with no significant relaxation
difference was observed in response to SNP.
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Table 16 The maximum responses of small and large sized vessels to different vasoactive
agents in HO.
R_ Small Larae Pvalue
Noradrenalin 5.7 ± 0.1 mN 13.1 ± OJ mN < 0.0001
Endothelin-l 11.1 ±0.2mN 12.7 ± OJ mN 0.0004
U46619 14.l ±0.3mN 16.0±0.4mN 0.002
An~otmsinn 7J ± 0.2 mN 11.9± OJ mN < 0.0001
Vasopres~ 15.1 ± OJ mN 16.8 ±0.4mN 0.004
Bradykinin 35.6± 0.7 % 46.2±0.9% < 0.0001
Acetylcholine 36.1 ± 1.2% 38.7 ± 1.8 % 0.250
Sodium nitropusside 59.4± 1.2% 64.2 ± 1.9 % 0.043
Abbreviaions; Rt.,mamnmn response in mN;%, percesage of relaxaion; Data aremean ±
SEM, and comparison is by t-test.
Table 17 The maximum responses of small and large sized vessels vessels to ditTerent
vasoactive agents in controls.
R_ Small Large Pvalue
Noradrenalin 5.6 ± O.l mN 11.1 ± 0.5 mN < 0.0001
Endothelin-l 8.9±0.6mN 11.7 ± OJ mN 0.003
U46619 9J ± OJ mN 12.4± 0.4mN <0.0001
Angiotensin n 4.8±0.2mN 6.0±0.2mN 0.001
Vasopressin 7.0±0.4mN 11J ± 0.5 mN < 0.0001
Bradykinin 40.1 ± 0.6 % 52.8 ± 0.8 % < 0.0001
Acetylcholine 53.8±lJ% 6S.6± 1.4 % < 0.0001
Sodium nitropussidt 63.4± IJ % 65.8 ± 1.7% 0.272
Abbreviafices; R max, muimmn response in mN; %, percentage of relaxation; Data are mean ±
SEM and comparison is by Hest.
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3.4.3 Correlation or ex vivo data with in vivo haemodynamic measurements of lID
patients
Haemodynamic measurements including Pulse wave velocity (PWV), systolic
blood pressure (SBP) and diastolic blood pressure (DBP) for each individual HD patient
were measured in vivo as described in section 3.3.4. Tables 18 and 19 illustrated the
relationship between haemodynamic measurements in HD patients with the maximum
vasoactive response and with the percentage of maximum contractile- KPSS response
respectively. PWV was significantly correlated with the maximum contractile response
of large arteries to vasopressin (r = 0.829. P = 0.042), see Figure 23.1 (B). However,
when the data was expressed as the percentage of maximum KPSS response. a positive
correlation was also seen between PWV and percentage of maximum contractile
response of small arteries to vasopressin (r = 0.886, P = 0.019). However, the correlation
of PWV with the percentage response of large vessels to vasopressin was lost. The
correlation between PWV and the other vasoactive agents was not statistically
significant.
With regard to the correlation of ex vivo myography data with blood pressure, a
significant inverse correlation was observed between the DBP of HD patients and the
response of large vessels to SNP (r = -0.974, P = 0.016), see Figure 23.2 (D). There was
also a negative correlation between DBP and the percentage of contractile response of
small arteries to vasopressin-KPSS responses (r = -0.829, P = 0.042). However, there
was no significant correlation between SBP and the response of isolated arteries of HD
patients to vasoactive agents.
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17. 1 Demographic detaik of in vivo measurements of HO patients
------ ..-----~---
Characteristk HD
(:"= 11)
Age (yean I 62.H: 15.6
Sex :'-1=S.f=3
Systolic BP (/1/11/ Hg. P16±:0.6
Drastclic BP (:11111 HgJ -S ..l:i: 10.~
~1AP 1100~~S.1
PWY (111 s ) S ..l = 21
Smoker (1/) 3
D\I ...
-
IHD ...
-
C',A 0
Control Pvalue
(:"= 26)
63.9 ± : 1.2 0.936
:'-1= 1.l. F = 2 ~S
13+.2 ~ 16.~ O.-SI
SO.6 ± 9.5 O.S91
9S.- ~ -.1 O.3~6
10
Abbreviation: PWV. pulse wave velocity; SBP. systolic blood pressure; OBP, diastolic
blood pressure; OM. diabetes mellitus. IHO. ischemic heart disease; eVA,
cerebrovascular accident: (rn/s), meter/second.
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Table 18 Correlations of in vivo data with ex vivo vasoactive responses of isolated different-
sized vessels of HD patients to different stimuli.
Y.'ioadlu Yf'i\fldu PWY SBP DBP
AgfD~
r 'aht~ Pnlu~ r value P,a1u~ r value Pnlue
Noradrenaline Small 0.r6 O.-IS- C..:.9~ OJ ~~ -o.~r C.-9-
Large :) ~O(l O.-S3 o oeo I.O~O O.!OO (6S3
Endothelin-I Sn.all :)1-1: 0.S01 -0.:00 0.-13 0.31-1 0.~63
Large -OJJO C.683 0.000 1.050 0.105 0.-S3
C'-I6619 1,,:all J.l-l-l 0.S01 -0.-163 0.355 -J"+6: O.:~~
arge J.13: 0.6~8 0.015 1.000 O.OJO 1.000
Al.giulCl1;)iu II SI/lull J ...!~S 0-119 oms 1.000 -0 2~- 0.6:8
Large JI00 0.9~0 -O.SOO O.~33 0.100 0.-83
v asopressin SIIIUI,' O~~- 0.6~S 0.5-11 C9- -a 1-+1 O.SC·:!
LOI-ge OS~9 0.(-11- -C600 0.1-11 -0.31-1 C~63
Bradykinin
~";a!l -0 .13 ~ C65S -0.05- 0.919 0.3"6 0.-19-
arge J.OOO 1.000 O.SO·) 0.133 0.:00 C.-S3
Acetylcholine Smol] -0 -_. U01 -0. ~-I1 0.SC'1 0.31-1 0.~63
Large -O.DO C9~0 0.000 I.O~O -0.153 0'-83
Sodium nitroprusside Ssnc]] :).~.j: 0.:9- 0.1~- C6~S -0 -I1S 0.-119
Large -OJJO C6S3 O.(tOO 1.0~0 -0.9- -I CO 16"
Abbreviation: PWV. pulse wave velocity: SSP. systolic blood pressure; OSP, diastolic blood
pressure: r value. correlation coefficient: small. *Correlation is significant at the 0_05 level (2-
tailed), **Correlation is significant at the 0.01 level (2-tailed)
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Table 19 Correlation of;1I vivo data with the % maximum vasoconstrictor-KPSS induced
response of HD patients
Correlation of PWV, SBP, and OBP with the % maximum vasoconstrictor-KPSS induced
response of isolated different-sized vessels ofHO patients to different vasoconstrictors.
"asocon~trlctor Vessel size PWY SBP DBP
-KPSS AgeD~
rlalue Pnlue r value P,"alae r value P,"alUt'
Koradrenaliue Siv ail OJ:~ 0.~63 0.100 ;)'-13 ·O.~O;) 0.-13
Large 0'-00 0.133 0.200 0.-83 0.200 0.-S3
Endothelm-l 5,,'ail OJ -1 OA9- 0.r1 0..+9- 0.~~2 0.29-
Lorge 03(10 0.683 ·0.100 0.95;) -0 S:O 0.:33
t".t6619 l,,'ail ocs O-H) 0.6;)0 0.2-H 0.+25 OH)
arge 08:8 OO~S 0.1+1 O.SO~ -0.028 I.CIOO
Angiotensin II 511/a,'/ 031+ 0.~63 005~ 0.919 -0.+28 0.+ 19
Large 09(10 0.083 -O.-WO O.~16 -C.-HO O.~ 16
vasopressin Suall 0.556 0.019' _I).~-+: 0.29- ·0.529 0.0-+2 '
Large -OJ -1 O.4~- 0200 0'-13 0.600 0208
Abbreviation: PWV. pulse wave velocity; SBP, systolic blood pressure; OBP, diastolic blood
pressure; r value. correlation coefficient; s; *Correlation is significant at the 0.05 level (2-tailed),
**Correlation is significant at the 0.01 level (2-tailed).
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Figure 23.1 Correlation Plots of Pulse Wave Velocity (PWV) of HD patients with the
maximum contractile response (Rmax) of small vessels (A) and large vessels (B) in
response to vasopressin.
Panels C and 0 describe the correlation of PWV with the Rmax of small and large vessels
in responses to U46619 respectively. Correlation coefficient (r) and P values are shown
in each panel.
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Figure 24.2 Correlation Plots of diastolic blood pressure (OBP) of HO patients with the %
relaxation responses of small vessels (A) and large vessels (B) to BK.
The correlation of OBP with the % relaxationof small and large vessels to SNP are shown
in curves (C and D) respectively. In each panel. correlation coefficient (r) and P values
are shown.
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3.5 Discussion
Endothelial dysfunction is a crucial element in the pathophysiology of increased
cardiovascular risk amongst CKD patients, including those on HD. Limited human
studies reported to date (Morris et al., 2001, Luksha et al., 2011) have examined the
effect of uraemia on vascular function in isolated subcutaneous arteries. These studies
were conducted on small arteries isolated from ESRD patients (with a very wide range of
dialysis vintages), investigating a limited suit of vasoactive agents. The current study was
therefore conducted on subcutaneous different-sized arteries isolated from HD patients
investigating different vasoconstrictors and vasodilators.
The present study provides a number of key findings. Firstly there is a markedly
increased responsiveness of isolated arteries from HD patients to different
vasoconstrictors even with low drug concentrations. Secondly, impaired endothelium-
dependent vasodilatation, while preserved endothelium-independent vasodilatation were
observed in subcutaneous arteries of HD patients. Thirdly, different-sized arterial
responses were correlated to clinically relevant in vivo assessment of cardiovascular
system function.
The data published to date on enhanced vasocontractile responses of isolated
arteries have been somewhat contradictory. Increased contractile responses of isolated
subcutaneous arteries have been reported before in CKD patients (not HD), characterised
by greater and more prolonged response to NA and ET-1 (Morris et al., 200 1). These
vascular responses have not been replicated in subsequent study (Luksha et al., 2011). In
later study similar contractile response of small arteries to NA, ET-t, and AngII was
observed between uremic and control groups. This is in contrast to our study with
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consistently observed significant increments in the arterial contraction in isolated
different-sized arteries of HO patients in response to NA, ET-I, U466I9, AngII, and
vasopressin. Small and larger isolated arteries from HO patients show significant
enhanced contractile response to U466l9, AngII, and vasopressin compared with
controls. In small arteries, we did not demonstrate significant differences in the potency
of pressor agents; however the overall contractile response was markedly higher in HD
patients compared to controls. Furthermore, the large arteries of our HD patients had
higher sensitivity to U46619 and vasopressin than control values and were characterized
by statistically significant difference in the EC50• When all vasocontractor data were
expressed as a percentage of KPSS response, the difference in the contractile response
between both groups was maintained with greater response in HD compared to controls
in all vasoconstrictors. Similarly, large arteries of HD patients showed highly sensitivity
to vasopressin and U466l9. This may reflects enhanced vascular response secondary to
vascular changes such as arterial stiffness which has been demonstrated previously in HO
patients (Shinohara et al., 2004. Chung et al.• 2010) or probably vascular hypertrophy
that described in experimental uraemia (Amann et al., 1995b). in addition to that, higher
levels of vasopressin plasma concentration have been observed in HD patients than that
of normal controls (Nord and Danovitch, 1979).
The data derived from our study are consistent with a previous report on isolated
subcutaneous arteries with more sustained contraction at the highest concentration of NA
and ET-1 was observed in patients with ESRD (Morris et al., 200 1), but is in contrast
with the earlier myography study by Aalkjaer et al, in which a similar response to NA
and AngII was observed between controls and patients with chronic intermittent dialysis
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(Aalkjaer et al., 1986), also in contrast with the recent study that showed no differences
in response to NA, ET-I. and AngII between uremic and control patients (Luksha et al.,
2011). Our population was unselected (no survivor or transplant bias) and all had been
exposed to a very similar and short period of HO «90 days), furthermore a larger
number of arterial segments were studied with the benefits of robust normal volunteer
comparators.
In addition to excessive pressor response of isolated arteries from HD patients, all
showed significant decreased in the vasorelaxation. This was exclusively endothelium-
dependent vasodilatation (to BK and Ach). This defect was observed regardless of vessel
sizes in HO patients. Vasorelaxation response to SNP (endothelium-independent
vasodilator) was preserved in HO group. Previous studies on isolated subcutaneous
arteries of uremic ESRD patients have demonstrated impaired vasodilatory function in
response to Ach (Morris et al., 2001, Luksha et al., 2011). In both studies Ach response
was significantly blunted among uremic patients with normal SNP-induced relaxation.
Furthermore, recent study by Luksha et al. found that the percentage relaxation and the
sensitivity (EC50) to both BK and Ach were reduced in isolated small arteries of patients
commencing PD (Luksha et al., 2012). Similar results have been reported previously in
vivo using non-invasive techniques such as Doppler ultrasound measurements of brachial
artery or dorsal hand vein in adult HO patients (Hand et al., 1998), as well as, in study
using forearm plethysmography in patients with chronic renal failure (Morris et al.,
2000). Conversely, Cupistis et al. showed similar Ach-induced vasorelaxation of skin
microcirculation (measured by laser Doppler flowmetry) in non-hypertensive uremic
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patients (as compared to controls) with reduced vasorelaxation response to Ach (Cupisti
et al., 2(00).
This impaired relaxation response could be due to NO dysfunction or decreased
ability of vascular endothelium to produce and release vasodilator substances such as
endothelium-derived hyperpolarizing factor (EDHF). These vasodilators act by
stimulating release of both NO and NO-independent factor (possibly EDHF), from the
endothelium of human resistance arteries (Mcintyre et al., 1998), However, the exact
mechanism underlying endothelial changes is still unclear. Circulating uremic factors in
HO patients may responsible for these changes. These retained toxins have being widely
considered and include elevated plasma homocysteine level (Mallamaci et al., 2002),
increase reactive oxygen species (Ferraro et al., 2003, Hasdan et al., 2002), and elevated
plasma levels of nitric oxide synthase inhibitors such as ADMA in dialysis patients
(Vallance et al., 1992, Kielstein et al., 2002). The manner of endothelial dysfunction has
previously been determined in other conditions including diabetes (van Etten et aI., 2002)
and hypertension (Taddei and Salvetti, 2002). However, in our study diabetic patients
were excluded and both controls and HO patients had similar systolic and diastolic blood
pressure. The arteries were examined after being removed from exposure to humeral
consequences of CKD.
An interesting observation in our data is that the contractile and relaxation
responses varied from small to large arteries. Previous data on diabetic patients have
shown greater contractile response to NA and ET-l observed in large than small arteries
(Hadoke et al., 2(00). However, the present study extends this principle to include
various stimuli. We showed that the contractile response to NA, ET-I, U46619, AngII,
134
and vasopressin was significantly higher in large arteries compared to small vessels in
each group. Moreover. our results showed that larger size arteries from HO patients
significantly relax more to BK and SNP than smaller size. This variable relaxation
response when it comes in Ach stimuli a trend of more relaxation appears in large
arteries compared to small, though the difference was not statistically significant. This
response has not been reported in uremic patients before; though Hadok et al conversely
observed that different-sized vessels of diabetic patients had similar response to BK and
SNP (Hadoke et al., 2(00). Therefore, these observations may indicate presence of
functional heterogeneity between small and large resistance arteries obtained from
subcutaneous fat of different human tissue. These vascular alterations, particularly
damage of large arteries. are the major contributory factor to the high cardiovascular
morbidity of patients with ESRD (Blacher et al., 2(02).
This study represents the first attempt to systematically examine the association
between in vivo cardiovascular performance and ex vivo arterial function. PWV as a
measure of arterial stiffness positively correlated with a greater response to vasopressin.
These findings reflect the aberrant haemodynamic response of isolated arteries in HO
patients which can be characterised by an exaggerated vasocontractile response and
deficient relaxation. However, we did not observe any significant correlation between
PWV and the vascular response to the other vasoconstrictors.
In addition, the present study compared the ex vivo vasocontractor and vasodilator
data with the in vivo measurement of BP in HO patients. It was found that the DBP was
inversely correlated with the contractile response of small arteries to vasopressin, as well
as, negatively correlated with the vasorelaxation response of large arteries to SNP. The
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existence of overhydration in those dialysis patients which have been identified as
hypertensive is far from universal. Wabel and co-workers measured pre-dialysis SBP and
fluid status in 500 HO patients by bioimpedance monitoring (compared to a matched
healthy population). Only 15% of patients fitted the stereotype of fluid overload with
hypertension. 13% of patients had hypertension despite dehydration and 10% had fluid
overload despite normal BP or hypotension (Wabel et al., 2(08). Similar findings were
seen in another study using the same methodology in 639 patients using PD. These
studies highlight that although physicians often estimate hydration status by BP, the two
factors are often dissociated in the setting of the profound physiological derangement
characteristic of dialysis dependant CKD. A wide variety of potential other
pathophysiological processes characteristic of dialysis patients may contribute to
generating hypertension without recourse to simple fluid overload, and enhanced pressor
response of abnormal uremic resistance vessels appears important.
In summary, this study demonstrated additional insights into the effect of HD on
vascular function characterized by incremental increased in vasocontractility and blunted
endothelium-dependent vasodilatation. The detailed mechanistic responses underlying
these changes are still unclear. However, exaggerated pressor response and endothelium
based failure of relaxation are associated with in vivo measurements of markers of
cardiovascular performance we already know to be important in determining HO patient
survival. In addition this defective vascular response may be important in sensitising HD
patients to recurrent cumulative ischaemic end organ injury driven by the circulatory
stress of HD.
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Chapter 4
Results of obese patients
Chapter 4: EefTects of obesity on vascular function in isolated
subcutaneous arteries.
4.1 Introduction
The increasing incidence and prevalence of obesity across developed countries
worldwide has an enormous impact on elevated cardiovascular risk (Frisbee, 2007).
Obesity is frequently associated with a number of well-recognised risk factors including
insulin resistance, oxidative stress, and inflammatory conditions which can damage the
endothelium (Meyers and Gokce, 2007, Karalis et al., 2(09). Changes in the
microcirculation of isolated arteries including vascular wall thickening and a reduction in
the internal lumen have been recognised in obesity milieu (Grassi et al., 201Ob). It also
well demonstrated in essential and secondary hypertension (Mulvany, 1990, Schiffrin,
2004, Levy et al., 2(08), and type II diabetes mellitus (Levy et al., 2008, Rizzoni et al.,
2oo1a). These alterations may contribute to an increase in peripheral resistance. Not only
the vascular structure altered in obesity but also functional responses, especially
endothelium-dependent function. The exact mechanisms by which obesity can cause
endothelium dysfunction are unclear, however several factors may possibly responsible
for obesity-related endothelial alterations, including insulin resistance, inflammatory
conditions (Zeidan et al., 200S), oxidative stress and reactive oxygen species (Karalis et
al., 2(09), activation of renin-angiotensin system and sympathetic nervous system
(Grassi et al., 2009). These obesity-associated factors may contribute to the development
of cardiovascular disease (Poirier et al., 2006).
137
Impaired endothelial function as measured by vasodilator response to Ach has
been demonstrated in human small resistance arteries of hypertensive (Cupisti et al.,
2000), diabetic (Rizzoni et al., 2001b), and uremic(Luksha et al., 2011) patients.
However, few data are available about the functional study of isolated arteries from
severely obese patients undergo bariatric surgery. Several in vivo studies have examined
the vascular function in obesity. For example, significantly greater vascular response to
AngII infusion has been observed in obese patients compared to non-obese subjects using
venous occlusion plethysmography (Nielsen et al., 2004). Other studies have also
examined the vascular function in human forearm vessels using non-invasive methods
(Perticone et al., 2001. Sciacqua et al.• 2(03).These studies observed reduction in the
endothelium-dependent vasorelaxation in response to Ach in obese patients compared
with healthy controls. In animal models. Boustany-Kari et al. observed enhanced
vascular reactivity of coronary arteries to phenylephrine and impaired endothelium-
dependent vasodilatation of coronary blood flow in obese rats (Boustany-Kari et al.,
2007).
Limited ex vivo human studies have examined vascular remodelling and vascular
function in obese patients. especially those without diabetes or hypertension. Recently,
Grassi et al. evaluated vascular structure and function in 17 severely obese patients
compared to 16 non-obese individuals. Small resistance arteries were dissected from
abdominal subcutaneous fat and conducted using wire myography (Grassi et al.,
2010b).The study observed that media thickness and media-to-Iumen ratio were
significantly greater in obese subjects than in non-obese subjects. It also showed
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impaired Ach-induced endothelial-dependent vasodilatation in obese patients. In
subsequent study the author observed that media thickness and media-to-Iumen ratio
were markedly greater in obese patients compared to lean controls, and Ach-induced
vasodilatation was impaired in obese patients compared to lean controls (Grassi et al.,
20IOa). Impaired endothelium-dependent vasorelaxation has also been observed in the
subcutaneous arteries of severely obese patients (De Ciuceis et al., 2011). This study
compared three groups of patients: hypertensive non-obese, severely obese and non-
obese controls. It observed that Ach-induced vasodilatation was significantly reduced in
obese and hypertensive patients compared to normotensive non-obese controls. The exact
mechanisms of endothelial dysfunction in obese patients are still understood, however
several factors were advocated to explain the obesity-related endothelial alterations,
including insulin resistance, inflammatory conditions, oxidative stress and reactive
oxygen species (Karalis et al., 2009, Zeidan et al., 2005).
In addition, some studies proposed that different mediators associated with
obesity such as free fatty acid (FFAs), tumour necrosis factor alpha (TNF- (1,),
interleukin (IL)-6, resistin, and leptin, have been shown to have a direct and / or indirect
effects on the vascular endothelium. For example leptin has been demonstrated to cause
direct effect on the endothelial production of NO (Winters et al., 2000). These trigger
factors may cause vascular alterations through thickening of intima and media of the
vascular wall (Ouchi et al., 2003).
Large vessel compliance (arterial stiffness), as measured by increased pulse wave
velocity (PWV), is higher in obese patients compared with the general population. PWV
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measured in the upper limbs was increased significantly in obese people (n = 27)
compared to non-obese controls (n = 25) independent of age, gender, and blood pressure
(Toto-Moukouo et al., 1986). In the overall population, a significant positive correlation
was observed between PWV and the degree of obesity (r = 0.85, P < 0.001) (Toto-
Moukouo et al., 1986). It has also been shown that obesity is associated with increase in
aortic stiffness, independent of age and blood pressure level (Sutton-Tyrrell et al., 2001).
This change in the arterial elasticity has been shown associated with impaired
endothelium-dependent vasodilatation (Arcaro et al., 2(02). The pathophysiological
mechanism of vascular stiffness in obese people is still largely unknown. However,
adipocytes have an elevated lipolytic activity that results in increased free fatty acids
release and insulin resistance (Safar et al., 2006). Indeed, obese patients with high levels
of leptin have been shown to be correlated with decrease in arterial distensibility
(Singhal, 2(05).
Patients undergoing bariatric surgery have decreased overall mortality compared
to those who do not have surgery (Sjostrom et al., 2007). Weight loss post bariatric
surgery has been shown to improve a number of cardiovascular risk factors including left
ventricular relaxation (Leichman et al., 2008), and left ventricular hypertrophy
(Ikonomidis et al., 2007). Marked decrease in body weight and BMI, together with
reduction in the blood glucose level, serum cholesterol, triglycerides and plasma lipids
have been observed in one-year follow-ups of severely obese patients who had
undergone bariatric surgery (De Ciuceis et al., 2011). However, very few data are
presently available about improvement of vascular function in isolated vessels from
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obese patients following surgery. On the other hand, several in vivo studies have
established that, reduction in the body weight and changes in the lifestyle can improve
endothelial function. Sasaki et al observed enhanced forearm blood flow in response to
Ach-induced endothelium-dependent vasodilatation in obese patients following diet-
induced weight loss (Sasaki et al., 2(02). Raitakari et al. showed that weight loss with
low calorie diet can improve flow-mediated vasorelaxation in obese patients (Raitakari et
al., 2(04). Similar findings have been demonstrated by Hamdy et aL. who observed
improvement in the macrovascular endothelial function in obese patients following six
months weight loss and exercise (Hamdy et al., 2(03). Sciaqua et al. demonstrated that
energy-restricted diet induce a significant and clinically improvement in Ach-mediated
vasodilatation of forearm vessels in obese healthy individuals (Sciacqua et al., 2003).
Moreover, significant reduction in media thickness and media-to-lumen ration was also
observed in this group of patients after one year following bariatric surgery (De Ciuceis
et al., 2011), however a few number of patients had improvement in endothelium-
dependent vasorelaxation in response to Ach following the surgery. Also, a marked
improvement in Ach-mediated vasodilatation has observed in dorsal hand vein of obese
patients after weight loss induced by bariatric surgery (Vazquez et al., 2005). Persistent
reduction in the body weight following bariatric surgery seems to improve vascular
function and reduces vascular structural alterations; however the responsible mechanisms
for that are still not understood. Some studies (Intengan and Schiffrin, 2001, Savoia and
Schiffrin, 2007) have proposed the possible roles of oxidative stress and inflammation in
the development of both endothelial dysfunction and vascular alterations.
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4.2 Aims
In light of the literature, we hypothesized that obesity can alters vascular structure
and function. Such alteration was observed previously in isolated arteries (small sizes)
obtained from obese patients, investigating a limited suit of vasoactive stimuli.
(Georgescu et al., 2011, De Ciuceis et al., 2011). Therefore, the current project was
focused to extend this principle of investigation to include different-sized arteries
isolated from severely obese patients who were undergoing bariatric surgery with
comparison to appropriate matched non obese control arteries. This was to understand
the vascular reactivity in obese patients through measurement of their responses to
different stimuli, and to establish whether obesity alters the vascular function by
impaired endothelium-dependent vasodilatation and preserved endothelium-independent
function. The study was also aimed to assess changes that might underlie altered vascular
responses following bariatric surgery (decrease in weight), and whether reduction in
weight will improve endothelial function. We also intended to characterize the relation
between ex vivo vascular responses and in vivo assessment of vascular function in obese
patients.
4.3 Materials and Methods
4.3.1 Participants and subcutaneous fat samples
Subcutaneous fat samples were obtained from 12 obese patients (7 males; average
age 38.7 ± 10.9), who were severely obese (average BMI 54.2 ± 6.1) undergoing bariatric
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surgery. Control fat samples were obtained from 26 appropriately consented healthy
volunteers (24 males; average age 63.9±11.17) without documented obesity and diabetes
mellitus, who underwent elective surgery (elective hernia repair). The ethical approval
was sought and granted by the Derbyshire Research Ethics Committee and the local NHS
R&D department. Informed written consent was obtained in accordance with Good
Clinical Practice guidelines according to the principles expressed in the Declaration of
Helsinki. Details on obtaining baseline fat samples and at six month after bariatric
surgery described in methodology chapter section 2.2.3. In the present study, different
size arteries (small < 600 urn and large> 600 urn) were dissected from each sample and
mounted as a ring preparation on wire myography as previously described in section
2.4.3.
Four abdominal subcutaneous fat samples were also obtained from six month
follow-up post bariatric surgery patients. Arteries were dissected from these samples in
each patient and investigated to the same vasoactive agents that used in the baseline ones.
Details on the biopsy procedure transfer of fat samples for experimental study and the
techniques of arterial dissection and mounting on wire myography are described in
section 2.4.
4.3.2 Preparation of vasoactive agents
Vasoconstrictor and vasodilator agents that used per experiments in this project to
investigate the vascular function in obese subjects were include NA, ET-I, AngII,
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U46619, vasopressin, BK, Ach, and SNP. Details of the purchases and preparation of
these agents and the physiologic solutions are described in detail in section 2.3.
4.3.3 Protocol of experiment
Following mounting, arteries were kept for 15-30 minutes to be acclimatised and
then subjected to normalisation process. The general protocol of experiment is described
in detail in the methodology chapter section 2.5. The internal diameter of arteries was
calculated as described before in section 2.4.3.
For the vasoconstrictor protocol, following a wash out of vessels and re-establish
the base line, cumulative-concentration response curves were constructed for the
following vasoconstrictors; NA (10.10 mol/L - 10-4mollL), ET-l (10-12 mollL _ 10-6
mol/L), U46619 (10-12 mol/L - 10-6 mol/L), AngII (10-12 mollL - 10-6 mol/L), and
vasopressin (10-12 mol/L - 10-6mollL) starting with the lowest concentration of the drug
allowing 3-5 minutes per concentration.
Separate protocol was carried out for experiments testing vasodilator drugs.
Following washout period and re-establishment of the baseline (as described before in
the general protocol), arteries were first contracted by stimulating them to a combination
of (100 nmol/L U46619 and 1 nmol/L ET-1). Once the peak steady contraction had
reached, cumulative-concentration response curves for different vasodilators including;
bradykinin (BK), acetylcholine (Ach), and sodium nitroprusside (SNP) were constructed
starting with the lowest concentration of the drug to the highest concentration, which was
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100 pM (l0-1Omolar) to 100 JlM (l0-4 molar) for all vasodilators allowing 3-5 minutes
per stimulation (as described in section 2.5.2 and Table 6).
4.3.4 In vivo haemodynamic measurements
Carotid-to-femoral arterial PWV was measured using an oscillometric device
(Vicorder, Skidmore Medical Ltd, Bristol, UK). Brachial artery blood pressure was
measured in the non-fistula arm using an oscillometric device (Datex-Ohmeda, GE
Healthcare, USA). PWV is calculated by the software by dividing arterial transit time by
measured distance. The mean of 2 measurements was recorded (as described in section
2.5.3).
4.3.5 Statistical analysis
Contractile responses were expressed as an increased contraction in milliNewtons
(mN) above the isometric baseline. The maximum contractile response (Rmax) for each
agent in all groups were calculated and EC50 value (defined as the concentration of drug
required to produce 50% of the maximum response), while the response for vasodilators
BK, Ach, and SNP was expressed as maximum % of relaxation from the preconstriction
state. Details on Lab Chart data calculation are described in section 2.6. All data were
expressed as mean with standard error of the mean (mean ± SEM) and the analysis was
using GraphPad Prism-5 software. The differences were tested at multiple dose-response
time points for all data. All continuous variables were tested for normality using their
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histograms and normality tests. The comparison between all groups was performed by
using students t-test and differences were considered significant when P < 0.05. In regard
to correlation of in vivo with ex vivo data, we correlated the PWV and blood pressure
data of each patient with each vasoactive drug in each vessel size. All PWV and blood
pressure data was expressed as mean ± SEM. Relationships between in vivo and ex vivo
data was determined using spearman's rho correlation coefficient, which considered
significant at *p = 0.05, and **p = 0.01 levels (2-tailed). All statistical analysis was
undertaken using GraphPad Prism-5 software and SPSS VI2.
Differences in the arterial responses of obese patients before and after surgery
were determined either by paired Hest or repeated measures of two-way analysis of
variance (ANOVA) with Bonferroni's post tests for multiple comparisons.
4.5 Results
The background characteristics of obese and control groups are described in
(Table 20). The mean age of obese patients was younger than that of controls, and sex
were similar between both groups. As expected, BMI was significantly higher in obese
patients compared with controls. There was no significant difference in systolic and
diastolic blood pressure between both groups. Patients and controls had similar renal
function and smoking habits. Five patients were on angiotensin converting enzyme
inhibitors (ACEIs), and two patients were on angiotensin receptor blockers (ARB).
146
4.5.1 Vascular size
The total number of all small vessels tested in all vasoactive agents was 53 in
obese (07 arteries were discarded) and 72 in control groups (11 arteries were discarded),
whereas the total number of all large arteries was 47 in obese (05 arteries were discarded)
and 65 in controls (07 arteries were discarded) (Table 21). In small vessels used per
vasocontractile agent, the average arterial size in obese patients was ranged between 235
urn - 577 urn in diameter, whereas in normal controls was between 220 urn - 575 urn, In
small arteries, the internal diameter (ID) was similar between obese and control groups
440.7 ± 82.9 urn in obese (n = 33), and 447.6 ± 76.4 urn in control groups (n = 45), P =
0.951. Similarly, there was no significant difference in the size of large vessels between
both groups, it was 730.2 ± 94.3 urn (n = 30) and 716.5 ± 78.6 urn (n = 40) in obese and
controls respectively, P = 0.911. In vessels that investigated per vasodilator drugs, there
small arteries size was similar between obese and controls with average ID (urn) 492 ±
53.4 urn in obese (n = 20), and 517.6 ± 45.1 urn in control groups (n = 27), P = 0.715.
While the average ID of large arteries tested per vasodilator drugs was 738.3 ± 81.1 urn
(n = 17) and 717.7 ± 45.1 11m (n = 25) in obese and controls respectively, P = 0.812.
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Table 20 Characteristics of obese and control patients
Characteristic Obese Control
(N= 11) (N=:6 )
Age: (veari 38.7 ± 10.9 63.9 - 11.2
Sex ~I=7,F=5 1\1= 24, F = 2
systolic BP (111111 HgJ 137.~= 12.7 1H.: = 16.5
Diastolic BP (111111 HgJ S1.2= 10.5 80.6 = 9.5
~IAP 100.0=9.3 98.' = '.1
Creatinine unn LI 82.9 = 11.3 84.8 = 5.9
~GFR (mlminI. i 3 m-) is.l=lIA g-t ..:l = 5.2
B~lI 5..L2 = 6.1 26.2 = 2.3
Smoker
-+ 10
D~I ...
.'
HTN -l 3
IHD :
eVA 0
P value
O.O"!_:J
0.899
0.969
0.915
0.8"'0
0.564
<: 0.0001
)."s
)."s
)."S
)."5
~s
Abbreviation: N, number of patients; eGFR, estimated glomerular filtration rate; BP, blood pressure;
MAP, main arterial pressure; BMI, body mass index; OM, diabetes mellitus; HTN, hypertension;
IHO, ischemic heart disease; CVA, cerebrovascular accident; NA, non-applicable; NS, non-
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Table 21 The internal diameter of small and large arterial sizes in obese and controls
AUarteries size of the used experiments testing the etTects of obesity on vasoactive agents.
Obese Control Pvarue
Small SmaD
Noradrenaline
7
401J°::l: 65.1Eumber 419.4 ::1:623 0.84
~dothehn-l 7 9umber
502.2 ::I: 85.1 47U ::I: 101.6 0.82
U4
Eumber 7 9452.4 ::1:98.5 424.4: 129.1 0.86
t~y,t:w n 6 8
396.8 : 101.3 435.5 : 39 ..2 0 ..85
Vaso~ressin 9Num er
484.1 :67.4L" 453.7:67.3 0.69
H~t'~ 7 9
L" 478.8::1:26.4 521..2::1:46.6 0.47
Ac~lecholine
486.8: 82.4
~
~ er 504.2::1: 60.1 0.86
So~ nitr1.wrosside 7 9N er
L. 482.2::1:21.3 519.4: 41.8 0.48
Obese Control P value
Luge Large
Noradrenaline
6Number 9
L. 735.8 : 78.3 683.8 ::1:42.2 0.53
Endothehn-l
Number 6 9
L. 770.4: 80.5 749.2 ::I: 92.6 0.87
U46619 8umber 7
L. 733.8 : 84.6 702.1: 42.8 0.73
AnRiotensi II
Number 6 7
L 686.8 : 54.4 693.1 ::1:66.2 0.94
Vasopressin
7Number 5
L. 724.1::1:68.1 681.1 :57.5 0.63
Bracfvkinin
Number 5 8
L- 738.6: 52.9 715.2 :41.1 0.86
Acetv1echoline
Number 6 8
L· 692.8: 45.8 710.8: 55.9 0.92
Sodium nitruprosside
9Number 6
L· 748.6: 62.5 729.1::1:79.5 0.68
.---.----. ¥--'--'-~-----'---"-'------"--'--'-"-~--'--""--- ., • ~"~"'·"·"·'A ___'_.• •
Number, is the numberoflarge arteries that usedper concentration-response CUJVeto an vasoactive
agents. Lo is the nonnalized internal diameter of arteries. Data are expressed as mean e SlIM and the
comparison is byt-test.
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4.5.2 Vascular function
4.5.2.1 Effects of obesity on the KPSS contractile response.
The maximum KPSS contraction in all each-sized arteries was similar between
control and obese patients. In small size vessels. the KPSS contraction was 9.1 mN ± 6.2
in obese (n = 53). and 6.9 mN ± 1.8 in controls (n = 72). P = 0.701. Similarly, in all large
arteries the difference in the maximum KPSS response between both groups was not
significant. it was 15.4 mN ± 7.9 in obese (n = 47) and 13.0 mN ± 6.5 in controls (n =
65), P = 0.890. However. we observed that arteries with large diameter size had a higher
maximal contractile response to KPSS in each groups (Figure 24).
Smell .Iz.arterlea
j
r
/
KPSS contraction
Large alz. arterlea
KPSS contraction
Figure 2S The maximum KPSS contraction in smaU and large arteries of obese and controls
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4.5.2.2 EtTects of obesity on the contractile response of different-sizes arteries to
different vasoconstrictors
In small vessels, results for the maximum contraction of arteries (Rmax), and the
potency of drug (ECso) to all vasocontractile agents in small arteries are presented in
Table 22. Greater contractile response to all vasoconstrictors was observed in small
arteries isolated from obese patients compared to controls. This contraction was highly
significant in response to U46619 and vasopressin (P<O.OOOI)(see Figures 25 C, D and
E). Significantly greater contractile responses to NA, ET-l and AngII were also observed
between both groups (P = 0.015, 0.006 and 0.004 respectively). The highest contractile
response in each group was observed in response to U46619 (Rmax, 12.7 mN ± 0.3 in
obese and 9.3 mN ± 0.3 in control groups), while the lowest contractile response was
observed in response to NA and AngII. The potency of NA, ET-I, AngII and vasopressin
was similar between the two groups. However, small vessels of obese patients were
highly potent to U4 than small vessels of control group (ECso, 9.0 molar ± 0.1 in obese
and 8.3 molar ± 0.1 in controls, P = 0.(02) (see Table 22 and Figure 25 C).
In large arteries, Table 23 and Figure 26 showed the results for all
vasoconstrictors of in both groups. Greater contractile responses to all vasoconstrictors
were obtained in large arteries of obese individuals compared to controls. The difference
in the contractile response to NA, ET-1, U46619 and AngII was highly statistically
significant between both groups with P < 0.0001 in each drug. A significant greater
contractile response to vasopressin was also observed in large vessels of obese patients
than controls (P = 0.001). These results also showed that the highest contractile response
obtained in both groups was in response to U46619 (17.3 mN ± 0.4 in obese and 12.4
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mN ± 0.4 in controls), whereas the lowest response was in AngII response (8.4 mN ± 0.3
and 6.0 mN ± 0.2 in obese and controls respectively), as described in Table 23. Our data
also observed that large arteries of obese patients were highly potent to U46619 and
vasopressin than large vessels of controls, characterized with significantly less
concentration of both drugs were required to produce 50 % of the maximum response in
compared with controls (P = 0.001 and P = 0.019 respectively), see Figures 26 C and E.
The ECso of the other vasoconstrictors (NA, ET-I, and AngII) was similar.
Table 22 The maximum response of small arteries and Potency of aU vasoconstrictors in
obese and controls.
R_ Obese (n = 12) Control (n = 26) P value
Noradrenalin 6.2±0.1 mN 5.6±0.1 mN 0.015
Endothelin-l 10.3 ±0.2mN 8.9±0.6mN 0.006
U46619 12.7±0.3 mN 9.3 ±0.3 mN <0.0001
Angiotensin II 7.4 ±0.1 mN 4.8±0.2mN 0.004
Vasopressin 11.1 ±0.4 mN 7.0±OAmN <0.0001
sc.,
Noradrenalin 7.9 ±0.2 8.2±0.1 0.171
Endothelin-l lOA ± 0.1 10.3 ±0.1 0.519
U46619 9.0±0.1 8.3±0.1 0.002
Angiotensin II 9.1 ±0.1 9.4 ± 0.2 0.132
Vasopressin 9.9±0.1 10.1 ± 0.2 0.638
Abbreviations: Rca. maximum response inmN; %, percentage of relaxation; EC se- potency 0f drug;
(expressed as the negative logarithm of the ECso)' Data are mean::!: S~ and comparison is by
students t-test.
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Small arteries
A -- Control (n=10)
-- Obese (n=7)
*
8
·10 -8 -8 -4
log concentration of Noradrenaline (molar)
B -- Control (n=9)
-- Obese (n=7)
·12 ·10 -8 -8 -4
log concentration of Endothelln-1 (molar)
c -- Control (n=9)
-- Obese (n=7)
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***
-12 ·10 -8 -8 ·4
Log concentration of U4 (molar)
D -- Control (n=8)
-- Obese (n=6)
t 8
.5 6
**
I:
·12 ·10 -8 -8 -4
log concentration of Angiotensin II ( molar)
E
-- Control (n=9)
-- Obese (n=6)15
·12 ·10 -8 -8 -4
log concentration of Vasopressin (molar)
Figure 26 Concentration-response curves for vasoconstrictors in small vessels of obese and
controls
Data are expressed as mean ± SEM. NA (A), ET-l (B), U4 (thromboxane A2) (C), AngII
(D) and vasopressin (E). The differences were tested at multiple dose-response time
points for all data. Comparison is by students t-test, *p < 0.05, **p < 0.001, ***p <
0.0001.
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Table 23 The maximum response of large arteries and Potency of aU vasoconstrictors in
obese and controls
R_ Obese (n = 12) Control (n =26) Pvalue
Noradrenaline 15.3 ±0.3 mN 11.1 ±O.SmN <0.0001
Endothelin-l 14.6±0.3 mN l1.7±O.3 mN <0.0001
U46619 l7.3±0.4mN l2A±OAmN <0.0001
Angiotensin n 8.4±O.3mN 6.0±O.2mN 0.0002
Vasopressin l4.5±0.4mN 11.3 ±O.5 mN 0.001
ECso
Noradrenaline 7A±0.1 7.7±0.1 0.117
Endothelin-l 10.1 ±O.l 9.8±0.2 0.129
U466l9 9.8 ±0.1 8.9 ±OA 0.001
Angiotensin II 9.5 ±0.3 9.6±O.6 0.714
Vasopressin 9.9±0.1 9.3±0.1 0.019
Abbreviations: R.max.maximumresponseinmN; %,percaltage of relaxation; ECwpotencyofdrug
(expressed as the negative logarithm of the ECso Data are mean± SEM, and comparison is by students r-test.
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Large arteries
c -- Control (n=8)
-- Obese (n=7)
20 ***
A --- Control (n=9)
-- Obese (n=6)
20
***
-12 -10 -8 -8 -4
log concentration of U4 (molar)
o
-- Control (n=7)
-- Obese (n=6)
-- Control (n=9)
...... Obese (n=6)
1
I
-10 -8 -8 -4 -2
log concentration of Noradrenaline (molar)
B
-12 -10 -8 -6 -4
log concentration of Angiotensin. (molar)
***
1
I
l'
E
-- Control (n=7)
-- Obese (n=5)
.e
-12 -10 -8 -8 -4 _11
log concentration of Endothelln-1 (molar) §
-12 -10 -8 -8 -4
log concentration of Vaaopr8881n (molar)
Figure 27 Concentration-response curves for vasoconstrictors in large vessels of obese and
controls
Data are expressed as mean ± SEM. NA (A), ET-l (B), U4 (thromboxane A2) (C), AngII
(D) and vasopressin (E). The differences were tested at multiple dose-response time
points for all data Comparison is by students t-test, "P < 0.05, **p < 0.001, ***p <
0.0001.
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4.5.2.3 Effects of obesity on the contractile response of different-sized arteries to
vasoconstrictors- KPSS
Vasocontractile response of both sized-vessels to different vasoconstrictors was
assessed as a percentage maximum KPSS-induced contraction in an effort to normalise
the data. The percentage of maximum contractile response was maintained as a greater
response of all sized vessels to all vasoconstrictors was observed in obese patients
compared to controls. In obese patients the maximum contractile response of small
arteries to ET-I, U46619, AngII, and vasopressin was significantly higher compared to
controls (Table 24), while it was not significant in response of NA. In obese group, the
highest % maximum contractile response of small vessels was in response to vasopressin
(138.2 ± 3.6 % KPSS). In control group, it was in response to U46619 (120.9 ± 3.1 %
KPSS). In both groups, the lowest % of contraction was in response to AngII (84.8 ± 2.4
% KPSS in obese versus 65.3 ± 2.1 % KPSS in controls). However, the potency of all
vasoconstrictors was similar between both groups.
In large vessels, statistically significant difference in the % maximum contractile
response to ET-I, U46619, AngII, and vasopressin has obtained with greater response in
obese group compared to controls (Table 25), whereas no difference has observed in NA
response. In obese and controls, the vasopressin contractile response was the highest in
the group (125.6 ± 3.6 % KPSS in obese and 113.2 ± 3.7 % KPSS in controls, P =
0.043). Whereas in obese patients, the lowest % was in response to NA (85.2 ± 2.6 %
KPSS), and in controls, it was in response to AngII (74.6 ± 1.9 % KPSS). In obese group,
large arteries were highly potent to vasopressin and U46619 than controls. In vasopressin
response, the potency was (9.3 ± 0.1 in control and 9.8 ± 0.12 in obese, P = 0.023), while
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in U46619 (8.9 ± 0.1 in control versus 9.7 ± 0.3 in obese, P = 0.012). Similar drug
potency of NA, ET -1, and AngII was obtained between the two groups.
Table 24 The % maximum KPSS -induced contraction in small arteries of obese and
controls
Obese (n = 12) Control (n =26) P value
92.5±3.·"'0 89.9 ± 2.S °0 0.56-1
II.U ±:U D;' 101.5 ± 1.700 0.009
136.6±3.i% 120.9± 3.1 00 0.006
S-LS±2A 'lo 65.3 ± 2.1 °0 < 0.0001
138.::± 36°0 90.6 ± 3.1 °'0 < 0.0001
'{ oread rer a I·ne
Endothelin-I
J-t6619
Ar.gictenstn II
Vasopressin
Abxeviations : • DMax KPS S. percentage of maximrn; KPSS contracnon; Data are mean = StM.
and comparison is by t-resr
Table 2S The % maximum KPSS-induced contraction in large arteries of obese and
controls
%MaxKPSS Obese (n = 12) Control (n = 26) Pvalue
Noradrenaline 85.2±2.6~/o 80.4±2.5 % 0.280
Endothelin-l 105.4±2.6% 96.8±2.7% 0.015
U46619 1l0.8±3.6% 99.5 ± 3.6 % 0.048
Angiotensin II 101.4±1.4% 74.6± 1.9% <0.0001
Vasopressin 125.6±3.6% 113.2±3.7% 0.043
Abbre\iations; % Max ms, percentage of maximum KPSS contraction; Data are mean ±SEM,
and comparison is by students t-test.
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4.5.2.4 Effects of obesity on the vasorelaxation response of different-sized arteries to
different vasodilators
In small arteries, results for the percentage relaxation (Rmax)of small arteries and
the potency of drug (EC50) to all vasodilators (BK, Ach, and SNP) in the two groups are
described in Table 26 and Figure 27. There were some differences in the baseline
relaxation starting points between both groups (but not significant), however, we used a
combination of low concentration of (lOO nmol/L U46619 and 1 nmol/L ET-I) for
preconstriction until got a steady contraction before starting vasorelaxation response
curves. There was no significant difference in the potency of these drugs between obese
and controls. However, the % of relaxation in response to Ach and BK (endothelium-
dependent vasodilators) was significantly lower in obese patients compared to controls
(Figures 27 A and B). The % relaxation in response to Ach was 49.4 % ± 0.6 and 53.8 %
± 1.3 in obese and controls respectively (P = 0.021). While in BK, it was 37.4 % ± 0.7 in
obese and 40.1 % ± 0.6 in controls, P = 0.008. Relaxation to SNP was similar in the two
groups (62.7 % ± 1.6 in obese and 62.4 % ± 1.3 in controls, P = 0.886).
In large arteries, Table 27 and Figure 28 illustrate the percentage maximum
relaxation (Rmax)of larger arteries to all vasodilators including Ach, BK, and SNP, and
the potency of these drugs (EC50). Despite similar observation in the vasodilator drug
potency in large vessels of obese and control groups, the maximum vasorelaxation
response to BK and Ach obtained in obese patients was also significantly less than that
obtained from controls (Figures 28 A and B). The % relaxation in Ach group was 56.7 %
± 1.8 in obese and 65.6 % ± 1.4 in controls, P < 0.0001. The % relaxation in BK group
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was 48.8 % ± 0.9 in obese and 52.8 % ± 0.8 in controls, P = 0.009. The Relaxation
response to SNP was similar between both groups (Figure 28 C).
Table 26 The % relaxation of small arteries and potency of aU vasodilators in obese and
controls
...._-;.,_----
R_ Obese (n = 12) Control (n =26) ~va1ue
Bradykinin 37.4±0.7 % 40.1 ±0.6% 0.008
Acetylcholine 49.4±0.6% 53.8 ± 1.3 %, 0.021
Sodium nitroprusside 62.7± 1.6% 62.4 ± 1.3 % 0.886
Bradykinin
Acetylcholine
6.8±0.1 6.9±0.1
7.1 ±0.1
0.427
6.9±O.2 0.117
Sodium nitroprusside 6.8±0.1 7.1 ±O.3 0.100
Abbreviations: Ram, maximumresponseinmN; %, percentage of relaxation; ECS(l,potency ofdrug
(expressed as the negative logarithm of the ECS(l).Data are meane SEM, and comparison is by t-tes1
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Table 27 The % relaxation of large arteries and potency of all vasodilators in obese and
controls
Obes (n = 12) Contt (n = 26) P value
Bradykinin
Acetylcholine
48.8±0.9% 52.8 ±O.S% 0.009
56.7 ± 1.8% 65.6±1.4% < 0.0001
Sodium nitroprusside 66.7±0.2 % 67.5 ± 1.3% 0.629
ECso__ ...£::L ,_, ",.,.• .• ' • •0''"_.''." • • _." ,,,.,.
Bradykinin
Acetylcholine
7.4±0.3 7.2 ±O.l 0.131
7.2 ±0.1 7.4±0.2 0.365
Sodium nitroprusside 7.4 ±0.2 7.2±0.3 0.646
Abbreviations: R mil, maximum response inmN; %, percentage of relaxation; ECso' potency of drug
(expressed as the negative logarithm of the ECso)' Data are mean± SEM, and comparison is by t-test
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Figure 28 Concentration-response curves for vasodilators in small vessels of obese and
controls
Data are expressed as mean ± SEM. BK (A), Ach (B), and SNP (C). The differences
were tested at multiple dose-response time points for all data Comparison is by students
t-test, *p < 0.05, **p < 0.001, ***P < 0.0001.
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Figure 29 Concentration-response curves for vasodilators in large vessels of obese and
controls
Data are expressed as mean ± SEM. BK (A), Ach (B), and SNP (C). The differences
were tested at multiple dose-response time points for all data Comparison is by students
Hest, *p < 0.05, **p < 0.001, ***p < 0.0001.
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4.5.2.5 EtTects of obesity on ditTerent vasoactive response in each vessel size
To investigate the pattern of the vascular response in different vessel size in obese
patients, we analyzed the arterial response in small and large arteries. The contractile
response (Rmax) to all vasoconstrictors was significantly higher in large vessels compared
with small ones (P < 0.0001 in each drug response). In vasorelaxation responses, our
results observed that the percentage relaxation to all endothelium-dependent and
endothelium-independent vasodilators was significantly higher in large than small
arteries, this difference being highly statistically significant in response to BK (P <
0.0001) see Table 28.
Table 28 The maximum responses of aU sized-vessels to different vasoactive agents in obese
patients
Ram Small Large Pvalue
Noradrenaline 6.2±OJ mN 15.3± 0.3 mN <0.0001
Endothe1in-l 10.3±O.2 mN 14.6±O.2mN <0.0001
U46619 12.7± OJ mN 17J±0.4mN <0.0001
Angiotensin n 7.4±O.l mN 8.4±0.3 mN 0.004
Vasopressin 1l.1 ± 0.4 mN 14.5± 0.4 mN <0.0001
Bradykinin 37.4±O.7% 48.8 ± 0.9 % <0.0001
Acetylcholine 49.4±O.6 % 56.7 ± i.s % 0.004
Sodium nitroprusside 62.7 ± l.6 % 66.7±0.2 % 0.038
Abbreviations: R.mx, maximwnresponsein mN; %, percentage ofrelaxation; Data are mean ±SEM, and
Comparisonis by students I-test.
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4.5.3 EtTects of weight loss on the vascular function in obese patients following
bariatric surgery
The study investigated the vascular function in isolated small arteries obtained
from obese patients at six months after bariatric surgery. The results from six month
samples were compared with those before surgery (baseline samples) for each vasoactive
agent in each patient. Background data on the total number of small arteries used per
vasoactive agent and their internal diameter (ID) in all obese patients following surgery
are illustrated in Table 29. The vessel size in each vasoactive drug was similar between
pre-surgery and post-surgery groups. The average ID was 502.2 ± 58.3 urn in pre-surgery
group, while it was 495.4 ± 62.6 urn in post-surgery group. In KPSS response, there was
no significant difference in the maximum KPSS contraction in obese patients before and
after surgery. The total average KPSS contraction of small arteries was 9.3 ± 5.6 mN (n =
26) in obese patients before surgery, and 8.0 ± 2.9 mN (n = 26) after surgery, P = 0.875
(Figure 29).
Small arter'"
I
I
J
KPSS contraction
Figure 30 The maximum KPSS response in small arteries (Obese vs Post surgery).
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Tables 30 and 31 described results of the average maximum response (Rmax) of
small arteries to all vasoactive agents and the potency of these agents (ECso) in obese
individuals before and after surgery. In regard to the effect of surgery on the vascular
response to different stimuli, a similar vasocontractile response of small vessels to NA,
ET-I, U46619, AngII, and vasopressin was obtained in obese patients before and after
surgery. However a trend of maximum contractile response to each drug was obtained in
pre-surgery group compared with those post-surgery (Figure 30). We also observed that
the highest contractile response obtained in both groups was in response to U46619 (13.5
± 0.3 mN pre-surgery vs 11.6 ± 0.4 mN post-surgery group) and vasopressin (11.5 ± 0.4
mN pre-surgery vs 10.3 ± 0.3 mN post-surgery group), whereas the lowest arterial
contraction in both groups was observed in response to NA (6.5 ± 0.1 mN pre-surgery vs
6.1 ± 0.2 mN post-surgery patients). Similarly, there was no significant difference in the
potency (ECso) of each vasocontractile agent observed between the two groups (Table
31).
In the vasorelaxation response of isolated vessels to BK, Ach, and SNP (Figure
31), our results observed that the average % of vascular relaxation in obese patients
before and after surgery was not statistically significant, though the response to BK and
Ach was slightly more in post-surgery patients compared with those before surgery. In
BK response, the % of vasorelaxation was 37.3 ± 0.8 % in pre-surgery and 40.6 ± 1.1 %
in post-surgery group, P < 0.240, while in Ach response; it was 49.1 ± 0.9 % and 51.8 ±
1.8 % in pre-surgery and post-surgery groups respectively, P < 0.324. The % of
vasorelaxation in response to SNP was 63.1 ± 2.0 % in pre-surgery and 62.7 ± 1.6 % in
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post-surgery group, P < 0.924. The potency of each vasodilator drug was similar between
both groups. These results were also analysed using two-way repeated measures of
ANOYA to find out the effect of surgery on the vascular response. We observed that no
significant difference in the potency and the maximum response of small vessels to NA,
U46619, AngII, and vasopressin was obtained between the two groups. However, the
contractile response to ET-l was statistically significant (P = 0.043).
Table 29 The internal diameter of smaUarteries of obese patient's pre and post- surgery
Pre-surgery tn =4) Post-surgery (n =4)
Noradrenaline
Number 4 4.
1.. 492.7 %53.3 461.5 ± 76.8
Endothelin-l
Number 3 3
1... 489.7 %72.6 522.6 ±35.3
U4
~umber 3 3458.2 %68.8 517.2±48.4
An2iotensiII
3Number 3
L. 511.4 ± 93.4 538.9 ± 88.3
Vasopressin
~umber 3 3509.8 ± 73.9 463.8 ± 112.3
~~~Djn 3 3
525.6 %38.5 492.6 ± 74.5
A=holineNum 4 4
1.. 482.3 ± 76.5 504.8 %64.3
Sod1um nitruprosside
~umber 3 3548.6 ±47.5 511.3 %21.3
Pvalue
0.604
0.837
0.668
0.689
0.885
0.462
0.759
0.357
Number is the number 0 fsmaB arteries that complete the concentration-response curve. to is the normalized
intemal dWneterofarteries. Data are expressed asmean% SEM andthecomparisonis by studentst-test.
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Table 30 The maximum vasoactive response of small arteries in obese patient's pre and
post-surgery
R_ Pre-surgery Post-surgery Pvalue *Pvalue
(n = 4) (n = 4)
Noradrenaline 6.5 ± 0.1mN 6.1 ± 0.2 mN 0.277 0.679
Endothe1in-l 11.5±0.4mN 9.1 ± 0.3 mN 0.114 0.043
U46619 13.5±0.3mN 11.6±0.4mN 0.261 0.457
Angiotensin D 8.5±0.2mN 7.9±0.2mN 0.138 0.084
Vasopressin 11.5± 0.4 mN 10.3 ±0.3 mN 0.371 0.551
Bradykinin 37.3 ± 0.8 % 40.6 ± 1.1 ~/D 0.240 0.143
Acetylcholine 49.1 ± 0.9 % 51.8 ± 1.8% 0.324 0.390
Sodium nitroJlllsside 63.1 ± 2.0 % 62.7 ± 1.6% 0.924 0.301
Abbre\'iations: n,number of patients; R II1II., average maxim\D'!l response of aD patients; %, average percentage
ofrdaxation; Data a.remean ± SEM, and Comparison is bypail'ed t-test (P). and 2-way ANOVA C*P).
Table 31 The potency of all vasoactive agents in small arteries of obese patient's pre and
post-surgery
ECso Pre-surgery Post-surgery Pvaluc
(n = 4) (n=4)
Noradrenaline 7.6 ± 0.1 7.3 ± 0.2 0.251
Endothe1in-l 10.5 ± 0.1 10.2 ± 0.6 0.580
U46619 9.3±OJ 9.1±0.7 0.705
Angiotensin n 8.9 ± 0.1 9.1 ±0.2 0.504
Vasopressin 9.3 ± 0.5 9.7 ± 0.5 0.187
Bradykinin 6.8± 0.2 6.9±0.2 0.767
Acetylcholine 6.9 ± 0.1 6.8 ±O.l 0.647
Sodium ninoprusside 6.9 ± 0.1 7.0±0.1 0.521
Abbreviations: n,number 0fpatients; EC 5~'avelage potency of drug (; expressed as the negative logaritlun of
the ECso).Data are mean±SEM andcomparisonis by paired t-test.
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Figure 31 Concentration-response curves for vasoconstrictors in obese patients (pre-
surgery vs post-surgery)
The differences were tested at multiple dose-response time points for all data. Data are
expressed as mean ± SEM. Comparison is by paired t-test.
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Figure 32 Concentration-response curves for vasodilators in obese patients (pre-surgery vs
post-surgery)
The differences were tested at multiple dose-response time points for all data. Data are
expressed as mean ± SEM. Comparison is by paired t-test.
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4.5.4 Correlation of ex vivo data with in vivo haemodynamic measurements of obese
patients
Haemodynamic measurements including Pulse wave velocity (PWV), systolic
blood pressure (SBP) and diastolic blood pressure (DBP) for each individual (obese
patients pre-surgery and post-surgery) were measured in vivo as described in section
3.3.4. Tables 32 and 33 illustrated the relationship between haemodynamic
measurements in obese patients with the maximum vasoactive response and with the
percentage of maximum contractile-KPSS response respectively. PWV was significantly
correlated with the maximum response of large arteries to U46619 (r = 0.928, P = 0.006)
see Figure 33 B. It is also positively correlated with the maximum response of small
arteries to vasopressin (r = 0.885, P = 0.033) (Figure 33 C). These correlations lost when
the data was expressed as a percentage of maximum KPSS response (Table 33). The
correlation of PWV with other vasoactive agents was not statistically significant.
With regard to the correlation of ex vivo myography data with blood pressure, a
positive correlation was obtained between SBP of obese patients and the response of
large vessels to U46619 (r = 0.785, P = 0.048) (Figure 34 B). However, there was no
significant correlation between DBP and the vascular response of isolated vessels in
obese patients. In obese patients following surgery, our results observed no significant
correlations between ex vivo vasoactive response and in vivo measurement of PWV and
blood pressure, however a number of correlated points were small.
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Table 32 Correlations of in vivo data with ex vivo vasoactive responses of isolated different-
sized vessels of obese patients to different stimuli.
Vasuaenve vesset sue P\VY SDP DDP
.A2tnts
r value Pvalue r value P value r value P value
Noradrenaline S/llal/ 0.000 0..t61 0.150 0.59.t -O..t1.t 0.353Large 0.714 0.136 0.608 0.141 0.018 1.000
Endothelin-l Small 0.11.t 0.661 0.185 0.556 -0,185 0.556Large 0.31.1 0.563 -0.028 1.000 0.028 1.000
U46619 Small 0.46.1 0.301 0.392 0.395 0.607 0.166
Large 0.918 O.006~· 0.785 0.048~ 0.036 0.963
Angiotensin II SIT/all 0.371 0.497 0.3~7 OA97 0.142 0.802Large 0.771 0.102 -0.637 0.175 0.314 0.563
vasopressin Small 0.885 0.033" 0.376 0.497 0.521 0.297Large 0.600 0.350 0.153 0.783 0.500 OA50
Bradykinin ST11a/l
-0.357 0.444 -0.418 0.353 -0.321 0.497
Large
-0.300 0.683 0,600 0.350 -0.359 0.516
Acetylcholine Small
-0.485 0.355 -0.71-1 0,136 -0.231 0.658Large
-0.3 71 0.497 -0.3.1 7 1,497 0.600 0.2-11
Sodium nitroprusside Small
-0.571 0.100 -0.126 0.781 0.702 0.088Large
-0.600 0.2-11 -0.666 0.175 0.405 0.419
--~...--.-.-.- ..--.-.-- ..-....-.--.------ ..-.....----~_.__ ...,._ ...._-_ ......._---
Abbreviation: PWV, pulse wave velocity; SBP, systolic blood pressure; OBP, diastolic blood
pressure; r value, correlation coefficient; small, *Correlation is significant at the 0.05 level (2-
tailed), **Correlation is significant at the 0.01 level (2-tailed)
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Table 33 Correlation of in vivo data with the % maximum vasoconstrictor-KPSS induced
response of lID patients
Correlation of PWV, SBP, and DBP with the % maximum vasoconstrictor-KPSS induced
response of isolated different-sized vessels of HD patients to different vasoconstrictors.
Ya!loactln- Ye!l!lrl size PWY SBP DBP
KPSS Agents
r \ alur P \ alue r \ ulue p, alue r value P value
Noradrenaline Smail -0..t6~ 0.302 0.200 0.713 -0.200 0.713
L(J,.~e O.31~ 0.563 0.200 0.783 0.200 0.783
Fndorhelin-l Sm(]" -0.071 0.906 0.3 71 0.497 0.5 42 0.297
Large -0.542 0.297 -0.100 0.950 -0.820 0.133
U46U19 SlIIull 0.5 71 0.200 0.600 0.2-11 0.428 0 ... 19
Large 0.607 0.166 0.142 0.802 -0.01& 1.000
Anziotcnsin II Small 0.711 0.136 O.OS5 0.1)11) -O.12S O. Ill)
Large OAR:' O.l":' -0.-100 0.:'10 -0.1 10 0.,"10
Vasopressin Small -0.141 0.801 -0.085 0.919 -0.100 0.713
Large -0.300 0.683 0.200 0.713 0.1-12 0.802
Abbreviation: PWV, pulse wave velocity; SBP, systolic blood pressure; DBP. diastolic blood
pressure; r value, correlation coefficient; s; *Correlation is significant at the 0.05 level (2-tailed),
**Correlation is significant at the 0.01 level (2-tailed).
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Figure 33 Correlation Plots of Pulse Wave Velocity (PWV) of obese patients with the
maximum contractile response (R.u.,.) of smaUvessels (A) and large vessels (B) to U46619.
Panels C and D describe the correlation of PWV with the Rmax of small and large vessels
in responses to vasopressin respectively. Correlation coefficient (r) and P values are
shown in each panel.
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Figure 34 Correlation Plots of systolic blood pressure (SBP) of obese patients with the Rmax
of smaU vessels (A) and large vessels (B) to U46619.
The correlation of SBP with the Rmax of small and large vessels to vasopressin are shown
in curves (C and D) respectively. Correlation coefficient (I) and P values are shown in
each panel.
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4.8 Discussions
Impaired endothelium-dependent function has been demonstrated in isolated
vessels of obese patients (Grassi et al., 2010b, Georgescu et al., 2011). These studies
were mainly focused on the Ach-induced vasorelaxation. This chapter reports interesting
key findings on the effects of obesity on the vascular function of isolated subcutaneous
arteries obtained from obese patients who have undergone bariatric surgery. Firstly,
hyper-responsiveness of these arteries to different vasoconstrictors compared to control.
Secondly, impaired endothelium-dependent vasodilatation in response to Ach and BK
was observed in subcutaneous different-sized arteries of obese patients. Thirdly, there
was no significant improvement in the vascular function in a small group of patients six
months after bariatric surgery.
4.8.1 Isolated arterial function in response to vasoconstrictors
In light of the literature, greater contractile response to NA and ET-1 has been
observed in isolated vessels of diabetic (Hadoke et al., 2000) and uremic (Morris et al.,
2001). However, few data are available on the effect of obesity on the vasocontractility
of isolated vessels. Recent studies showed significant enhancement in the vascular
contraction (in response to NA) of isolated arteries in obese patients and obese patients
with diabetes compared to controls (Georgescu et al., 2011). In contrast, De Ciuceis et al.
observed no significant difference in the vasocontractile response of isolated vessels to
NA between obese, hypertensive obese, and control groups (De Ciuceis et al., 2011).
Therefore, to address that, we extend this principle of increased vascular reactivity in
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isolated vessels of obese patients by testing different-sized arteries to various stimuli
including NA, ET-I, U46619, AngII, and vasopressin.
The current study demonstrates that obesity can produce a significant vascular
hyper-reactivity to different vasoconstrictors. Although, the potency (EC50) of some
vasoconstrictors in small and large vessels was similar between the two groups, isolated
vessels of obese patients were significantly more constricted than that of controls. This
vasoconstriction was highly significant in response to U46619, AngII, and vasopressin
than that observed in NA, ET-l. These findings were similar to the response of isolated
small arteries from HD obtained in chapter 3. This may indicate that isolated vessels
from HD and obese patients are highly responsive to these drugs and / or these agents are
potent vasoconstrictors. However the isolated vessels of obese patients were highly
potent to U46619 and vasopressin. This may indicate that subcutaneous vessels of obese
patients are highly sensitive in response to these agents. Furthermore, the vascular
response was maintained when the data expressed as a percentage of KPSS response,
where significantly higher percentage of vasoconstriction in response to all
vasoconstrictors showed in obese patients compared to controls.
The exact mechanism by which the isolated vessels of obese patients showed
increment vascular contractility has not been known yet, however one proposed reason
could be due to the vascular alteration such as vascular hypertrophy and stiffness.
Recently, alteration in the vascular function in obese patients has been shown to be
accompanied with changes in the vascular structure including increase media thickening
and media-to-Iumen ratio (Grassi et al., 201Ob, De Ciuceis et al., 2011). Moreover, these
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structural changes together with impaired endothelium-dependent function in response to
Ach have also been recently demonstrated in isolated small arteries of obese patients
(Rizzoni et al., 2012), and patients with obesity and metabolic syndrome (Grassi et al.,
201Oa). All these findings might suggest presence of a mechanistic links between
functional abnormalities and structural changes among this risk group. However, the
present findings suggest presence of vascular dysfunction in obese patients characterised
by exaggerated vascular contractility in obesity, which probably could be secondary to an
alteration in the vascular structure that have been demonstrated previously.
Recent data on obesity-related vascular hyper-reactivity of human gluteal
subcutaneous vessels clarified that both anti-contractile function of subcutaneous vessels
and increase in the NO function are reduced among this group (Greenstein et al., 2009).
Other authors suggested that some factors are amplified in obesity; these include insulin
resistance, sympathetic nervous system activity and rennin-angiotensin system activity
(Grassi et al., 2009). These factors responsible for increased the vascular contractility in
obese individuals either through direct arterial response and reduced compensatory
vasodilator response in obese patients (Kataoka et al., 2001) or by increased adrenergic
and sympathetic activity (Landsberg, 2001).
Our data also observed variability in the vasoreactive response in isolated
different-sized vessels of obese patients. Functional heterogeneity in isolated different
range of vessel sizes has been demonstrated previously in diabetic patients with greater
contractile response in large arteries compared with large veins and small arteries
(Hadoke et al., 2000). The author observed no difference in the relaxation response to
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BK and SNP between the three categories of vessels, however large arteries did not
produce an active relaxation to Ach compared with small vessels. In the animal model,
variable contractile response from the highest to the lowest vasocontraction has observed
in large, medium, and small isolated vessels from normal animals using isovolumic
myography method (Lu and Kassab, 2011). However, there are no data published on the
vasoreactive response of isolated different-sized vessels from subcutaneous fats of obese
patients. The results presented in this chapter showed significantly greater contractile
response to all vasoconstrictors in large arteries than that observed in small vessels.
Furthermore, the relaxation response to all vasodilators was significantly more in large
arteries.
4.8.2 Isolated arterial function in response to vasodilators
The current chapter also demonstrated impaired endothelium-dependent function
in obesity characterized by a significant decrease in BK and Ach-induced vasorelaxation
in obese patients. The effect of obesity and obesity-associated factors on the endothelial
function has been reported in several studies investigating isolated small resistance
vessels from subcutaneous fats of obese people. In sever obese humans, both Ach-
induced vasodilatation (Grassi et al., 201Ob) and BK-mediated vasorelaxation (Sato et
al., 2002) in subcutaneous small resistance arteries (diameter ranged between 150 urn -
450 urn) were reduced compared with controls. Moreover, marked reduction in the
vasorelaxation response to Ach in isolated subcutaneous arteries has been observed in
patients with obesity alone and obesity together with diabetes mellitus (Georgescu et al.,
2011). Recently, significant reduction in the vasodilatation response to Ach was observed
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in isolated small subcutaneous vessels of normotensive and hypertensive obese patients
compared to controls (De Ciuceis et al., 2011). In both studies only small vessels were
investigated either in response to Ach alone or Ach compared with SNP. However to
address that issue, the present study was focused to investigate the vascular function in
different-sized vessels by testing them to different vasodilators (BK, Ach, and SNP).
Interestingly, the results presented here show that there is a marked impairment in the
vasorelaxation response of different-sized vessels of obese patients to both endothelium-
dependent vasodilators (BK and Ach), while similar vasorelaxation response to SNP has
observed in both groups. Therefore, impaired endothelial function in obesity does not
only affect large arteries (Levy et al., 2008) it also impairs small vessels as well. Our
findings are in keeping with the recent results of human obesity described previously in
this section and with the results comparing isolated small vessels of severely obese
patients with controls using pressurized myoraphy (Grassi et al., 201Ob), in which
endothelium-dependent function in response to Ach was impaired. Since BK mediated
it's action through stimulation of endothelial cells to release either NO (Michel and
Vanhoutte, 2010) or EDHF (Bellien et al., 2008), Ach also promotes it's action through
stimulation of the endothelium release of EDHF (Garland et al., 2011). Thus impaired
endothelial function could possibly due to a defect in NO or EDHF pathway. On the
other hand, Sivitz et al. observed that in vivo vascular responses to both Ach and
nitroprusside were impaired to approximately the same extent in the forearm vessels of
obese patients (Sivitz et al., 2007), suggesting this defect does not reflect a specific
abnormality in the endothelium-dependent function. However there is a general
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agreement that obese individual alone or with other chronic diseases such as diabetes and
hypertension have impaired endothelium-dependent function.
The association between obesity and vascular dysfunction has been widely
discussed; however, the exact pathophysiological mechanisms by which obesity can
cause impaired endothelial function are still unclear. Many proposed that insulin
resistance can impair NO vasodilator function through reduce the expression of NO
synthase (eNOS) in obese human endothelial cells (Georgescu et al., 2011). Also,
enhanced production of tumour necrosis factor (TNF) in obesity can down-regulate the
expression of eNOS and up-regulate ET-l in human extracellular matrix (Jonk et al.,
2007). Furthermore, presence of some hormonal factors such as insulin resistance
(Gustafson et al., 2007) and increase sympathetic activity (Grassi et al., 2004), might
have a role in obesity-related endothelial dysfunction. Other metabolic mediators in
obesity field might also have multiple adverse effects on the vascular function; these
include leptin, adipokines, TNF-a, and excess release of reactive oxygen species
(Knudson et al., 2008). These factors can impair endothelial function through stimulation
of vascular smooth muscle hypertrophy (Zeidan et al., 2005, Knudson et al., 2008). In
conditions other than obesity, an early data suggested impaired endothelium-dependent
vasodilatation in diabetic (Johnstone et al., 1993) and hypertensive patients (Panza et al.,
1990, Taddei et al., 1993). In our study, however we did not exclude the diabetes from
obese patients, while we exclude it from the control group. Therefore, we can suggest
that either the circulating factors associated with obesity and I or other co-morbidities are
most likely the contributory factor responsible for endothelial dysfunction.
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In obesity, increased in the arterial stiffness and decreased in elasticity as
measured by elevated PWV has been shown to impair endothelium-dependent function
(Arcaro et al., 2(02). In the current study, PWV as a measure of arterial stiffness
positively correlated with a vascular response of isolated different-sized vessels of obese
patients to vasopressin and U46619. Moreover, the present study also observed
significantly positive correlation between SBP of obese patients and the vascular
response to U46619. These findings reflect the aberrant response of isolated vessels of
obese patients which can be characterised by an exaggerated vasocontractile response of
isolated vessels to different stimuli. This change in compliance is partially due to
material alterations in the conduit arteries; however it is also BP and endothelial
dysfunction related.
In this chapter, we also measured the vascular reactivity in obese patients at six
months following bariatric surgery. Limited studies have previously examined the effect
of weight loss on endothelial vasodilatory function in isolated vessels of obese patients.
Recently, De Ciuceis et al. observed improvement of Ach-mediated endothelial
vasodilatation in isolated subcutaneous arteries in a few number (4 of the total 8 recruited
for surgery) of obese patients following bariatric surgery (De Ciuceis et aI., 2011).
However, the current results did not show significant differences in the contractile and
relaxation response of the recruited small number of obese patients before and after
surgery though a trend of higher contractile response has observed in obese patients
before surgery compared with those post-surgery. On the other hand, greater decrease in
the body weight with pronounced improvement in endothelium-dependent function of the
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forearm vessels was observed previously in obese patients following gastric bypass
surgery (Gokce et al., 2(05). Conversely, vascular function in obese patients' brachial
artery assessed by flow-mediated dilatation and nitroglycerin-mediated dilatation did not
change after weight loss (Brook et al., 2004). Our data on isolated vessels did not
demonstrate significant improvement in the endothelium-dependent function after
surgery; however the corresponding in vivo results (data not shown) of the same patients
showed significant improvement in the renal function characterized by marked
improvement in eGFR and reduction in albuminuria.
Although the results provided about the effect of bariatric surgery on the vascular
function did not achieve the statistical significance, particularly improvement in the
endothelium-dependent function, the percentage of vasorelaxation response to BK and
Ach appears more in post-surgery group compared with pre-surgery (but not significant).
This finding might provide some suggestions about the possibility of improved
endothelium-dependent function in obese patients with persistent weight loss induced by
bariatric surgery. Therefore, a large study with long-term follow-up is helpful to confirm
such improvement. Since impaired endothelial function in obese patients is associated
with increased future cardiovascular risks (Gokce et al., 2005), this kind of surgical
intervention might be associated with long-term clinical benefits.
In summary, obesity is associated with marked functional alterations in isolated
subcutaneous arteries of obese patients which are characterized by significant increment
responsiveness of subcutaneous resistance arteries to a wide range of vasoconstrictor
stimuli, and impaired endothelium-dependent vasodilatation in response to BK and Ach.
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Similar findings were observed in chapter 3, in which similar endothelial dysfunction
was observed in HD patients, indicating that vascular endothelium in HD and obese
patients would seem a reasonable target for uremic and obesity-associated factor
respectively. These changes highlights the elevated risks of cardiovascular, cerebral and
renal events reported in these risk groups. Improvement in the renal function and BMI
was observed after decreased in weight induced by bariatric surgery; however we did not
observe a significant improvement in the endothelial function in obese patients at six
month after surgery assessed by the response of isolated small arteries to endothelium-
dependent vasodilators (Ach and BK) investigating a small number of patients.
Therefore, further longer studies with large number of participants are needed to confirm
that.
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Chapter 5
General discussion
Chapter S: General discussion
Previous studies have identified impaired endothelium-dependent vasodilatation
in isolated subcutaneous small vessels of both uremic (Morris et al., 2001, Luksha et al.,
2011, Luksha et al., 2012) and obese patients (Georgescu et al., 2011, De Ciuceis et al.,
2011). Several reports established that ESRD and obesity are associated with vascular
alteration including functional and structural changes (Guerin et al., 2005, Grassi et al.,
201Ob, Rizzoni et al., 2012). Although, the effect of uremic on the vascular function in
isolated subcutaneous resistance arteries was demonstrated in ESRD patients, particularly
those on peritoneal dialysis (PD) and renal transplantation, very little information is
available on the effect of HD on the isolated vascular function. Enhanced vascular
contraction of isolated subcutaneous vessels from uremic patients in response to
vasoconstrictors has been reported before in one study (Morris et al., 2(01), though other
studies have not (Luksha et al., 2011, Luksha et al., 2012). These studies demonstrated
impaired endothelium-dependent vasodilatation in subcutaneous vessels of uremic
patients.
Therefore, the main aim of the current project was to establish whether the
isolated subcutaneous arteries of HD and obese patients show enhanced vascular
response and impaired endothelium-dependent function, and whether the bariatric
surgery improves vascular function. In obesity, exaggerated responses of isolated vessels
to vasoconstrictors (Georgescu et al., 2011), and impaired endothelium-dependent
function (Georgescu et al., 2011, De Ciuceis et al., 2011) have been reported before. We
dissected different sized-vessels, assuming that the vascular response varies depending
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on the size of the vessel; however lack of data to-date on the effect of uremia and obesity
on the vascular response of isolated different sized vessels. Therefore, we extended the
principle of vascular response in previous work to include investigation of isolated
different-sized vessels from the three groups (HD, obese, and controls) by testing them to
various stimuli.
In the first part of this project (chapter 3), we have examined the vascular
function (using wire myography technique) in isolated different-sized vessels in a group
of homogenous patients starting HD, and correlating the ex vivo myography data with in
vivo haemodynamic measurements of PWV and BP. The major finding in this part of the
project was that HD patients had impaired endothelium-dependent vasodilatation and
enhanced vasocontractility. This vascular enhancement in response to vasopressin was
significantly correlated to the in vivo measurement of PWV. The present data also
observed an inverse correlation of diastolic BP of HD patients with the contractile
response of small arteries to vasopressin, and with the vasorelaxation response of large
arteries to SNP. In light of these findings, we can suggest that PWV as a measure of
arterial stiffness positively correlated with a greater response to vasopressin. This may
reflect the aberrant haemodynamic response of isolated arteries in HD patients which can
be characterised by an exaggerated contractile response and deficient relaxation. The
reason for that could be due to an alteration in the vascular structure including arterial
calcification and thickening of muscular media that have been reported previously in this
risk group of patients (Adragao et al., 2009). These findings, however strengthens an
association between HD and increased conduit arterial stiffness.
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The vascular fmdings in this project are consistent with previous studies
highlighting impaired vasorelaxation response to BK and Ach (both endothelium-
dependent vasodilators) in uremic patients (Morris et al., 2001, Luksha et al., 2011,
Luksha et al., 2012). Similarly, these findings have also been demonstrated in human
with severe obesity (Grassi et al., 201Ob), and in patients with obesity alone or obesity
with chronic diseases such as diabetes mellitus and hypertension (Georgescu et al., 2011,
De Ciuceis et al., 2011). Only small isolated resistance vessels were investigated in all
these studies ex.amined a limited suite of vasoactive stimuli. In order to examine this
further in the current study small and large isolated arteries from the three groups of
participants were directly investigated to different vasoactive agents using wire
myography. This will ex.tend the study research area to a different range of vessel sizes
and a wide range of stimuli.
We provide some major findings on the effect of both HD and obesity on the
vascular function. In chapter 3, we demonstrated significant incremental increase in the
arterial contraction in both small and large arteries of patients who are purely on HO.
Such response has not been observed before in HO patients. However, this finding is in
keeping with uremic study by Morris et al. 2001, at least in part with enhanced response
of small vessels to NA and ET-1 in uremic patients compared to controls (Morris et al.,
2001), but in contrast with the recent study of Luksha et al. 2011, in which uraemia had
no effect on the response of small isolated vessels to NA, ET-I, and AngU (Luksha et al.,
2011). However in both studies, impaired endothelium-dependent vasodilatation was in
agreement with our observation that the vasorelaxation response to Ach and BK was
significantly blunted in HD patients. This will support the concept of an impaired
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endothelial function in the uremic milieu in all late stages of CKD including those on
dialysis. Interestingly, similar results (enhanced vascular contractility and impaired
endothelium-dependent function) were obtained in isolated different-sized vessels of
obese patients (in chapter 4).
In obesity, previous studies that examined the endothelial function in isolated
small vessels were focused on the assessment of Ach-induced relaxation in patients with
obesity alone or associated with chronic diseases. In chapter 4, our data was in keeping
with the results that show enhanced response to NA and ET-l in isolated small vessels
from patients with type 2 diabetes (Hadoke et al., 2000), and in patients either with
obesity alone or obesity with diabetes (Georgescu et al., 2011). However it was in
contrast with the fmdings observed that isolated vascular contractility in response to NA
was not altered in obese and hypertensive obese patients (De Ciuceis et al., 2011). The
vascular response in these studies has not been investigated with regard to different sized
vessels and different stimuli. Therefore, to address this issue, the current project was
examined the vascular function in different -sized vessels by testing them to various
stimuli. In all vessel sizes of obese patients, we showed that the vasocontractile response
to different vasoconstrictors was greatly enhanced and the endothelium-dependent
relaxation, to Ach and BK was significantly decreased. However, in effort to normalize
the data, similar vasocontractile results in all vessel sizes in both HD and obese patients
were observed when these results were expressed as a potentiated maximum KPSS
response.
An interesting finding in this project was that small and large vessels of both HD
and obese patients show highly contract to U46619 and vasopressin more so than the
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other vasoconstrictors, while these vessels contract less to NA and AngII. Furthermore,
large vessels of both groups are highly potent to U46619 and vasopressin, which could
indicate that these vessels are highly sensitive to both vasoconstrictors. In light of these
results, we highlighted presence of endothelial defect in both groups of patients
characterized by failure of all sized vessels to relax in response to Ach and BK, while
they normally relaxed to SNP. One proposed reason for such failure is alteration in the
vascular structure such as vascular hypertrophy, thickening of vascular media, and
arterial stiffness that have been reported recently in HD (Chung et al., 2010) and obesity
(Grassi et al., 201Ob). In obesity, it has also been found that alteration in the vascular
structure can lead to vascular dysfunction appears as increased in the vascular
contractility and reduced endothelium-dependent vasorelaxation (Georgescu et al., 2011).
In regard to this explanation, there may be an association between changes in the
vascular function and alteration in the structure of the vascular wall. This possibly was
emphasized in our HO and obese patients by significant positive correlation between
enhanced vasocontractility in response to vasopressin and PWV (in HO patients) and
significant positive correlations between PWV and SBP with vasocontractile response to
U46619 (in obese patients). These observations may indicate presence of alteration in the
vascular wall structure, particularly conduit vessels, among this risk group of patients.
This correlation may strengthen the link between ESRD and elevated arterial stiffness
(Peralta et al., 2009). However, elevated peripheral vascular resistance and increased
sympathetic activity in ESRO patients could also be enhance the vasoreactivity in this
group of patients. These vascular alterations, particularly in large vessels, may predict
cardiovascular mortality as described previously (Blacher et al., 2002).
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The results in chapters 3 and 4 showed that different sized isolated arteries in both
HD and obese patients fail to relax in response to endothelium-dependent vasodilators
(Ach and BK). This particular impairment in subcutaneous vessels has not been
published before. Previous ex vivo myography studies on uremic and obese patients have
examined only small-sized isolated arteries (Morris et al., 2001, Luksha et al., 2011,
Georgescu et al., 2011). In our HD and obese patients the size of the vessel was ranged
from small to large arteries. In the current project, endothelial dysfunction in the
microvasculature of HD and obesity was further strengthened by significantly blunted
vasorelaxation response to BK and Ach, and preserved response to SNP in all vessel
sizes.
Taken with the results in chapter 3 and chapter 4, we suggest that uremia and
obesity can alter the vascular reactivity of subcutaneous isolated arteries by enhanced
vasocontractility and impaired endothelial function. However, the exact underlying
mechanism of endothelial dysfunction is unclear. Several reports have proposed that
circulating uremic factors in HD patients, as well as obesity-related factors (mentioned in
chapters 3 and 4) may be responsible for these changes. It is also important to note that
ED can occur in other conditions such as hypertension (Taddei and Salvetti, 2002),
diabetes mellitus (van Etten et al., 2002), and cigarette smoking (Heitzer et al., 1996),
and seems to be controversial in hypertension. Our HD patients were non-diabetic, and
they had similar BP with controls. There were no obvious cardiovascular diseases in HD
patients, and the average BMI was normal in HD. Thus in uremic HD, it is more likely
that uremic toxins, and not the existing co-morbidities, are the main factors responsible
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for altered vascular function and ED. Therefore, the present findings may contribute to
the explanation of the relationship between uraemia and vascular alteration.
In obesity, several reports have suggested that impaired NO bioavailability (Jonk
et al., 2(07) and alteration in the vascular structure (Zeidan et al., 2005) are the primary
responsible factors that affect the endothelial function through different
pathophysiological mechanisms involving metabolic and hormonal factors associated
with obesity. These include insulin resistance, adipocytokines, and excess release of
reactive oxygen species. We did not investigate these factors in this study; however
incremental increase in the vasocontractility together with failure in the endothelium-
dependent vasorelaxation in our obese patients may suggest alteration in the vascular
structure or could probably a defect in NO function, where all sized vessels of obese
patients were normally relaxed to NO donor (SNP). However, the exact underlying
mechanism is still unclear. Therefore from the results obtained in chapters 3 and 4, we
can suggest that there are some associated factors linked in HD and obese patients that
alter the vascular function which, in our results, are characterized by vascular hyper-
responsiveness and impaired endothelium-dependent vasodilatation.
In order to further investigate whether the vascular function will be improved in
obese patients following bariatric surgery, small isolated arteries from the same patients
were investigated to the same vasoactive drug after six month follow-up post-surgery.
Improvement in the endothelium-dependent function in obese patients after bariatric
surgery has been observed in few numbers of isolated subcutaneous arteries (De Ciuceis
et al., 2011), as well as, in forearm vessel (Gokce et al., 2(05). This is in contrast to the
in vivo study by Brook et al. in which endothelium-dependent vascular function in
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brachial artery did not change in obese patients following surgery (Brook et al., 2004).
Therefore, the effect of surgery on the vascular function is still controversial. In chapter
4, results of obese patients following bariatric surgery did not significantly differ from
the baseline results. However a noticeable trend of higher contractile response to all
vasoconstrictors was observed in obese patients before surgery compared with the same
patients after surgery. In regard to the vasorelaxation response, our results did not reveal
a significant improvement in the endothelium-dependent function following surgery,
though the percentage relaxation to Ach and BK appeared more in obese patients after
surgery, but this difference was not statistically significant. This may likely indicate that
reduction in the body weight might decrease the vasoreactivity and improve the vascular
relaxation in obesity. However, further large studies with extensive follow-up are needed
to confirm these results.
In regard to the difference in the vasoreactive response of different-sized vessels
in all groups of participants, our data observed that the contractile response varies along
the vascular tree. Previous data on diabetic patients have shown greater contractile
response to NA and ET-l observed more in large arteries than small (Hadoke et al.,
2000). However, the present study extends this principle to include various
vasoconstrictors in different subjects including HD, obese, and controls. In the present
study, large arteries from all groups were significantly contract to all vasoconstrictors
than small vessels. Moreover, in our obese patients, large arteries significantly relax to all
vasodilators more so than small arteries. While in HD group, similar results were
obtained in response to BK and SNP but not Ach. These findings have not been reported
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before in uremic and obese patients; though Hadok et al. conversely observed similarity
in the response of isolated different-sized vessels of diabetic patients to BK and SNP
(Hadoke et al., 2000). Therefore, these observations might indicate presence of
functional heterogeneity between small and large resistance arteries obtained from
subcutaneous fat of different human tissue.
The focus of this project is investigating ex vivo vascular function in a high-risk
group of subjects; HD and obese patients, and the conclusion from chapters 3 and 4 is
that there is enhanced vascular contractility and impaired endothelium-dependent
function. These findings suggesting that vascular endothelium in HD and obesity would
seem a reasonable target for uremic and obesity-associated factor respectively. The exact
underlying mechanism of impaired endothelial function in both groups is complex and
yet unclear. It might be that there is impaired NO function or could probably be an
alteration in the vascular structure, which has been reported previously in uraemia and
obesity milieu, but with different associated factors involved in the complicated
pathophysiological mechanisms.
5.1 Limitations and future work
The key aspect of this thesis was to investigate ex vivo vascular function in high-
risk and selective patients, HO patients and severely obese individuals who had
undergone bariatric surgery. The results in this project provide interesting findings on the
effects of HO and obesity in isolated vascular function despite a small number of
participants, which may limit the greater applicability of the results. The reason for
recruiting a small number of HD patients is the nature of subcutaneous fat sampling with
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extra incision required in this highly sensitive group of patients. Together with minor
complications of the procedure such as minor bleeding and scar formation. All of which
could result to either refuse the patients or withdraw them from the participation in the
study. However, a large number of arterial segments from different-sized vessels were
recovered from a homogenous group of incident dialysis patients, and a large number of
control participants were included in the study. Since the mechanism of endothelial
dysfunction in uraemia and obesity is multi-factorial, several reports have suggested that
impaired NO function through elevated ADMA (Kielstein et al., 2004),
hyperhomocystinaemia (Mallamaci et al., 2(02) and excessive oxidative stress (Pawlak
et al., 2004) play crucial roles in the mechanism of endothelial dysfunction in uraemia.
Also, insulin resistance (Poirier et al., 2(06), adipocytokines (Knudson et al., 2008) and
excess reactive oxygen species (Silver et al., 2007) may be responsible for the same
mechanism in obesity. However, we did not measure these circulating indices that could
support our results.
Although we demonstrated an interesting positive correlation between the
contractile response of small and large vessels in response to vasopressin with the in vivo
measurements of PWV, a large number of patients had an additional association between
in vivo hemodynamic measurements and the ex vivo functional findings. These would
allow us to raise new possible mechanisms of vascular dysfunction, thus necessitating
further study of the effect of vasopressin response on vascular function. Arterial function
could have been affected either by the biopsy procedure or use of local anaesthetics,
however, all arteries that completed the experiments were tested for their ability to
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contract at least 5 mN either to a high KPSS or U46619, and the endothelium function
was assessed using BK.
As a result of the relatively few number of obese patients evaluated post
operatively, our results did not provide enough information about the effect of surgery on
vascular function, which may also limit the discussion about the vascular response
following surgery in obese patients. The reason for recruiting only small numbers of
post-surgery obese patients could also be due to the nature of an extra incision needed to
collect subcutaneous fat samples in patients who already had major surgery six months
prior. Although these results are derived from a small HD and obese sample size, a large
number of control participants were included in the study, and statistical significance was
achieved between the patient and control groups. Endothelial dysfunction in ESRD and
obesity are likely to occur in the earliest stages of the disease, thus, further studies are
necessary to identify ways of preventing such a defect; this includes haemodynamic and
biochemical investigation.
Despite these limitations, our study demonstrated that HO and obesity can alter
the vascular function in isolated different-sized vessels through impaired endothelium-
dependent vasodilatation and enhanced vasocontractility. The future aim would be to
extend the myography study to further investigate the role of endothelium-dependent
function through abrasion of the endothelial layer lining the isolated vessels using human
hair. Also, by using NO synthase inhibitors, such as NG-nitro-L-arginine methyl ester
(L-NAME), we could investigate the role of endothelium-derived NO. Moreover, the
future work would be to extend the same investigations into these risk groups correlating
ex vivo vascular response with biochemical measures of circulating factors that might be
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responsible for endothelial dysfunction in HO and obese patients. A larger study would
further investigate the association between the circulating markers and functional
responses in the isolated vessels would be helpful in finding new insights into the
underlying mechanisms. A morphological examination of isolated vessels, including
measurement of vascular wall thickness and media-to-lumen ratio to determine their
histological features, should be considered as well.
5.2 Conclusion
The overall aim of this thesis was to investigate the ex vivo vascular function in
HO and obese patients using wire myography. This project provides new insights into the
effect of HO and obesity on human resistance artery function. We show that HO and
obesity affects endothelial function via incremental increase in the vascular contractile
response to various stimuli and blunted dilatation response to endothelium-dependent
agonists, while preserved endothelium-independent function in isolated different-sized
vessels. The detailed mechanistic responses underlying these changes are still unclear.
However, the failure of arterial relaxation is mediated by endothelial dysfunction. The
association between HO and obesity with endothelial dysfunction in isolated arteries
would be expected to accelerate the cardiovascular risk which impacts on cardiovascular
morbidity and mortality. These findings further highlight the general state of endothelial
dysfunction in both ESRD including those on dialysis and obesity with or without
associated hypertension and diabetes mellitus. We therefore propose that development of
cardiovascular disease in such risk patients is mediated, at least partly, by functional
alterations at the level of microcirculation. An ex vivo vascular function of isolated
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vessels from HO and obese patients were correlated to in vivo assessment of arterial
function characterised by an exaggerated vasocontractile response and deficient
relaxation, which in turn, strengthens an association between these risk groups and
increased conduit arterial stiffness. Proper weight loss following bariatric surgery may
improve the renal function and BMI; however, these are not accompanied by the
improvement in the endothelial function though further large studies with longer time
follow-up or increased the patient's number are necessary to establish the effect of
surgery on improvement of endothelial function.
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7 Appendix
7.1 Protocol for myograph calibration ( Small jaws for resistance vessels)
• Turn on myograph and turn on the heat
• Add 3-5 ml of distilled water to each chamber, and wait until 37°C
• Attach a wire to the 'transducer' jaw. Make sure the wire is on tight and there is
no slack - it should look like below:
Aim to place the
balance arm in this
• Open a chart file
• Onchannel I, place the calibration bridge over the transducer jaw. Make sure
that the tip of the balance arm is in the space between the jaw on the inside of the
wire as shown in the diagram (think about the fact that the arm will press against
the wire causing the change in tension to be recorded on the transducer)
• On channel I, open 'input amplifier'
• Turn off the unit conversion (so amplifier is reading in V)
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• On the myograph, so to the calibration screen and select the channel you want t
calibrate by pressing F2.
• Itwill read 'No force on Force l' - press F2 to continue and now read the 'Y'
value on the chart file - should be around O.OOOY (no force should = no V)
• Next it will read '2 gram on Force l' - place the 2 g weight on the transdu er
arm. When the reading is stable, press F2: cal and read the 'V' value on the chart
file.
• Now go back to the Units Conversion section in 'Input Amplifier' and enter the
value in Y obtained at 0 force and the value obtained at with the weight - we
measure in mN, which is 9.81mN. Make sure the units conversion is on bef re
leaving the screen.
9.!24 mN
"I~ Input!
Point!: (!)I~ J.I~___ __J rri'4
Polnt2: (!)[?~ _..J.~.8C J mN
2V
.:J2V
Unts".
Untts: ( rri'4
Dedmal placeS! !3 :~
Set units for:
I
(0) New data only
...
JI
.:J
so
1-._---1 ~
o
,.- · '40
30
20
10
M
o
.:Jzv
-so
OK Cancel II AppIv I [ ~
t •
• The channel is now calibrated!
227
• Repeat for the other 3 transducers
7.2 Normalization of arteries by wire myography
• Turn on lab chart version 5 ensuring it is calibrated. Important to calibrate it
before conducting the experiment if the myography has not been calibrated in the
past two weeks.
• Mount the vessels as described before
• Once the vessels are mounted start the chart reader running
• From the top tool bar select DMT and normalization settings. Enter the following
information below
Eye piece calibration
Target pressure 13.3 KPA
ICI/IC 100 0.9
Online averaging time
Delay time
2 seconds
60 seconds
• Then select DMT and channell, 2, 3 and so on for the desired amount of
channels you wish to normalise. Once selected in put the following data
Tissue end point I and 3
Wire diameter 40J..lm
• Bring the jaws together until the reading is at a negative number >30mN is fine
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• Allow the first reading to be taken then move the jaw slightly apart so that the
number on the myography screen is as close to zero as possible.
• Allow the normalization to begin, add tension giving the vessel around 2mN
tensions. Let the software time the normalization for 60 seconds. Once this has
happened you will need to take note of the micrometer screw reading and add this
to the programme.
• Keep adding tension until a pressure of 13.3 KPA has been reached. When this
occurs then take the final micrometer reading and input it into the programme.
• The programme will then return the corresponding micrometer position that will
give 13.3 KPA, the programme will also return the inner circumference of the
vessel. Using this circumference it is thus possible to work out the diameter by
dividing the circumference by 1t.
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